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Breast cancer has multiple sub-types, designated in clinical practice by the presence or 
absence of prognostic and predictive biomarkers: oestrogen receptor, progesterone receptor 
and the human epidermal growth receptor 2 (HER2). Molecular imaging offers the opportunity 
firstly to non-invasively and dynamically interrogate in vivo tumour sites to provide prognostic 
and predictive evaluation at clinically meaningful on-treatment time points. Secondly, it may 
address diagnostic challenges in the metastatic setting by enabling assessment of inter- and 
intra-lesion heterogeneity without requirement for tissue acquisition from multiple sites.  
This thesis describes pre-clinical evaluation of a novel HER2 targeted DARPin radiotracer as an 
in vivo diagnostic across multiple tumour sites in murine models. Metastatic breast xenograft 
models were developed and validated using bioluminescence imaging and definitive histology 
for in vivo evaluation of a novel HER2 targeted DARPin radiotracer. In subsequent preclinical 
testing the DARPin radio-tracer failed to differentiate HER2 status of pre-clinical tumour 
xenografts models and this data raises significant questions regarding   suitability of the 
DARPin radiotracer for clinical evaluation as a HER2 diagnostic. 
Additionally this work reports the set-up of a Phase 2 imaging feasibility study designed in two 
parts to evaluate post-cycle 1 PET response using the FLT- and FDG-PET imaging tracers to 
address clinical questions concerning tracer selection, scan acquisition and interpretation for 
validation of Positron Emission Tomography (PET) response as a predictive biomarker of 
neoadjuvant response in the triple negative breast cancer (TNBC) phenotype. Part A 
(participant recruitment completed) delivers the first phenotype specific repeatability 
constraints for the most commonly reported standardised uptake parameters (SUV); maximum 
(SUVmax), mean (SUVmean), peak (SUVpeak) and lean body mass corrected peak (SULpeak), 
assessed at conventional (90 minutes) and exploratory (120 and 180 minute) acquisition time 
points.  The TNBC SUV intrinsic variability was 12-24% in both tracers and is dependent on scan 
acquisition time and SUV parameter. The FDG tracer has progressed to the second phase, Part 
B, to provide the first TNBC phenotype specific response data at a post-cycle 1 time point.  The 
data suggests SUV change can predict later residual cancer burden and that >40%  threshold 
change will be required to differentiate RCB 0-1 vs 2-3 response, a change that exceeds current 
EORTC/PERCIST recommendations for solid tumour chemotherapy response prediction.  The 
study will inform future use of early FDG-PET as an exploratory biomarker in window of 
opportunity and novel therapy neo-adjuvant trials in TNBC  
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 Background literature review 3
 Introduction 3.1
Breast cancer is the commonest female malignancy accounting for almost one third of cancers 
(1).  About 30% will relapse and it is second only to lung cancer as the leading cause of female 
cancer death.  Breast cancer has multiple sub-types, designated in clinical practice by presence 
or absence of oestrogen receptor (ER), progesterone receptor (PR) and the human epidermal 
growth receptor 2 receptor (HER2). Better understanding of breast cancer biology and 
development of associated targeted therapies has driven improvement in outcomes 
particularly in hormone receptor positive and HER2 positive disease and guides therapy in 
these phenotypes (2, 3). 
Triple negative breast cancer (TNBC) describes the 15-20% of breast cancers that are hormone 
and HER2 receptor negative. Clinical challenges in TNBC arise from the lack of targeted therapy 
and heterogeneity of response to standard cytotoxic therapy. Subgroups are highly sensitive to 
neoadjuvant chemotherapy achieving pathological response (pCR) and excellent long-term 
outcomes following sequential anthracycline-taxane regimens. However response is 
heterogeneous and overall TNBC is characterised by higher rates of distant recurrence than 
other phenotypes (4, 5) and little durable benefit from therapy at relapse (6). Molecular 
imaging shows promise as a predictive factor for chemosensitivity but there remains a need for 
validated surrogates of later pathological response and survival outcomes to clearly 
differentiate populations unlikely to derive benefit from standard neoadjuvant chemotherapy 
early in the course of treatment.  
HER2 receptor amplification, present in 20-30% of breast cancers, has prognostic significance 
identifying a population of women at relatively increased risk of metastatic visceral and 
cerebral relapse (7, 8) which can be beneficially impacted by HER2 targeted therapy.  HER2 
evaluation is a mandatory part of the pathological assessment of new primary breast cancer, 
informing neoadjuvant and adjuvant use of HER2 targeted therapeutics such as Trastuzumab. 
In metastatic disease, evolution of HER2 molecular targeted therapies now offers clinicians a 
range of HER2 targeted options and coordinated transition though approved agents at 
radiological progression has improved survival for those with advanced disease over the last 
decade (9). Whilst pathological HER2 assessment is straightforward in primary disease, 
practical issues associated with tissue acquisition from metastatic sites frequently preclude re-
evaluation of HER2 status. Consequent the clinical assumption of constancy in gene expression 
from primary disease through to metastasis diagnosis has significant therapeutic implications 
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and risks futile use or inappropriate omission of HER2 targeted agents for some individuals (10, 
11). 
Molecular imaging offers the opportunity to non-invasively interrogate tumour sites at 
baseline and during the course of therapy, potentially providing prognostic and predictive 
evaluation at clinically meaningful diagnostic and on treatment time points.  Developing 
validated imaging biomarker strategies offer opportunities to address specific clinical 
challenges posed by the different breast cancer subgroups, specifically the ability for timely on 
treatment response assessment and phenotype evaluation across a totality of metastatic 
disease sites. This would then facilitate individualised therapeutic selection unfettered by the 
practical or time point constraints inherent to current tissue diagnostic and cross-sectional 
imaging response evaluations relied upon in current clinical practice.  
 Molecular imaging as a predictive response biomarker in TNBC  3.2
 Rationale for monitoring neoadjuvant systemic therapy response in TNBC 3.2.1
Curative treatment for locally advanced or inflammatory breast cancer increasingly includes 
systemic therapy given in the neoadjuvant setting to facilitate breast conservation whist 
delivering at least the same magnitude of survival advantage as the same adjuvant therapy 
(12-14). Pre-surgical sequencing also uniquely enables assessment of in vivo sensitivity to 
therapy. The absence of residual invasive tumour within breast or axilla at definitive surgery 
(pathological complete response, pCR) independently predicts better disease free and overall 
survival regardless of breast cancer subtype (Figure 3.1 A). Pooled data from 12 international 
neoadjuvant trials confirms this predictive impact of pCR is driven by the TNBC (EFS: HR 0·24, 
95% CI 0·18–0·33; OS: 0·16, 0·11–0·25) and the trastuzumab treated HER2-positive (HER+), 
hormone-receptor-negative tumour (EFS: 0·15, 0·09–0·27; OS: 0·08, 0·03, 0·22) subsets 




Figure 3-1 Prognostic importance of pathological response on survival outcomes 
A) Association between pathological complete response (pCR) and event-free survival (EFS) and 
overall survival. Responder analysis from 12 international trials including 11 955 patients. pCR 
defined as  ypT0/is ypN0. HR=hazard ratio. Figure reproduced from Cortazar et al 2014 (15) 
B) Frequency and estimated 10-year relapse free survival (RFS) of residual cancer burden (RCB) 
classes in breast cancer subsets following taxane-anthracycline neoadjuvant 
chemotherapy(16). In TNBC, RCB-II/III defines high-risk patient post chemotherapy 
subpopulations. Figure adapted from Symmans et al 2013 (16) 
The prognostic insight provided by evaluation of pCR which predicts disease free survival (DFS) 
has the potential to more efficiently evaluate promising new agents in the early breast cancer 
context particularly in luminal B/HER2-negative, HER2-positive (non-luminal), and triple-
negative disease (17)(14, 15). Recognising this, pCR has been the primary endpoint in recent 
neoadjuvant trials (18, 19) and accepted by the U.S. Food and Drug Administration (FDA) as a 
suitable surrogate efficacy endpoint leading to accelerated drug approval. However, the 
magnitude of increase in pCR rate required for a novel therapeutic to deliver meaningful rates 
of improved survival remains uncertain. Furthermore some categories of patients with 
incomplete response derive good long term outcomes from standard treatment implying that 
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dichotomous separation into pCR or not oversimplifies the prognosis for those with residual 
disease, ignoring primary tumour characteristics and magnitude of chemotherapy response 
(20, 21).  With the aim of relating degree of partial response to subsequent survival outcome a 
spectrum of histopathological scoring systems have been described. These include binary pCR 
or not (NSABP-B18); linear histologic response in breast only (Miller-Payne(20)) or breast and 
lymph nodes (Sataloff (22)); algorithms integrating breast and nodal response including 
formula (Nottingham Prognostic Index (23)) or Web calculator (Residual Cancer Burden, RCB 
(21)); and, finally, those which  integrate pretreatment clinical stage (C), ER status (E), and 
grade (G) with post-treatment pathological stage (PS) such as the CPS EG) (24)  have been 
described.  Overall, scoring systems which include amalgamated breast and nodal response 
better correlate with survival (25) and RCB is a recommended standard for use in neoadjuvant 
trials (26).  RCB considers residual primary tumour dimension, cellularity and axillary nodal 
burden to calculate a score which can be categorised into four independently prognostic 
classes across all breast cancer phenotypes (21). Achieving RCB 0 or 1 (pCR or minimal residual 
tumour burden) predicts an excellent long term prognosis whereas RCB 2 and 3 (moderate and 
extensive residual tumour burden) identifies individuals at increasing risk of relapse, the 
magnitude of which is driven by the underlying breast cancer phenotype but is worst in the 
context of triple negative disease compared with other breast cancer subtypes (Figure 3.1 B)  
(16, 27). 
Improving TNBC survival outcomes requires better understanding of heterogeneity in disease 
and therapy response.  Tissue evaluations performed on the diagnostic biopsy specimen may 
indicate potential chemo-sensitivity but despite consistently greater pCR rates reported in 
triple negative, HER2+ breast cancer or in the molecularly defined basal-like and HER2+ 
subgroups compared to ER+ subgroups (5, 28) (29) the baseline features predictive of good 
response overlap with those predicting progression (30). At present prospective differentiation 
between later responding and RCB non-responding individuals remains an aspiration.  
Neoadjuvant on treatment monitoring relies on clinical examination prior to each cycle and 
cross-sectional imaging performed at baseline, the mid-point of sequential therapy and prior 
to definitive surgery after 6-8 cycles of sequential taxane-anthracycline treatment. High spatial 
resolution contrast enhanced magnetic resonance imaging (CE-MRI) is the gold-standard 
imaging modality. The Response Evaluation Criteria in Solid Tumour (RECIST version 1.1) 
formally quantifies response by defining and monitoring change in evaluable disease using 
minimum unidimensional size criteria (31). Serial imaging classifies into four categories of 
response; complete (disappearance of all tumour foci sustained for at least 4 weeks); partial 
(decline of ≥30% in tumour diameter), stable (response that does not meet criteria for 
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progression nor response) and progressive (≥20% increase in size or new tumour lesions). 
Inevitably there is a time lag between therapy initiation and measurable size change and 
available data does not support MRI RECIST assessment earlier than the suggested interval of 
6-8 weeks (32). Hence the first cross sectional imaging opportunity follows a minimum of 3 
cycles of therapy. As this approaches scheduled transition to the second component of 
sequential taxane-anthracycline chemotherapy, RECIST provides little opportunity for therapy 
modification.   
With the aim of facilitating earlier neoadjuvant response MRI assessment the multicenter 
Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And 
moLecular Analysis (I-SPY TRIAL) investigated MRI- and tissue-based biomarkers for predicting 
response and survival (33, 34). For RCB prediction, the MRI derived functional tumour volume 
(FTV) was superior to clinical examination at all timepoints with the greatest relative benefit at 
following cycle 1 chemotherapy. However end of treatment MRI FTV best predicted  RCB class, 
and equal contribution of MRI FTV following 2 cycles and the histopathological variables (RCB 
class and tumor subtype defined by hormone and HER2 receptor status) provided the 
strongest predictor of  RFS (33). Further to this data,  the currently recruiting I-SPY 2 trial (NCT 
NCT01042379) utilises an adaptive trial design which aims to integrate clinical, imaging 
including MRI function tumour volume response, and genomic data to identify agents for 
different molecular phenotypes early in the drug development cycle that improve pathologic 
response. Importantly early FTV does not independently predict later RCB or survival outcomes 
and is not suitable for adoption into routine clinical practice.             
GeparTrio is the largest reported neoadjuvant breast cancer study to prospectively evaluate 
the concept of response adaptive chemotherapy (35). In this study the magnitude of USS  
response in the primary breast tumour following 2 cycles of combined anthracycline-taxane 
regimen defined randomisation to prolongation of the same regimen in the responding subset 
(further 6 vs. 4 cycles of the same regimen) or continuation vs. early chemotherapy transition 
to capecitibine/vinoerlbine in non-responders. Overall, disease-free survival was significantly 
longer in the USS response-guided groups than in the conventional groups combined (HR = 
0.71, P = .0003) and exploratory subset analysis suggested greatest efficacy for response-
guided therapy selection in hormone receptor–positive tumors. However the mix of 
phenotypes and unknown efficacy impact of transition to vinorelbine/capecitabine 
combination in poorly responding TNBC mean questions remain about the broader 
applicability of the strategy. Alternative approaches relying on significant residual disease to 
define high risk post neoadjuvant populations eligible for recruitment to adjuvant trials are 
possible but impractical for all but the least toxic adjuvant interventions given the impact of 
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the proceeding cytotoxic on fitness. Biopsy derived biomarkers such as ki-67 may have 
prognostic and predictive potential (36) and therapy induced changes in the tumour 
potentially correlate with subsequent survival outcome (37) and may add to RCB (38). 
However repeated invasive biopsy for in vivo response monitoring and potential confounding 
effect of intra-tumour heterogeneity (39) make serial tissue acquisition unattractive for 
routine clinical application. In contrast a validated imaging biomarker selected to reflect the 
biology of the disease in question and predictive of the pathological response surrogate may 
better realise opportunities afforded by the pre-surgical window for efficient evaluation of 
therapeutics. However without a validated means of early on-treatment monitoring in TNBC, 
pathological efficacy outcomes are only reached at therapy completion currently meaning that 
opportunities to tailor therapeutic strategy to in vivo tumour response are missed. 
 PET Functional Imaging for neoadjuvant response prediction in TNBC 3.2.2
Single Photon Emission Computerised Tomography (SPECT) and (Positron Emission 
Tomography (PET) molecular imaging are real time imaging techniques which map expression 
of molecular markers within humans or animals following the administration of radiolabelled 
tracers (40). Radioisotopes, which emit a single gamma photon, are detected following 
collimation to exclude those with a non-parallel trajectory and computer reconstruction of the 
spatial distribution of events generates 3D SPECT images. In contrast radioisotopes used in PET 
imaging emit positrons that annihilate after combination with an electron to generate two 
180◦ opposing gamma photons. These are detected by paired coincidence coupled detectors, 
which locate the source of the annihilation event generating the spatial information required 
for computer reconstruction. For both modalities high contrast image acquisition requires a 
match between the physical radionuclide half-life and circulation half-life of the conjugated 
targeting ligand. Specific imaging requirements of targeting ligand are rapid delivery to the 
tumour site (efficient tissue delivery, cell penetration, high tumour specificity and high target 
affinity) and rapid excretion of unbound ligand to minimise the interval from tracer infusion to 
optimal image acquisition. Both modalities have an established role in clinical practice but PET 
has advantages of greater sensitivity, higher spatial resolution, and more accurate 
quantification.  
The ability of PET to detect drug induced changes in tumour metabolism and proliferation that 
may anticipate size change has led to an emerging role informing escalation/de-escalation 
strategies within the research setting in highly proliferative malignancies such as lymphoma 
(e.g.NCT01304849, NCT00392314, NCT01361191). Given the importance of pathological 
response in TNBC, similar prospective trials testing early imaging response in adaptive 
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neoadjuvant chemotherapy approaches would be of clinical interest. However in a phenotype 
characterised by absence of molecular targets for imaging or therapy the most appropriate 
imaging biomarker remains unclear. 
 2-[fluorine18]fluoro-2-deoxy-D-glucose (FDG) as a candidate imaging biomarker  3.2.3
2-[fluorine18]fluoro-2-deoxy-D-glucose (FDG) is the most widely used PET tracer for staging 
and response assessment in cancer. Uptake reflects an increase in general cell metabolism 
requiring glucose as an energy source.  The tracer is not tumour specific however increased 
expression of glucose transporters and hexokinase (glucose phosphorylating enzyme) as a 
result of oncogenic transformation leads to increased rates of glycolysis and glucose transport 
in most malignant tissues (41).  Following intracellular phosphorylation, FDG becomes trapped 
and concentration within a tumour represents the glycolytic activity of viable malignant cells. 
The magnitude of FDG uptake could be impacted by effective therapy. Although potential false 
positive FDG uptake in areas of inflammation risks confound specificity for therapy (42), 
changes in biopsy derived measures of apoptosis (43) and proliferation (34) following cytotoxic 
therapy have both been shown to correlate with change in FDG uptake. Consequently, serial 
FDG PET imaging may indirectly provide important prognostic information about the viable 
tumour burden and anti-proliferative effect of cancer therapy. 
Established biological factors predicting enhanced baseline FDG breast cancer uptake include 
high Ki-67 proliferative index, negative oestrogen receptor status and non-lobular histology 
(32, 44-49) (50). Differences in tumour blood flow, glycolysis and intracellular phosphorylation 
may account for heterogeneity of uptake (51-53).  Expression of the facilitative glucose 
transporter 1 (GLUT-1) is particularly associated with enhanced FDG uptake (51) and overlap 
between genes associated with increased glucose metabolism and ER- molecular phenotypes 
has been reported (49). GLUT-1 expression characterised in 286 breast tumour samples 
classified as basal like breast cancer (BLBC) or otherwise using immunohistochemical (IHC) 
criteria reported significant association between GLUT-1 expression and BLBC (76.4% BLBCs vs. 
23.8% non-BLBCs showing immunostaining for GLUT-1 , p < .001) (54). 
 FDG PET for TNBC response assessment 3.2.3.1
A literature search (Appendix 11.1) identified 32 published neoadjuvant FDG response 
evaluation studies. The majority (23 out of 33 studies) have considered FDG performance in 
mixed breast cancer phenotypes. Data interpretation is further complicated by heterogeneity 
of response definition, cytotoxic regimen, and timing of response evaluation, which may 
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account for the marked variability in published thresholds, sensitivities and specificities for pCR 
prediction. A 2012 meta-analysis (19 studies) supported the use of FDG-PET imaging early in 
the course of therapy (55) but relationships between phenotype, magnitude of SUV change 
and later response remained unclear. Subsequent to the meta-analysis a single study in a pre-
specified TNBC population suggested <42% threshold change in SUVmax after 2 cycles defines 
a subpopulation at high risk of residual disease and early relapse (100% vs. 45% according to 
response; p= 0.014 and 44% vs. 0%; P = 0.024 respectively) (56). In a  2014 update of this study 
(n=50), the HR for relapse was 3.68 (95% CI 1.13-11.99) for patients with <42% decrease in 
SUVmax after 2 cycles anthracycline based chemotherapy (57). At the post cycle 1 time point a 
trend for the most marked SUV reductions has been observed in TNBC and HER2- populations 
but no data prospectively addresses the TNBC population specifically (58-61).  
 Areas of uncertainty in FDG breast cancer response assessment 3.2.3.2
 Which reporting parameter should be used for serial FDG scan assessment? 3.2.3.2.1
The majority of breast cancer response evaluation studies (Appendix 11.1) used a single static 
scan to measure and report changes in the standardised uptake value (SUV). This is a semi-
quantitative measure, which describes the ratio of tissue concentration and injected activity 
without considering tracer kinetics. Normalisation is usually to body mass but may also be to 
lean body mass (SUL) or body surface area. A variety of SUV parameters are reported within 
the published literature (Figure 3-3A) and comparative data is required to establish the most 
clinically meaningful predictive measure for differentiating FDG response .  
SUVmax, the hottest pixel within the tumour volume (figure 3.3B), is the most widely reported 
parameter in oncology publications.  SUVmax is easily quantified on commercial workstations 
and more resistant to partial volume effects in small tumours than other SUV parameters 
which may be advantageous in breast cancer. However wider concerns about adverse impact 
of imaging noise on quantification of cancer treatment response led to development of 
PERCIST guidance advocating  the use of the peak parameter defined as the average SUV 
within a small, fixed-size region of interest (ROIpeak) centred on the highest uptake part of the 
tumour but not necessarily including the SUVmax pixel (62) (Figure 3-4A). Superiority of peak 
over max parameter is uncertain and in a predominantly HER2+ve and ER+ve breast cancer 
cohort two cycles of chemotherapy induced parallel therapy changes for the two parameters 
(32). The peak parameter has not been widely adopted and most (21 of 25 breast cancer FDG 
response studies) publications during or subsequent to 2009 continue to report therapy 




Figure 3-2 Schematic PET image of radiotracer uptake in tumour 
A. Schematic PET image of radiotracer uptake in tumour (purple line) demonstrating impact of 
ROI definition on SUV parameters within a tumour volume (delineated in pink) (63). SUVmax 
refers to maximal pixel in tumour.  SUVpeak is the average SUV within a small fixed-sized 
region of interest whose value will vary according to placement with the tumour. Image taken 
from Vanderhoek et al  2012(63). 
B Number of human FDG oncology papers that included use of tumour SUV, as function of year 
of publication (62). SUVpeak and SUVmax as above. SUV isocontour refers to the mean SUV 
value across an irregular ROI defined by isocontour set at a percentage of the maximal pixel. 
SUV manual refers to the mean SUV across a manually drawn ROI. Only a subset of these 
papers describes response assessment studies. Image taken from Wahl et al 2009 (62). 
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The peak and max parameters provide an SUV estimate for the most metabolically active 
region of the tumour volume (figure 3.3A) but a mean SUV reporting glycolysis across the total 
tumour may potentially be advantageous for tumour response evaluation.  In squamous cell 
carcinoma of the head or neck metabolically active tumour volumes (MTV) 
delineated using FDG PET are superior to those defined on CT or MRI when compared to 
reference volume assessed from surgical specimens, (64) and the isocontour at 40% of 
maximum SUV (SUV 40 isocontour) delivers the best compromise between accuracy and risk of 
underestimating tumour extent (65). Similar, tissue comparative data supports superiority of 
SUV40-42 isocontours in cervical and lung cancer (66, 67) but relationships with pathological 
size in breast cancer are unknown. PERCIST suggests SUVmean as an exploratory response 
parameter but acknowledges limited data and this parameter is reported in few breast cancer 
response publications (Appendix 11.1). In ER+ HER2- disease, Total Lesion Glycolysis (TLG, the 
product of metabolically active tumour volume and SUVmean) was reported to have better 
predictive value than SUVmax (68).  However in a heterogeneous breast cancer population 
SUVmean (42% isocontour) conferred no advantage over SUVmax response at post cycle 1, 
midpoint or end of treatment timepoints. In 16 patients (19 lesions) with mixed metastatic 
solid primary tumours undergoing mid and end of treatment PET response assessment 
conflicting response categorisation was present in 80% of participants due to significant 
differences in magnitude of SUV change between the different SUV measures (max, mean, 
peak and total)(63). There is a lack of comparative data in TNBC but it is likely that 
classification of PET response will similarly be dependent on SUV parameter, supporting the 
need for clinical trials to select the most predictive SUV measure for assessment of therapy 
response. 
 Defining FDG PET response in TNBC? 3.2.3.2.2
Level of SUV threshold change to define responders will likely be influenced by the objective of 
PET imaging. The clinical aspiration is for early identification of high risk subpopulations in 
whom escalation or novel therapeutic approaches would be of interest. In this context the 
post cycle 1 time point has maximal potential to prevent ineffective therapy in non-
responders. In breast cancer it is known that the greatest magnitude of change occurs after 
the cycle 1 chemotherapy (Figure 3-3) (69-73). The 2012 meta-analysis supported early FDG 
PET response assessment after the 1st or 2nd cycle of chemotherapy and suggested a 
discriminatory threshold of 55-65% but cautions that these data are from mixed breast cancer 
phenotypes with an unknown or minority TNBC proportion (55). Very early assessment (day 8 
following first chemotherapy) risks confounding evaluation of SUV increase through detection 
of therapy instigated inflammatory response rather than active tumour (72). Therefore an 
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interval of at least 2 weeks between completion of the chemotherapy cycle and the [18F]-FDG 
PET scan is likely required to avoid transient increases. 
 
Figure 3-3 Sequential SUV change in breast and axillary lesions through neoadjuvant chemotherapy 
A Figure adapted from adapted from Rousseau et al 2006 (69). Change in the relative 
standardized uptake value (SUVmax; mean) for breast lesions imaged through neoadjuvant 
chemotherapy(69). Pathological response scored according to the Sataloff scale which 
categorises  grades A complete response (blue), B good response (red) and nonresponse grade 
C + D (green). A significant difference was observed in breast uptake across the response 
groups (p<10-4), noticeable from after the first cycle of chemotherapy (p<10-5). B Figure 
adapted from Rousseau et al 2011 ((70). Change in the relative standardized uptake value 
(SUVmax; mean) for axillary lesions during neoadjuvant chemotherapy.  Pathological response 
scored according to Sataloff scale; grade B good response (blue) and nonresponse grade C + D 
(green). A significant difference was observed in axillary nodal uptake across the response 
groups (p<10-5), noticeable from after the first cycle of chemotherapy (p<10-7) 
 
EORTC PET guidance proposed thresholds for partial metabolic response dependent on 
interval between response assessment scan and first treatment, suggesting a ≥15% decrease in 
SUV after one cycle or ≥25% after more than one cycle to differentiate responders (74). 
PERCIST recommends uniform threshold change of ≥30% reduction in SULpeak that is not 
adjusted according to on treatment interval (62). Both sets of guidance apply generically across 
the spectrum of malignant disease but recognise need for tumour specific data. The published 
work in breast cancer reports a breadth of threshold SUV change for pCR prediction ranging 
from 15% to >80% of baseline at 1 cycle (Appendix 11.1). Phenotype specific data at this time 
point is lacking. Nevertheless the data overall suggests discriminatory SUV change may exceed 
EORTC and PERCIST thresholds (55). In practice relatively higher thresholds may be required 
for sub-selection for the best responders (low false -ve rate, 1-specificity, type 1 error) with a 
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view to therapy de-escalation compared to identification of non-responders with a view to 
offering escalation or transition to novel therapies within future clinical trials.  
Breast and regional nodes are commonly involved in TNBC and an interpretation strategy for 
PET is required for multiple lesions. Most publications considered breast lesion only response 
but more recent studies have adopted an alternative strategy defining target as the single 
lesion with the greatest SUVmax at baseline, accepting that axilla rather than breast may be 
the index lesion (57, 75). PERCIST recommends evaluating up to five lesions but considers only 
% difference in SUL between the most intense tumour on study 1 and study 2 for response 
assessment. This lesion may differ between scans provided both lesions were present on the 
two studies and no progression is evident on the study 1 target.   
Compared to dynamic analyses SUV assessment has the advantages of rapid scan duration but 
risks introducing errors due to potential therapy impact on tracer metabolism. A retrospective 
evaluation of dynamic FDG PET in 14 patients with mixed breast cancer who underwent 60 
minutes dynamic acquisitions at baseline and midpoint of neoadjuvant chemotherapy has 
been performed (76). Scans were evaluated using a 2 compartment model, using a 1.5cm VOI 
placed over maximal tumour activity and blood input was derived from the cardiac blood pool. 
FDG transport (k1, ml/min/g) and FDG metabolism flux constant (K1, ml/min/g) were selected 
as response measures for comparison with DCE-MRI parameters and pathological response in 
the breast. Changes in tumour size, metabolism and vascularity measured by FDG PET and DCE 
MRI were well correlated and predictive of pathological response suggesting kinetic 
parameters may potentially provide further prognostic insight. In mixed breast phenotypes, 
model optimisation software was used to evaluate FDG Ki and compare with SUVpeak 
measured derived from a 45-60 minute acquisition performed at baseline and midpoint of 
neoadjuvant treatment (77). Average Ki and SUV were both greatest in ductal, high grade and 
hormone receptor negative tumours and changes in both dynamic and static parameters 
predicted subsequent pathological response, however only Ki change was able to predict later 
relapse.  
 Quality assurance in serial FDG PET acquisition and scan evaluation 3.2.3.2.3
European Association of Nuclear Medicine (EANM) guidance recommends common quality 
control/quality assurance procedures to ensure consistency in patient preparation, scan 
procedure and image reconstruction for FDG image interpretation (78). Conventionally FDG 
PET-CT scan acquisition commences 60-90 minutes after tracer injection, but the optimal 
timing in breast cancer is uncertain.  Data derived from dynamic acquisitions in 40 patients 
with newly diagnosed locally advanced breast cancer demonstrated approximately linear rise 
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in SUVmax over the 27-75 minute acquisition time interval (79).  However the rate of change 
differed between individual tumours such that in those with low initial uptake SUVs showed 
minimal change with acquisition time but up to 25% SUV increase over the final 15 minutes 
was observed in those with high early uptake. Consequently, failure to adhere to uniform 
imaging acquisition time across sequential scans may differentially confound interpretation of 
SUV change and a tolerance of +/-5 minutes for response assessment is recommended (78). 
Ongoing uptake has been reported several hours after tracer injection particularly in high 
grade breast tumours (80-82). Relationships between breast cancer receptor status and time-
uptake are undefined but it is possible later image acquisition may optimise diagnostic 
accuracy at baseline and subsequent response assessment in TNBC. 
In the majority of breast cancer response publications (Appendix 11.1), methodology used to 
define lesions suitable for PET analysis is either not stated or based on visual scan inspection 
by an experienced nuclear medicine reader. Humbert et al. (2014) (61) pre-defined 
hypermetabolic lesions suitable for follow up response imaging as those where baseline 
tumour SUVmax exceeded hepatic SUVmax. Alternative strategies require target lesions to 
exceed a particular size or SUV value (73, 83). PERCIST suggests baseline tumour uptake must 
exceed a threshold calculated from mean background, and background uptake within 20% of 
baseline on subsequent response scans (62).  Specific application of PERCIST requirements has 
not been described in any of the publications listed in Appendix A.   
A literature search identified no published test-retest data reporting intrinsic variability of FDG 
PET in breast cancer generally or its phenotype subsets. Meta-analysis of data from 
predominantly thoracic and GI sites report the combination of an absolute change in SUVmean 
of >1.2 units and relative change of >20%, and for SUVmax relative change of >30% and 2 unit 
absolute change exceeds the 95% test-retest variability and is likely to indicate a true therapy 
change rather than measurement error (84).   In this meta-analysis SUVmean performed better 
than SUVmax, and factors including baseline high uptake and a delineation method using an 
isocontour technique were associated with improved repeatability and may be relevant to 
TNBC. However given the heterogeneity of uptake within breast cancer, TNBC phenotype 
specific data with regard to scan parameters and their repeatability is required to ascertain the 
biological significance of therapy induced change in SUV biomarker. 
It is possible that SUV evaluation may be impacted by the chosen therapeutic independently of 
tumour response. The majority of published data (Appendix A) report FDG PET response 
following anthracycline first sequencing or mixed chemotherapy protocols. In the only 
chemotherapy comparative data, the interval PET was performed prior to the scheduled 
therapeutic transition in 60 women receiving   taxane-anthracycline (Group A) or the reverse 
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sequence (Group B) (85). pCR rates did not differ between the two treatment groups. The 
mean change in SUVmax after 4 cycles of chemotherapy was 87.7%  in those achieving pCR  vs. 
27% in those who did not (p<0.01). In contrast no significant difference in SUVmax response 
according to pathological response was present for women in arm A.. Limitations of this study 
include inconsistent scan acquisition time post tracer injection (median 60 minutes range 45 to 
75 minutes) and disparity in ER and nodal status between groups (71% vs. 52% ER+ve  and 90% 
vs. 10% node positive in Groups A vs. B respectively). Nevertheless these data suggest choice 
of therapeutic agent may itself influence SUV uptake and should considered when interpreting 
FDG PET response.  
 3’deoxy-3’-[18F]fluorothymidine (FLT) as a candidate imaging biomarker  3.2.4
FDG is not tumour specific and changes in uptake may be confounded by increased uptake due 
to post-therapy inflammation within the tumour or surrounding tissues, potentially falsely 
indicating a lack of response (44). Strategies with greater specificity for tumour metabolism 
may provide a better imaging surrogate for early tumour response in TNBC. The FLT tracer is 
an imaging biomarker of proliferation, reflecting use of thymidine (86). FLT enters cells by a 
combination of passive diffusion and active transport (ENT1), is phosphorylated in S-phase by 
thymidine kinase and trapped in its monophosphate form without incorporation into DNA. 
Recent meta-analysis has confirmed correlation between FLT uptake and the Ki-67 
proliferation marker at a number of primary tumour sites including breast (87) but 
relationships with other cycle specific proliferation biomarkers have not been reported to 
date. Reduction in tumour Ki-67 during neoadjuvant chemotherapy is well recognised, and 
there is some evidence indicating that the magnitude of change is greatest in those who 
respond to treatment (37). However whilst Ki-67 change has been used as a pharmacodynamic 
marker in window of opportunity or neoadjuvant trials there are little validated data to define 
clinically meaningful change in response to cytotoxic therapy (88). 
Review of published data identified nine studies in breast cancer. In unselected breast cancer a 
single study confirms FLT repeatability (SUV acquisition at 90 minutes, mean difference 10.5%, 
intra-class correlation coefficient 0.99) (89) and change in FLT uptake at one to two weeks 
following therapy initiation predates imaging or marker response in advanced disease (Table 1) 
(89-92). However ability of FLT tracer to predict pathological tumour response following 
neoadjuvant treatment is uncertain (93, 94) and phenotype specific data is required. 
Nevertheless as mitotic rate, which is typically high at baseline in TNBC, therapy impact on 
high baseline proliferation would be expected to occur rapidly following exposure to effective 
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systemic therapy suggesting FLT SUV change might provide a particularly useful response 
surrogate in this population.    
 
 Molecular imaging as a HER2 diagnostic 3.3
 Rationale for HER2 targeted tracers for breast cancer imaging 3.3.1
The HER family of transmembrane tyrosine kinase receptors (HER1-4) are collectively 
important for regulation of cell survival, growth and differentiation. HER2 receptor kinase 
activation follows ligand-mediated heterodimerisation with another HER family member, or by 
complex formation with other transmembrane receptors particularly where the receptor is 
overexpressed or mutated. The transphosphorylated intracellular domains then interact with 
intracellular signalling molecules to activate or inhibit downstream pathways and cross talk 
with other signalling pathways leading to increased cell proliferation, cell motility, tumour 
invasiveness, progressive regional and distant metastases, accelerated angiogenesis and 
reduced apoptosis (95).  
The humanised murine monoclonal immunoglobulin trastuzumab (Herceptin®, Roche) was the 
first HER2 targeted therapy to enter routine clinical practice. Following impressive clinical data 
in the first line metastatic setting, trastuzumab in combination with chemotherapy established 
a clear place in treatment of advanced HER2+ve disease (96, 97). Subsequently, combined 
hazard ratios (HR) from eight adjuvant/neoadjuvant studies involving 11,991 women 
demonstrated robust benefit for trastuzumab-containing regimens over chemotherapy alone 
(HR for OS and DFS 0.66; 95% CI 0.57 to 0.77; P<0.00001 and 0.60; 95% CI 0.50 to 0.71; 
p<0.00001 respectively) (98). Given the magnitude of benefit for trastuzumab, HER2 
evaluation according to American Society of Clinical Oncologists/College of American 
Pathologists (ASCO/CAP) guideline recommendations is a mandatory diagnostic tissue 
assessment for all patients with newly diagnosed breast cancer (99).   
Alternative approaches targeting the HER2 signalling pathway have been developed over the 
last decade with the aim of addressing the clinical challenge of metastatic progression due to 
trastuzumab or cytotoxic resistance.  Of these agents lapatinib (Tyverb®, GlaxoSmithkline; oral 
HER1/HER2 receptor tyrosine kinase inhibitor), Pertuzumab (Perjeta®, Roche; a humanised 
monoclonal antibody binding at the subdomain 2 epitope of the HER2 extracellular domain) 
and the immunoconjugate trastuzumab emtansine (T-DM1; Kadcyla®, Roche) have 
demonstrated benefit in phase III trial evaluation (100-103). With this evolution of HER2 
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targeted therapies coordinated transition though approved agents at radiological evidence of 
progression has improved survival for those with metastatic disease (9). Despite this, patients 
will ultimately develop resistance to targeted approaches and metastatic HER2+ disease 
remains incurable. Potential predictors of trastuzumab resistance have been proposed, but no 
molecular marker has currently been validated in prospective clinical trials as a means for 
targeted therapy selection at metastatic progression. Consequently HER2 positivity defined 
according to ASCO/CAP guidance (99) remains the most important predictive factor for 
response to  the spectrum of HER2 targeted therapies in routine clinical practice.  
Practical challenges associated with tissue acquisition from metastatic sites means historical 
HER2 status assessed from the original primary breast tumour must frequently inform 
treatment decisions at relapse. Assumptions of constancy in gene expression with progression 
to metastatic disease have therapeutically significant implications, potentially increasing risk of 
futile use or inappropriate omission of HER2 targeted agents for some individuals (10, 11). 
Recent meta-analysis of 48 studies (2987 tumours) investigating the stability of HER2 
expression between primary and metastatic disease reports pooled discordance proportion of 
10% for distant metastases (95% CI: 7–14%), and 6% for loco-regional relapse (95% CI: 3–9%) 
(p = 0.039) (104). Use of both IHC and FISH testing, compared to IHC alone, did not improve 
concordance (discordance rate 10% vs. 5%, p=0.02) making it unlikely that technical errors 
explain this finding. Loss of HER2 expression was more common in studies using both IHC and 
FISH, but the pooled proportion of negative and positive HER2 conversion was 15% (95% CI: 
10–21%) and 7% (95% CI: 5–10%) respectively indicating that initial HER2 status does not 
reliably predict direction of change in expression at relapse (104). Furthermore heterogeneous 
amplification, defined as the existence of two distinct or intermixed clones of breast cancer 
cells exhibiting different patterns of gene amplification is a well-recognised challenge to HER2 
diagnostics in primary disease (105) and raises questions about HER2 heterogeneity across 
metastatic sites. Retrospective autopsy series suggest congruence across metastatic sites to be 
good but contain very few patients overall, and numbers with initially HER2+ primary disease 
are in single figures (106, 107). 
Where metastatic tissue can be obtained sampling is invariably single site and single time point 
due to shared patient and clinician feasibility, safety and acceptability concerns precluding 
synchronous tissue acquisition from multiple sites within the same individual. Molecular 
imaging is a clinically attractive strategy for determining expression and localization of HER2-
overexpressing tumour lesions, and potentially permits non-invasive evaluation of receptor 
status across multiple and difficult to biopsy sites at a time point relevant to targeted therapy 
selection. Despite phenotype associated differences in breast cancer uptake and some 
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evidence supporting ability to predict response following neoadjuvant HER2 targeted agents 
(83), FDG has no role for predicting HER2 status of primary disease or for discriminating HER2 
status across metastatic sites. Consequently there is a clinical need for validated SPECT or PET 
radio-ligands targeting the HER2 phenotype that can inform targeted therapy selection and 
response evaluation. Ligands in preclinical or early phase clinical development include 
radiolabelled immunoglobulins (trastuzumab and pertuzumab), immunoglobulin fragments, 
and the non-immunoglobulin scaffolds, affibody and designed ankyrin-repeat proteins (108, 
109).  However no tracer has currently established its place in the clinic as a HER2 diagnostic 
outside the research context.  
 Antibody- based HER2 imaging 3.3.2
The high affinity and specificity for cell surface receptor targeting of intact monoclonal 
antibodies are ideal properties for molecular imaging.  Trastuzumab is the most evaluated 
targeting ligand used for HER2 molecular imaging, in addition to its mainstream therapeutic 
role. SPECT or PET imaging using trastuzumab radiolabelled with 111In (t½ 2.8 days) and 89Zr (t½ 
3.3 days) can differentiate high and low HER2 expression in subcutaneous xenograft models 
(110-112). HER2 downregulation in response to experimental heat shock protein 90 inhibition 
can be quantified using sequential PET (113) and, in  trastuzumab treated MDA-MB-361 
xenografts, sequential SPECT using 111In labelled pertuzumab sensitively detected early 
molecular response at a time point which significantly predated later IHC confirmed decrease 
in viable HER2 positive cells (114).  
The first clinical evaluations used 111In-DTPA-trastuzumab to investigate the ability of SPECT for 
prediction of trastuzumab induced cardiac toxicity (115). Although unsuccessful in this regard, 
previously undiagnosed metastatic sites were detected in 13 of 15 baseline scans. Despite this 
only 45% of known tumour sites were evaluable but it was postulated that superior spatial 
resolution of PET might improve on the relatively low SPECT detection rate.  In a feasibility 
study seeking to determine the optimal dosage and time of administration of 89Zr labelled 
trastuzumab, most known tumour lesions in the liver, lung, bone and brain and previously 
unknown brain and bone lesions were visualised on PET performed at 5 days post tracer 
injection (116). This study did not incorporate tissue biopsy but the currently recruiting clinical 
trial NCT01420146 includes molecular characterization of tumour samples with discordant FDG 
and HER2 PET-CT image. Findings from this trial will provide specificity data for 89Zr-
trastuzumab in HER2 positive metastatic disease.  
The high molecular weight (150 KDa) of monoclonal antibodies leads to relatively slow tissue 
penetration and long circulatory half-life giving the disadvantage of early images with very high 
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background signals. Preloading with unlabelled trastuzumab affords some improvement in bio-
distribution (116, 117) but despite this antibody kinetics inherently necessitate use of isotopes 
with long half-lives that permit image acquisition at least several days following tracer 
administration to ensure optimal tumour-to-blood ratio. The shorter half-life of 64Cu (t½ 12.7 
hours) potentially permits a target scan time of only 48 hours post tracer injection.  The first 
clinical data in 6 patients with at least 1 measurable non-contemporaneously tissue verified 
HER2+ breast cancer lesion confirmed feasibility for HER2 lesion evaluation despite relatively 
high liver uptake in trastuzumab naïve patients. (118). Further feasibility data for PET-CT using 
64Cu-DOTA-trastuzumab PET/CT at 48 hours in 8 patients with biopsy confirmed metastatic 
HER2+ve breast cancer reported detection sensitivity of 89% on day 2 post tracer injection, 
comparable to the detection sensitivity of 93% seen with FDG. Characterisation of tracer 
performance in a control HER2 negative population is planned (117).  
 Antibody Fragments 3.3.2.1
Imaging at 2 to 5 days post tracer injection poses significant feasibility and patient 
acceptability challenges that limit wider application of antibody imaging outside the clinical 
trial context. The critical antibody component for imaging application is the antigen binding 
sites located on the tip of the antigen binding (Fab) arms.  Engineering fragments with lower 
molecular weight and shorter half-life through removal of the redundant Fc IgG domain may 
facilitate earlier imaging without compromise to antigen binding (Figure 2.1) meeting the 
clinical aspiration for same day HER2 imaging (119). As an example, F(ab)2 antibody fragments 
have reduced uptake in the normal organs and clear 4 to 5 times more rapidly from the 
circulation and tumour sites than the corresponding IgG form (120). In HER2+ xenografts, PET 
imaging at 24 hours after F(ab)2  trastuzumab fragments DOTA conjugated with 68Ga (t½  1.14 
hours) was able to report HER2 downregulation in response to HSP inhibition that predated 
18F-FDG PET glycolytic change (121).  In subsequent clinical feasibility evaluation, only 7 
lesions in 4 of 7 women with tissue confirmed HER2 positive metastatic lesions showed 
appreciable uptake at one, two and three hours following tracer injection (122).  Sequential 
venous sampling confirmed relatively fast F(ab)2 clearance from the intravascular 
compartment and this combined with concomitant therapeutic trastuzumab for most of the 
HER2+  participants led the authors to postulate that competition for tumour targeting and 
rapid circulatory clearance may have resulted in inadequate time for extravasation and tumour 
localisation.  To address this dose adjustment in the context of therapeutic trastuzumab and 
use of a radionuclide with longer half-life permitting imaging at 6-24 hours is planned.   
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Even smaller antibody variants may improve imaging properties for clinical application. Single-
chain variable fragment (scFv) are fusion proteins comprising variable regions of the heavy 
(VH) and light chains (VL) of immunoglobulins connected with a short linker peptide of ten to 
about 25 amino acids. Diabodys, formed by linking two scFv, appear promising in their ability 
to function as an effective PET radiotracers. In pre-clinical murine models several agents have 
demonstrated HER2 targeting specificity and decreased PET signal in response to trastuzumab 
treatment (123-125) but have yet to be clinically evaluated. Nanobodies, the smallest (12-
15KDa) naturally derived antigen-binding fragment, are characterised by high stability, rapid 
targeting and fast clearance. In the preclinical setting the PET tracer 68Ga-NOTA-2Rs15dnti-
HER2 delivered high specific contrast imaging of HER2+ tumours at 1 hour after tracer injection 
and progression to clinical validation is planned (126). 
 




 Non antibody derivatives 3.3.3
It is possible that imaging requirements of efficient tracer extravasation, good tissue 
penetration, and fast blood clearance may require molecules even smaller than the mass of 
the smallest immunoglobulin fragments.  
 Affibodies 3.3.3.1
Affibodies are small (6-7KDa) 58 amino acid molecules with a non-immunoglobulin scaffold 
originally derived from the 58 amino acid IgG binding domain of staphylococcal surface protein 
A. Their 13 amino acid binding surface can be manipulated to give high affinity binding to a 
variety of antigen targets and good imaging properties (108, 127). In the preclinical setting, 
HER2 targeting affibodies have demonstrated efficient pharmacokinetics with rapid 
extravasation to tumour targets and blood clearance permitting optimal image acquisition as 
early as 30 to 60 minutes following tracer injection and (128-130). In murine models several 
affibody PET and SPECT tracers have demonstrated ability to assess HER2 expression and 
monitor possible changes of receptor expression in response to therapeutic interventions 
providing better contrast in HER2 imaging than trastuzumab (128, 131-134).  
The first clinical data using HER2 targeted affibody imaging was reported in 2010 (135).  Three 
patients received 111In- and/or 68Ga-labeled DOTA-ZHER2:342  (ABY-002) prior to SPECT or PET 
imaging. The first half-life was within 15 minutes of injection for both forms and rapid tracer 
kinetics permitted high contrast image acquisition 2-3 hours following injection. More recently, 
111In-ABY-025 underwent first-in-human study evaluation in 7 patients with FDG avid breast 
cancer metastases (136). SPECT acquisitions at 4, 24 and 48 hours following tracer injection 
were able to discriminate HER2 status of metastases and correctly predicted HER2 negative 
transition in one patient. However high hepatic as well as renal background uptake obscured 
sites of liver metastasis (135). Given the liver is commonly involved at HER2+ relapse this  may 
limit clinical application of current affibody tracers and a current focus is developing constructs 
with reduced liver biodistribution (137).  
 Designed ankyrin repeat proteins (DARPins) 3.3.3.2
DARPins are small recombinant non-antibody based ankyrin repeat proteins with low 
molecular weight (14-18 kDa) that can be radiolabelled for imaging applications. The G3 
DARPin has been developed as a novel HER2 imaging agent to subdomain 4 of HER2 ECD and 
has picomolar affinity for HER2 binding (138). In preclinical murine models excretion is 
predominantly renal and its short intravascular half-life permits same day imaging. Preclinical 
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evaluation in HER2+ ovarian cancer xenografts established using the SKOV3 cell line 
demonstrates high tumour:blood ratios at 1 hour  and good tumour visualisation (139). 
Moreover promising in vivo biodistribution and HER2 discrimination has been reported for the 
111In DOTA conjugated (HE)3-G3 DARPin (
111In DOTA- DARPin) following evaluation in BT474 
(HER2+ breast cancer cell line) subcutaneous xenograft models and first-in-man clinical 




 Rationale for work undertaken in this thesis 3.4
Molecular imaging offers the potential of optimisation and rationalisation of therapy at the 
individual patient level to facilitate therapy individualisation, reduce risk associated with 
complex metastatic site tissue acquisition by biopsy and ultimately reduce the of burden 
lengthy clinical trials to determine efficacy of novel agents. However tracer performance must 
be validated prior to clinical application as diagnostic and/or surrogate endpoint biomarkers.  
There is limited clinical data reporting sensitivity and specificity of HER2 targeted tracers with 
reference to pathological confirmation of HER2 status at both visualised and non-visualised 
metastatic sites and specifically whether tracers can accurately reflect heterogeneity of 
overexpression across multiple metastatic sites within individual patients. Questions 
concerning histological verification in primary and regional nodal disease may be addressed 
using a study design that relates pre-surgical imaging to subsequent definitive histology from 
the primary tumour and regional nodes. However, in metastatic disease individual lesion 
accessibility and the safety and acceptability of tissue acquisition at multiple sites will 
significantly constrain the ability to acquire sensitivity and specificity data for these tracers 
within the context of a clinical study. The G3 DARPin is scheduled to enter clinical evaluation 
but despite promising preclinical data in a single HER2 positive cell line further supporting 
preclinical data would be advantageous prior to the first-in-man clinical trial. The results 
chapter’s five  present experiments undertaken to establish pre-clinical in vivo metastatic 
models to provide additional data relating HER2 tracer uptake to standard imaging techniques 
and histology in order to inform subsequent tracer application for clinical diagnosis.  
In TNBC there is a clear clinical aspiration for early surrogate markers of the pCR and 
quantitative residual disease endpoint that can be applied to optimise neoadjuvant response 
assessment. Current evidence suggests FDG and FLT PET tracers may be informative after only 
one chemotherapy cycle. However work is required to ensure tracers meet characteristics 
required for clinical application as a predictive surrogate biomarker in TNBC before either can 
be adopted in routine clinical practice. Specifically breast cancer subtype specific experiments 
are required to provide data concerning tracer intrinsic variability, the optimal SUV reporting 
parameter and to define level of SUV change required for differentiating categories of later 
pathological response. Results chapters six to nine describe work undertaken to address these 




 Pre-Clinical Experimental Material and Methods 4
 Cell lines and cell culture 4.1
 Cell lines 4.1.1
Five human breast carcinoma cell lines were selected for use in this study in order to represent 
a spectrum of HER2 expression levels. The breast cancer cell lines BT474, HCC1954, SKBR3 and 
HCC1143 were provided courtesy of the Breakthrough Breast Cancer laboratory at KCL 
(originally purchased from the American Type Culture Collection, ATCC, Teddington, UK). The 
breast cancer cell line MDA-MB-231 was a kind gift from Dr. Gilbert Frühwirth, KCL. Clinical and 
pathological features of these cell lines are summarized in Table 2.1 






HCC 1143 1.08 
 
Figure 4-1 HER2 status of Breast Cancer Cell lines use in this study 
 Cell culture 4.1.2
The breast cancer cell lines HCC1954 and HCC1143 were cultured in RPMI 1640 (Gibco®, Life 
Technologies, Paisley, UK) supplemented with 10% heat-inactivated foetal bovine serum (FBS) 
(Gibco®, Life Technologies, Paisley, UK). BT474 and MDA-MB-231 cells were maintained in 
Dulbecco’s  modified Eagles medium (DMEM) (Sigma-Aldrich, Gillingham, UK) supplemented 
with 10% Fetal Bovine Serum (FBS). The SKBR3 cell line was cultured in McCoys media (Gibco®, 
Life Technologies, Paisley, UK) supplemented with 10% FBS. Cell lines were grown in the 
presence of penicillin and streptomycin (Sigma-Aldrich, Gillingham, UK).  
Cryopreserved cells were recovered from liquid nitrogen by rapid thawing at 37˚C. The 
suspension was then mixed with 1mL culture medium and cells were isolated by centrifugation 
at 1200 RPM for 5 minutes, and then re-suspended in medium prior to transferring them into 
tissue culture flasks (Helena Biosciences, Gateshead, UK). Cells were grown in a humidified 
incubator at 37˚C and 5% CO2. Upon reaching 80% confluence, cells were passaged by washing 
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once with sterile Dulbecco’s Phosphate Saline Buffer (PBS) (Sigma-Aldrich, Gillingham, UK), 
then adding 2-4 mL (according to flask size) of 1X Trypsine-EDTA (Sigma-Aldrich, Gillingham, 
UK) and incubating the cells at 37˚C for 1 to 5 minutes, depending on the cell line. Detached 
cells were then isolated by centrifugation at 1200 RPM for 5 minutes, and re-suspended in 
complete medium.  
Cell density was measured by mixing 10µL of the cell suspension to an equal volume of 0.4% 
Trypan Blue Solution (Gibco®, Life Technologies, Paisley, UK) then 10µL of the mixture were 
placed into a Countess Cell Counting Chamber Slide (Life Technologies, Paisley, UK). Cell 
density and viability were determined using the dye exclusion test by the Countess™ 
Automated Cell Counter (Life Technologies, Paisley, UK). 
For long-term storage in liquid nitrogen, cell line stocks were prepared at low passage 
numbers. 1 or 2 x106 cells were re-suspended in 1mL complete media supplemented with 10% 
dimethyl sulfoxide (DMSO, Sigma-Aldrich, Gillingham, UK) and transferred into cryovials, which 
were cooled at -80◦C overnight and subsequently stored in liquid nitrogen.  
Regular screens were performed using the MycoAlert Mycoplasma Detection Kit (Lonza, Basel, 
Switzerland) to ensure that all cell cultures remained mycoplasma free.  
 Antibiotic kill curve estimation 4.1.3
Breast cancer cell lines were plated at 40,000 cells per well, into 8 wells of a 12 well plate. At 
24 hrs post plating blasticidin was added at concentration of 0, 1, 2.5, 5, 7.5, 10, 15 and 20 μg 
per well (2-10μg/ml well recommended in manufacturer’s instructions).  The percentage of 
cells surviving at 48, 72 and 120 hours was visually estimated and used to generate kill curves 
from which the dose of blasticidin required for selection following lentiviral transduction was 
determined (Table 2.2). 
Puromycin dose use for selection was taken from kill curves previously performed in the 






Cell line Blasticidin Puromycin 
SKBR3 10µg/ml 1.5µg/ml 
HCC1954 7.5µg/ml 3 µg /ml 
HCC1143 2µg/ml  
BT474 7.5µg/ml  
MDA- MB-231 7.5µg/ml  
 
Figure 4-2 Antibiotic doses used for selection after lentiviral transduction 
 HER2 Protein Expression analysis 4.2
 Sample collection 4.2.1
Cells plated for 24 hours at 150,000 cells per well (6 well plate) were washed with PBS and 
then lysed in 200μl Laemmli buffer (0.2M Tris HCL, 8% SDS, 40% Glycerol, 10% β-
mercaptoethanol, 0.4% blue bromophenol). Following collection samples were incubated at 
95˚C for 5 minutes then rapidly cooled on ice prior repeated aspiration using an insulin syringe. 
Samples were stored at -20˚C. 
 Antibodies 4.2.2
The primary antibodies used in this study are listed in Table 4.3. HRP-conjugated mouse and 
rabbit secondary antibodies (RPN2124, GE Healthcare, Amersham, UK) were used at 1:50,000 
dilutions in 5% non-fat milk (Marvel) in PBS 0.05% Tween50. HRP-conjugated mouse and rabbit 
secondary antibodies (RPN2124, GE Healthcare, Amersham, UK) were used at 1:50,000 
dilutions in 5% milk  (Marvel). 






Rabbit 1:1000 185KDa 
β-actin Sigma-Aldrich Mouse 1:30000 42KDa 
 




 Western Blotting 4.2.3
Samples were loaded onto 5-15% acrylamide gels (mini-PROTEAN®TGX™ Precast Gel, Bio-Rad, 
Hemel Hempstead, UK) and electro-transferred onto nitrocellulose membranes (Bio-Rad, 
Hemel Hempstead, UK). Membranes were stained with Ponceau S solution (Sigma-Aldrich, 
Gillingham, UK) to confirm successful transfer. Following wash with 1xTBST membranes were 
blocked with 5% milk (Marvel) prepared in 1xTBST and this was followed with incubation with 
the primary antibodies listed in Table 2 for 1 hour at room temperature or overnight at 4˚C. 
Membranes were then washed six times with 1xTBST with and incubated in secondary 
antibodies diluted in 5% milk for 1 hour at room temperature. Following 6 further membrane 
washes with 1x TBST membranes were incubated in ECL prime (GE Healthcare, Amersham, UK) 
for visualisation. Hyper-films ECL (GE Healthcare, Amersham, UK) were exposed for varying 
times at the SRX-101A developer (Konica Minolta, Milton Keynes, UK).  
  Luciferase expression 4.3
 Firefly Luciferase Lentiviral transduction 4.3.1
Breast Cancer Cell lines were plated at 150,000 cells per well in tissue culture 6 well plates 
(Greiner bio-one, Stonehouse, UK) and incubated overnight at 37˚C and 5% CO2. LVP 439 
(EF1a-Luciferase [firefly]-2A-RFP [Bsd]) premade Lentiviral expression particles (Amsbio, 
Oxford, Uk) were thawed on ice and cells were then infected using a 1:3 virus:plain media 
ratio. The plate was incubated overnight at 37˚C and 5% CO2 and the infection medium was 
then replaced with fresh complete media the following morning.  Blasticidin selection for 
transduced cells (according to the predetermined antibiotic kill curve) was performed after a 
further 24 to 48 hours. The selected cells were not used for experiments until a minimum of 3 
days blasticidin selection.  
 In vitro confirmation of luciferase lentiviral transduction 4.3.2
Transduction was checked by visual estimation of RFP presence under a fluorescence 
microscope and confirmed by IVIS evaluation of the transduced cells lines (4.5.2) 
 In vivo breast cancer xenograft model establishment 4.4
Animal studies were carried out in accordance with UK Research Councils' and Medical 
Research Charities' guidelines on Responsibility in the Use of Animals in Bioscience Research, 
under UK Home Office license (PPL 70/7775; Title: Models of breast cancer heterogeneity and 
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biomarkers). Animals were maintained in either the Hodgkin or Rayne BSU, Kings College 
London.  
Female six to eight week old CD-1 Foxn1-/- Nude mice were purchased from Charles River 
Laboratories (UK). The animals were maintained under sterile conditions in filter topped cages 
on sterile bedding and fed an irradiated diet of standard mouse chow. 
Mycoplasma negative cell lines of interest engineered to stably express luciferase were used to 
establish in vivo tumour models for longitudinal imaging (bioluminescence or SPECT). To 
establish subcutaneous models, one million cells suspended in 50μl sterile PBS were injected 
into the mammary fat pad at day 0. To establish lung metastasis models mice were restrained 
and injected in the tail vein with 1 million cells suspected in 100μl PBS at day 0. Mice were 
monitored post procedure, the day following injection and at least once or twice weekly 
thereafter. Subcutaneous tumours were measured using calliper’s (mm) and volume calculated 
using the formula Volume= (length*width)2)/2). Mouse monitoring comprised assessment of 
weight, behaviour and palpable tumour size up to three times per week. In accordance with 
the PPL evidence of weight loss greater than 10%, moderate signs of behavioural distress 
and/or palpable tumour diameter ≥15mm (single tumour) or ≥10mm (multiple tumour) 
precipitated humane killing by Schedule 1 method. 
 Bioluminescence imaging 4.5
Bioluminescent imaging (BLI) was performed using (IVIS® Lumina Series III, Perkin Elmer). 
Imaging and quantification of signals was controlled by the acquisition and analysis software 
Living Image®.  
 Luciferin stock preparation 4.5.1
30mg/ml stock solution D-Luciferin Firefly, potassium salt (Calliper Life Sciences, Hopkinton, 
USA) for use in in vitro and in vivo experiments was prepared by dissolving 1g of D-Luciferin in 
33.3mls DPBS without magnesium or calcium and mixed prior to filtering through a 0.2μm 
syringe  filter (Merck Milliporem Watford, UK). Aliquots were frozen and stored at -80˚C. Prior 
to use aliquots were protected from light and thawed on ice. 
 In vitro imaging 4.5.2
Transduced bioluminescent cells lines of interest were trypsinised and counted to achieve 
stock dilutions of 1 million cells per ml.  Cells were plated into black clear bottom 96 well 
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plates at decreasing dilutions from 10000 to 100 cells per well in 200µl of the appropriate 
complete media.  
The next day 2 µl of D-Luciferin stock was added to each well (1:100 dilution) and the plate 
transferred IVIS™ Lumina Series III (Perkin Elmer) for BLI. Image times were 10-30 seconds per 
plate. For each cell line the light emitted per cell quantified from the ratio of photons per well 
and the total cell number.  
 In vivo bioluminescence imaging  4.5.3
Following cell injection at day 0, animals were serially imaged to monitor tumour formation 
using BLI (IVIS™ Lumina Series III, Perkin Elmer) until an experimental end point defined by 
severity limit (Tumour Max Diameter 10mm). Animals were imaged in cohorts of 3 to 5 mice. 
At each imaging session mice were intraperitoneal injected with D-Luciferin Firefly, potassium 
salt (Caliper life Sciences, Hopkinton, USA) 150mg/kg (30 mg/mL stock) at time 0. Animals 
were then anaesthetised in a clear Plexiglas anaesthesia box (2% isofluorane) and once fully 
anaesthetised transferred to the nose cones (2% isofluorane) attached to the manifold on the 
warmed stage of the light tight imaging chamber. Imaging times ranged from 1-30 seconds 
depending on tumour model and was performed at 6-12 minutes post luciferin injection. On 
completion mice were returned to their cages and monitored until recovery.  
BLI was repeated weekly until the severity limit determined experimental endpoint, when mice 
were culled immediately following their final imaging session using a Schedule 1 method. 
Removal of all tissues of interest was confirmed by ex vivo BLI of tissues and the residual 
cadaver using the IVIS® camera system. Excised tissues of interest were fixed in 10% formalin 
and prepared for histopathology verification.   
Light emitted from bioluminescent tumours or cells was detected by the IVIS® camera system, 
integrated, digitalised and displayed. Image analysis was performed using the Living Image® 
software (Xenogen). Serial scans across were reviewed and the colour scale normalised across 
the longitudinal series to facilitate visual comparison across scans. For quantitative comparison 
an appropriately sized region of interest (ROI) was selected to encompass subcutaneous 





 Single Photon Emission Computed Tomography (SPECT) imaging 4.6
 In vitro SPECT imaging 4.6.1
The NanoSPECT/CT® detection limit for cell lines imaged HER2 targeted radiotracer was 
determined. Tracer used in these experiments was either 111Indium DOTA conjugated (HE)3-G3 
DARPin (111In-DOTA-DARPin) or 111In-CHX-A”-DTPA-trastuzumab (111Indium trastuzumab) 
prepared by Dr Margaret Cooper (Appendix 4).  Cell lines used in these experiments were 
HCC1954 and MDA-MB-231 cells engineered to stably express RFP and Firefly luciferase and 
maintained under blasticidin selection or HCC1954 engineered to stably express RFP and 
Firefly luciferase with HER2 knockdown maintained under puromycin selection. 
Cell lines of interest were trypsinised and counted, 35 million cells were then re-suspended in 
7ml of filtered PBS + 0.5% Bovine Serum albumin buffer (Fisher Scientific, USA), to achieve a 
stock dilution of 5 million cells per ml. The stock was used to prepare serial dilutions to attain 
triplicate suspensions of progressively decreasing cell number from 5 million to 5000 cells in 
2ml Eppendorf tubes.  111In-labelled tracer was added to each tube to achieve a 10 nanomolar 
tracer incubation concentration, 1500ul total volume in each tube. Triplicate reference 10 
nanomolar standards were prepared at the same time and reserved.    
To mimic in vivo conditions suspensions were then incubated for 30 minutes at 37˚C prior to 
centrifugation at 1200 RPM for 5 minutes.  Pellets were washed twice in buffer and transferred 
to 500µl PCR tubes prior to a final spin and aspiration of the supernatant from each tube. Each 
tube was then positioned in a rack on the mouse bed of the NanoSPECT/CT Silver Upgrade 
(Mediso Ltd., Budapest, Hungary) and images acquired over a scan time permitting 60-70 
seconds per frame.  
On completion of their final scan, activity in tubes including reference standard was counted 
(Wallac 1282 Compugamma Perkin Elmer, UK). For each cell pellet size % tracer binding was 
calculated using (mean counts of the pellet triplicate as a percentage of mean counts of the 
triplicate reference standard). Following scan reconstruction SPECT image analysis was 
performed using VivoQuant™ version 1.23 
 In vivo SPECT imaging 4.6.2
Animals bearing subcutaneous mammary tumours or lung metastases were imaged using 
HER2 targeted radiotracer at a time point estimated from the IVIS data and animal monitoring 
to be optimal for tumour establishment. On the day of imaging for all experiments tracer was 
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prepared by Dr Margaret Cooper (see Appendix 11.5) and comprised either 111In-DOTA- 
DARPin (G3 DARPin provided by Dr Robert Goldstein, UCL) or 111In-trastuzumab. 
On day of scanning, mice were transferred from the Rayne BSU to the imaging laboratory and 
anaesthetised with isofluorane, O2 flow rate of 1.0-1.5L/min and isofluorane levels of 2-2.5%. 
Under anaesthesia mice were injected intravenously with tracer by a laboratory worker 
wearing double gloves. Syringe weights prior to and subsequent to injection were recorded for 
each mouse to permit calculation of the delivered injected volume. Residual activity in the 
syringe and on gauze used to compress the injection site was measured using the capintec and 
recorded for each mouse.  
For image acquisition, mice were positioned on the bed of the NanoSPECT/CT Silver Upgrade 
(Mediso Ltd., Budapest, Hungary) equipped with a multiplexed multipinhole (nine pinholes, 
aperture 1.0 mm) collimator.  Imaging was performed under 2% isofluorane anaesthesia. 
Helical SPECT images were acquired over 30-40 minutes (SPECT 60-70 seconds per frame, CT 
images 55kVp, 1000ms and 1 degree angular stepping.).  On completion of their final scan, 
mice were culled using a Schedule 1 method. The weight and activity of the culled mouse was 
measured.  Mouse organs (gut, liver, kidneys, spleen, lungs, heart, tail and palpable tumour 
sites) were removed and weighed. The residual carcass weight and activity were noted. Tissues 
from anticipated tumour bearing sites (mammary gland or lung) were placed into formalin for 
subsequent histological verification and stored in the hot lab fridge; the remaining organs and 
the gauze used tracer injection were stored in the histology freezer.  
Radionuclide images were reconstructed and fused with CT images prior to image analysis, 
performed using VivoQuant™ version 1.23 software.  
 Biodistribution calculation 4.6.3
Activity of the reserved organs, standards, gauze and background was performed using a 
gamma counter (Wallac 1282 Compugamma Perkin Elmer, UK) and used to calculate organ 
bio-distribution according to the method below 
 The counts from the eight standards were plotted against the volume of tracer and the 
gradient of the line calculated. From this the tracer volume for each organ and the 




 The total injection volume determined by the difference in syringe weight pre- and 
post-tracer injection. The mouse injection volume was then calculated by subtracting 
the volume of tracer for gauze and tissue from the total injection volume. 
 The formula ((organ volume/mouse injection volume)*100) was used to calculate the 
% injection volume for each organ 
 % injected dose per gram was calculated by dividing the % injection volume by the 
measured organ weight.  
 Histology 4.6.3.1
Excised tissues of interest were fixed in 10% formalin. Preparation for histopathology 
examination (paraffin embedded, 3-4 micron sectioning, and staining) was performed by the 
Breakthrough laboratory technician, Erika Francesch Domenech. Stains used were 
haematoxyin (H&E) and eosin for metastases evaluation, Bond Oracle Leica Kit #TA9145 for 
HER2 evaluation and PECAM CD31 (ab28365) for vascularity.  
H&E and HER2 immunostained slides representing a whole lung cross-section were scanned to 
the Digital Image Hub (Leica Biosystems, whole slide scanning system) for quantification of 
tumour burden.  The scanned image was examined (JG) to identify all metastatic sites within 
lung tissues. Metastatic burden relative to the whole lung area was quantified by delineation 
of all tumour regions of interest (Figure 4.4) and the whole lung area using the polygon area 
evaluation tool. The sum of tumour areas was expressed as a percentage of the total lung 
parenchyma. 
For vascularity scoring the most intense vascular areas (hotspots) on the CD31 stained tumour 
sections were selected subjectively from each CD31 stained tumour section and vessel count 
(Mean and SEM) quantified by counting the number of vessels present within three 0.3mm2 




Figure 4-4 Quantification of lung metastatic burden 
A. Lung H&E cross-section. The polygon drawing tool was used to delineate regions of interest 
around 2 metastatic sites (arrowed) for area evaluation using the Digital Image Hub (Leica 
Biosystems, whole slide scanning system). 
 Statistical analysis 4.7
Microsoft Excel was used to calculate mean, standard deviation and standard error of the 
mean and generate graphs for visual comparison of mouse groups. Other statistical analysis 
was performed using IBM SPSS version 22 statistical software.  Normality was confirmed using 
the Shapiro-Wilk test. For parametric data means of two independent groups were compared 
using the independent samples t-test. Comparison of means between more than two 







 Results: Preclinical HER2 imaging  5
 Aims 5.1
The objective of the experiments described in this chapter was to characterise the ability of 
the HER2 targeted molecular imaging tracer to differentiate the spectrum of HER2 expression 
seen in different breast cancer phenotypes.  
Breast cancer cells lines were engineered to express luciferase and assessed for their 
tumourogenicity in subcutaneous and intravenous (lung) metastasis models using longitudinal 
bioluminescent imaging (BLI) and ex vivo histological verification. The successful metastatic 
xenograft models generated by subcutaneous or tail-vein injection of HCC1954 and MDA-MB-
231 breast cancer cell lines with constitutive lentiviral delivered luciferase expression were 
chosen to evaluate 111In-DOTA conjugated (HE)3-G3 DARPin (
111In DOTA-DARPin) SPECT 
radiotracer tracer performance (141). The experimental models were assessed by in vivo 
SPECT CT imaging and ex vivo radiotracer bio-distribution. Cell lines and in vivo tumour models 
were also evaluated using radiolabelled trastuzumab imaging control and in vitro tracer 
binding experiments were performed with cell lines of interest to facilitate interpretation of 
the in vivo results.  
 Development of bioluminescent metastatic models 5.2
 In vitro evaluation of luciferase-transduced cell lines 5.2.1
The five breast cancer cell lines were infected with the firefly luciferase gene (LVP virus, 
Amsbio) and cells stably-expressing luciferase were selected as described in the methods 
section. HER2 status was confirmed with Western Blot of parental and Luc+ lines (Figure 5-1A). 
Luc+ cells from each line were serially diluted, plated and imaged as described Chapter 4. 
Bioluminescence images (Figure 5-1 B) demonstrate that at least 5,000 cells are detectable in 
all transduced cells lines, and as few as 100 cells are detectable in the Luc+ lines SKBR3 and 
HCC1954.  
Light emission was quantified using the Living Image software. Good correlation between total 
flux (photons per second) and the total number of cells was demonstrated in all transduced 
cell lines (Figure 5-1C i). Light emission per cell was calculated from the ratio of detected 
photons per well to total cell number (Figure 5-1Cii). Only the Luc+ BT474 cell line exhibited 
expression below 500 photons/cell/s and expression was 4 to 19 fold higher for HCC1954, 
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SKBR3, HCC1143 and MDA-MB-231 than for BT474 reflecting the ability to visualise fewer cells 
in vitro.  
 
 
Figure 5-1 In vitro bioluminescence of breast cancer cell lines expressing luciferase.  
A. Western blots for the 5 selected cell lines confirming HER2 expression in parental (par) and 
luciciferase transduced (luc) BT474, SKBR3 and HCC1954 cell lines only.  
B. SKBR3, HCC1954, MDA-MB-231, HCC1143 and BT474 Luc+ cell lines were plated 10,000 to 
100 cells and were imaged for 10 seconds at 10 minutes after addition of luciferin to the media. 
Wells containing media only served as negative controls.  
C. (i) Correlation between cell number per well and bioluminescence (photons per second per 
well (p/s per well)) for the five cell lines. R2 =0.95 for BT474 and 0.99 for all other cell lines (ii) 
Calculated photons per cell per second for each cell line.  
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In vivo bioluminescent imaging to monitor subcutaneous tumour growth  
Subcutaneous tumours were established in the HCC1954 and MDA-MB-231 groups (total of 4 
tumours and 3 tumours per group respectively) and monitored by BLI and bi-dimensional 
calliper measurements as described (4.4). By day 14, bioluminescence signalled successful 
tumour establishment, which predated calliper measurements of tumour volume (figure 5-2 A 
and B). At day 56 the SKBRR3, HCC1143 and BT474 cell lines failed to establish subcutaneous 
tumours monitored by both palpation or bioluminescence and mice were culled.  
 
 
Figure 5-2 Monitoring subcutaneous tumour growth and bioluminescence in vivo 
Data from mice bearing subcutaneous tumours established from Luc+ HCC1954 and MDA-MB-
231 cells.  Tumour growth was monitored by weekly bioluminescent imaging and calliper 
measurements (n=3 (HCC1954) or 4 (MDA-MB-231) tumours).  
A. Sequential bioluminescence.  Mean flux (photons per second) and SEM for each group are 
shown. Tumours were evaluable using bioluminescence by day 14 and further increase in total 
flux over time was observed in both groups. Technical failure on day 28 meant that final 
bioluminescence could not be performed prior to mouse cull (severity endpoint).   
B. Tumour volume was calculated from bi-dimensional calliper measurements (mm) using the 
formula Volume=((length*width)2)/2). Mean volume (mm3) and SEM for each cell line group 




 In vivo bioluminescent imaging to monitor growth of metastases  5.2.2
The in vivo ability of Luc+ cell lines to establish lung metastases was evaluated using the HER2+ 
(HCC1954, SKBR3 and BT474) and HER2-negative (MDA-MB-231 and HCC1143) cell lines. One 
million Luc+ cells were intravenous injected into CD-1 Foxn1-/- Nude mice, 3 mice per cell line 
group on day 0. BLI was performed on day 0 and weekly thereafter until an experimental 
endpoint determined by severity limit. 
Metastases were successfully established in all mice in the Luc+ HCC1954 and MDA-MB-231 
cohorts (Figure 5.4). The day 0 images confirmed cell arrest in the lungs. Although the in vitro 
cell flux was five times greater in the HCC1954 cell line compared to the MDA-MB-231 cell line, 
the day 0 lung total flux did not demonstrate the same magnitude of difference. Consistent 
with the images, the measured flux in both groups initially rapidly declines from day 0, as cells 
are cleared from the lung and increasing thereafter as metastases are established from those 
cells that stay resident in the lung. This is most marked in the MDA-MB-231, potentially 
reflecting the faster basal growth rate observed in tissue culture for this cell line compared to 
the HCC1954 cell (MDA-MB-231 doubling  time approximately three times that of HCC1954, 
1.34 vs. 3.6 days). In both groups concerns over mouse weight and health necessitated organ 
harvest by day 56. 
In the SKBRR3, HCC1143 or BT474 groups the day 0 images confirmed cell arrest in the lungs, 
however there was no subsequent BLI signal that mice had established metastases and mice 
were culled at day 82. 
 Histological confirmation of lung metastases 5.2.3
Metastases were confirmed ex vivo in H&E stained lung cross sections in all mice from 
HCC1954 and MDA-MD-231 groups (Figure 4.5). MDA-MB-231 tumour bearing-hosts had 
established metastases occupying mean 7% (SEM 0.02) lung cross sectional area, 0.74 
metastases present per mm2 lung parenchyma.  In the HCC1954 group metastases covered 3% 
(SEM 0.01) of the lung cross sectional area, 0.24 metastases per mm2 lung parenchyma. This 
confirms the greater efficiency of in vivo lung colonisation for the MDA-MB-231 cell line than 




Figure 5-3 Longitudinal bioluminescence monitoring of lung metastases established following intravenous 
HCC1954 and MDA-MB-231 Luc+ cell line injection 
A. (i) Representative whole mouse BLI on day of intravenous injection with the HCC1954 and 
MDA-MB-231 cell lines (day 0).  Lung regions of interest (ROI) are delineated by red box. The 
day 0 image provides a visual confirmation that injected cells arrest in the lungs. (ii) 
Bioluminescent images showing lung areas from two mice intravenously injected with HCC1954 
and MDA-MB-231 cell lines respectively. Bioluminescence declines from day 0 injection to a 
minimum at day 7-14 as cells are cleared from the lung that have not seeded as metastases. 
Bioluminescence incrementally increases thereafter as tumours are established.  
B. Lung ROI were designated for each bioluminescent image over the experimental time course 
and quantified as total flux (photons per second, p/s) using Living Image® software (Xenogen). 
(i) Total flux (mean and SEM for mice scanned at day 0 following tail vein injection. (ii) Mice 
were scanned from day 7 onwards and quantification of these images used the same ROI size 
across all mice at all-time points. The mean and SEM for mice in each of HCC1954 and MDA-
MB-231 groups are shown (n=3 per group). Consistent with the images, flux rapidly declines 




Figure 5-4 Histological verification of lung metastasis in HCC1954 and MDA-MB-231 models 
Histological evaluation of the lung sections confirmed presence of metastases in all HCC1954 
and MDA-MB-231 injected mice. Representative images (lung cross section (3μm) are shown. 
A. Low power view demonstrating multiple metastases (arrows) within the lung H&E cross 
section, HCC1954 model. Inset shows magnification of a single metastatic area within the 
cross-section (box). B. Low power view demonstrating multiple metastases (arrows) within the 
lung H&E cross section, MDA-MB-231 model.  Inset shows magnification of a single metastatic 
area within the cross-section.  
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C. Metastatic area expressed as percentage of lung parenchyma area. Mean and SEM for 
HCC1954 and MDA-MB-231 cell lines.  
 HER2 molecular imaging of in vivo models 5.3
Based on the preceding bioluminescence and histology data, the HER2+ cell line, HCC1954, and 
the HER2-negative cell line, MDA-MB-231, with constitutive lentiviral delivered luciferase 
expression were selected for use in these experiments. Cell lines were confirmed to be 
mycoplasma negative and maintained under blasticidin selection prior to tail vein injection. 
The xenograft models were maintained in the Rayne BSU but decommissioning of the IVIS® 
machine on that site precluded BLI confirmation of metastasis formation prior to SPECT-CT 
using the HER2 targeting 111In DOTA- DARPin for these cohorts. 
 Cohort 1 model preparation 5.3.1
An initial cohort of eight mice were taken through to SPECT-CT imaging and bio-distribution, 4 
following tail vein injection of Luc+ HCC1954 cell line, 3 following tail vein injection of 
Luc+MDA-MB-231 cell line and 1 naïve control. Day 0 injections took place with a view to 
scanning at day 33 post-injection.  This time point was selected based on the preceding IVIS 
cohort and it was intended to balance achieving reasonable disease burden whilst minimising 
respiratory compromise that could compromise anaesthesia for the duration of SPECT-CT 
imaging.  
Day 0 tail vein injection of CD-1 Foxn1-/- Nude mice with Luc+ MDA-MB-231 cell line took 
place without incident; 3 injected mice progressing to scheduled imaging at day 33 (M1, M2 
and M3).  Two HCC1954 injected mice became immediately unwell following cell injection and 
third mouse experienced respiratory arrest within minutes of injection. To ensure adequate 
models for the scheduled imaging session three further mice were injected 3 days later by a 
different operator.  Unfortunately injections were again poorly tolerated resulting in a further 
respiratory arrest and mouse death.  To address this Fresh HCC1954 cell stocks were recovered 
from liquid nitrogen and passaged three times prior to tail vein injection in a further two mice, 
2 million cells in 100μl in view of the 20 day interval to scheduled imaging without incident.  In 
total 4 mice who received HCC1954 tail vein injections were imaged at day 33 (H1), day 30 (H2) 




 SPECT-CT imaging  5.3.2
The mouse cohort was imaged over two days. 111In DOTA-DARPin tracer was freshly prepared 
for injection on both days by an experienced radiochemist (Appendix 4). Imaging was 
performed as described in the methods and took place without incident in seven of the eight 
mice. Mouse M2 died approximately 30 minutes post tracer injection. This may have been due 
to a greater disease burden. To ensure a delayed HER2 imaging signal was not missed, one 
mouse (H3) was allowed to recover and a later acquisition was performed the following day, at 
19 hours. Organs were harvested for tracer bio-distribution on completion of imaging in 
accordance with the methods. 
 Establishing a suitable time point for scan acquisition 5.3.2.1
With the aim of establishing a suitable time point for animal imaging following tracer injection, 
serial SPECT acquisitions were performed in two mice (H1 and H2) successfully injected with 
the HCC1954 cell line.  H1 underwent serial imaging with 6 acquisitions over 3 hours prior to 
cull and organ harvest for bio-distribution (60 seconds per frame for each SPECT acquisition, 
total 30 minutes per scan) commencing immediately following tracer injection.  However 
inspection of the thoracic blood pool (heart and descending aorta) suggested very rapid 
elimination of tracer from the circulation (Figure 4-1). Metastasis could not be visualised 
within the lungs at any time point on the serial images 
A second mouse, H2, underwent two early acquisitions at 0-30 and 30-60 minutes and was 
allowed to recover prior to delayed acquisition at 19 hours following tracer injection (SPECT 
scans 60 seconds per frame, total 30 minutes per scan).  Rapid tracer clearance from the blood 
pool at the early 30-60 minute time point was confirmed. Based on these data, the 30-60 
minute time point was determined to be a practical time point for SPECT acquisition and was 
adopted with all subsequent mice. However, tumour could not be visualised within the lungs 
at any time point on the acquired images 
 SPECT metastases evaluation 5.3.2.2





Figure 5-5 Serial SPECT images to establish planned scan time post tracer injection 
 
Sequential SPECT acquisitions were performed in the first scanned HCC1954 mouse (H1, day 33 
Luc+ cell line post-injection) in order to establish a suitable time frame for animal imaging 
following tracer injection. 
A. Six acquisitions were performed over 3 hours (60 seconds per frame) following tracer 
injection. Maximum Intensity projections (images shown) show rapid accumulation and 
retention of tracer within the kidneys (boxed) and a lesser degree of accumulation within the 
liver (blue arrow).   For the purposes of the figure colour scales have been normalised to 
facilitate scan comparison, however lung metastases were not visible in the thorax (red arrow) 
at any time-point on individual image evaluation. Later histological evaluation of fixed tissue 
confirmed presence of lung metastases in this mouse.  
B.  The same mouse, sequential sagittal views cropped to highlight cardiac area (red box). 
Tracer signal is most prominently present within this blood pool on the 0-30 minute scan and 
56 
 
very rapidly clears thereafter. Asterisk indicates location of mouse monitoring pad which has 
been removed from the images for scan clarity.  
 Biodistribution of 111In DOTA-DARPin tracer in tumour-bearing hosts 5.3.3
Organ biodistribution was calculated using the method described (Chapter 4.5.4). 
Unfortunately using this method the calculated mouse injected volume was observed to 
consistently exceed the known total injected volume, for example the calculated volume in 
harvested organs from mouse H1 was 85.6µl, yet the known injected volume (whole mouse 
including the tail and gauze used to compress the injection site) was 82µl (calculated from pre- 
and post-injection syringe weight). The cause of this was unclear but as standards were 
prepared on both of the scanning days by an experienced radiopharmacist it was thought 
unlikely to be due to error in standard preparation.  
The activity in the whole mouse prior to dissection, residual carcass activity post dissection, 
and syringe and gauze activity post injection had been measured using the well counter 
(Capintec, Pennsylvania) on the day of scanning. Therefore these measurements were used to 
calculate the harvested organ and the carcass activity as a percentage of the total injected 
activity. The injection volumes delivered to the whole mouse, harvested organs and carcass 
could then be estimated and the total injection volume delivered to the mouse body derived.  
Using this method the calculated % injected dose per gram for all mice in cohort 1 is shown in 
Table 5.1 below and graphically in Figure 5-6. The low kidney % injected dose per gram seen in 
mouse H1 can be explained by the relatively higher kidney weight (0.897 grams) in this animal, 
% injected dose being comparable across the group. Consistent with the visual images no 
statistically significant difference in lung biodistribution was present between HCC1954 and 
naïve or HCC1954 and MDA-MB-231 groups (p=0.52 and p=0.83 respectively, independent 





Cell line Lungs Liver Spleen Kidney Bowel Heart 
HCC1954 
H1 1.99 11.34 3.02 55.52 0.89 0.64 
H2 0.59 8.78 2.65 187.90 0.23 0.24 
H3 2.00 10.45 1.66 169.58 0.31 0.69 
H4 8.87 19.13 2.15 247.64 0.48 1.12 
Mean 3.36 12.42 2.37 165.16 0.48 0.67 
SD 3.73 4.60 0.59 80.33 0.29 0.36 
SEM 1.87 2.30 0.30 40.17 0.15 0.18 
MDA-
MB-231 
M1 2.66 10.94 5.38 133.62 0.01 0.23 
M2 2.47 9.05 1.70 124.10 0.98 1.73 
M3 2.20 10.41 3.86 158.92 0.82 1.66 
Mean 2.44 10.13 3.65 138.88 0.60 1.21 
SD 0.23 0.98 1.85 18.00 0.52 0.85 
SEM 0.13 0.56 1.07 10.39 0.30 0.49 
Naive N1 0.28 11.39 2.61 194.41 1.68 1.22 
 
Table 5-1 Cohort 1 
111
In DOTA-DARPin biodistribution 
Table summarising cohort 1, 111In DOTA-DARPin organ biodistribution. No clear relationship 





Figure 5-6 Cohort 1 
111
In-DOTA-DARPin biodistribution.  
Organ biodistribution following 111In-DOTA-DARPin was calculated for all mice in cohort 1 (n=4 
in the HCC1954 metastasis group, n=3 in the MDA-MB-231 metastasis group and a single naïve 
control mouse). In the HCC1954 group, organs were harvested at day 33 (H1), day 30 (H2), day 
20 (H3 and H4) after intravenous cell line injection.  In the MDA-MB-231 lung metastasis group 
organ harvest took place at day 33 (n=3) after intravenous cell line injection.  
A. 111In-DOTA-DARPin biodistribution for evaluated organs. The mean and SEM are shown for 
mice in the HCC1954 and MDA-MB-231 metastasis groups.  
B. Comparison of lung biodistribution across the 3 groups. Mean and SEM shown for mice in 
the HCC1954 and MDA-MB-231 metastasis groups. No statistically significant difference in lung 
biodistribution was present between HCC1954 and naïve, or HCC1954 and MDA-MB-231 
tumour-bearing hosts (p=0.52 and p=0.83 respectively, independent samples t  test).  
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 Histological verification of tumour burden 5.3.4
Examination of H&E lung cross-sections confirmed presence of lung metastases in four mice in 
cohort 1 (n=7). In the HCC1954 tumour-bearing group, multiple clear metastases were 
demonstrated in mice H1 and H2, and HER2 positivity of these metastases was confirmed 
using HER2 immunohistochemistry (Figure 5-7 A). Two mice in the MDA-MB-231 tumour-
bearing group (n=3) had HER2 negative lung metastases at histology.  
Comparison of confirmed metastatic burden with 111In DOTA-DARPin lung biodistribution fails 





Figure 5-7 HER2 immunohistochemistry to confirm presence of metastases in lung section 
Lungs from mice in cohort 1 were harvested for histological verification of metastasis at 
completion of 111In DOTA-DARPin SPECT imaging. In the HCC1954 tumour-bearing group, lungs 
were harvested at day 33 (H1), day 30 (H2) or day 20 (H3 and H4) after intravenous injection.  
In the MDA-MB-231 tumour-bearing group, organ harvest took place at day 33 (n=3) after 
injection. Following radioactivity counting for organ biodistribution, specimens were processed 
for histological evaluation. Metastases were confirmed in two mice in the HCC1954 group and 
two mice in the MDA-MB-231 group.  
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A. Immunohistochemistry confirmed HER2 positive lung metastases (brown circumferential 
membrane staining) in the HCC1954 group only. 
(i)  Mouse H1. Low power view (4x, scale 1mm) lung cross-section demonstrating at least 4 
Her2+ metastatic tumours, boxed to highlight.  A portion of the largest demarcated metastasis 
measuring 3.33mm, is shown at 40x magnification (scale bar). (ii) Mouse H2. Low power view 
(4x, scale 1mm) lung cross section demonstrating at least 5 HER2 positive metastases (boxed) 
in mouse H2. The largest demarcated metastasis measuring 3.33mm, is shown at 40x 
magnification 
B. Table summarising lung biodistribution following 111In DOTA-DARPin and presence of 
histology confirmed metastases. No relationship between tracer biodistribution and HER2 
positive metastatic burden is apparent from this cohort.  
 In vitro 111In DOTA-DARPin cell binding 5.4
To understand the failure of 111In DOTA-DARPin to detect metastases established using the 
HCC1954 cell line, a tracer-cell pellet binding experiment was performed to evaluate the 
minimum cell number that can be visualised using the SPECT equipment in vitro according to 
the methods (4.6.1). 
Tracer binding to the HCC1954 cell line was confirmed and high correlation was observed 
between HCC1954 cell pellet size and cell activity (Figure 5.8) (r2=0.965). In contrast, the HER2-
negative MDA-MB-231 cell line could not be visualised even at pellet size of 5 million cells and 
no activity was present.  The minimum number of HCC1954 cells visualised using SPECT 
imaging was 500,000 cells. Taken together these data indicate that a metastatic tumour below 
this threshold may potentially explain the failure to visualise the confirmed lung metastases in 
mice H1 and H2. The cell number contained within each metastasis can be approximated by 
counting the number of nuclei with in the tumour axial directions and applying the volume 
formula ((length x width)2)/2 to give an estimate of total cell number. Using this method the 
largest demarcated metastasis in mouse H2 (Figure 5.7Aii) might contain as few as 145,800 








DOTA-DARPin cell pellet binding 
To determine the minimum cell number detectable by SPECT-CT imaging, serial dilutions of 
HCC1954 and MDA-MB-231 cells were incubated in triplicate for 30 minutes at 37˚C with 111In 
DOTA-DARPin tracer.  SPECT-CT images were obtained for the washed cell pellets prior to 
gamma counting to quantify % tracer binding relative to 10 nanomolar incubation standard. 
A. SPECT-CT images of MDA-MB-231 and HCC1954 cell pellets following incubation with 111In 
DOTA-DARPin. Image of the three replicates from the top and side view through central pellet 
for each pellet size are shown. Only the HER2+ HCC1954 cell line could be visualised at a 
minimum pellet size of 500,000 cells.  
B. Graphical representation of cell pellet activity for the two cell lines.  The results represent the 
mean counts per minute and SEM, expressed as a percentage of the incubation standard, three 




 Cohort 2 model preparation 5.5
To further evaluate in vivo tracer performance in tumours established using the HER+ HCC1954 
cell line, a second cohort of 8 mice were prepared for SPECT-CT and biodistribution. Based on 
the experience with the first cohort, and data from the in vitro cell binding experiment, 
scanning was scheduled at day 46 following cell line injection with the intention of mitigating 
potential impact of inadequate metastasis formation on tracer performance. A mouse bearing 
a subcutaneous tumour (D1) and a naïve mouse provided positive and negative controls for 
the imaging.  
Six mice were intravenously injected with 1 million HCC1954 cells on day 0. One mouse 
experienced respiratory arrest within minutes of injection, however five IV injected mice were 
suitable for SPECT-CT imaging and biodistribution at the planned time point (mice H5-9). 
Tumour in positive control mouse D1 was allowed to reach maximum size permitted by the 
animal licence and measured 12x8mm on day of imaging (day 46).  
 111In DOTA-DARPin SPECT-CT imaging and biodistribution 5.5.1
 111In DOTA-DARPin Imaging in Cohort 2 5.5.1.1
SPECT-CT acquisition at 30-60 minutes following 111In-DOTA-DARPin failed to visualise the 
subcutaneous HCC1954 tumour (Figure 5.10 Ai) despite its large size (Tumour volume 
4608mm3, ex vivo weight 500mg on day of imaging). Acquisitions from mice H5, 6 and 7 failed 
to visualise metastases but showed early renal retention of tracer (images not shown, similar 
to Figure 5.5).  
 
Biodistribution data from the second cohort confirmed the previously observed renal activity, 
but no signal was observed with the tumour or lung. Combined biodistribution from cohorts 1 
& 2 showed no statistically significant difference in lung biodistribution between groups (p = 
0.525, one-way ANOVA).  
 
H&E lungs sections failed to confirm presence of metastases in mice H5, H6 & H7, despite the 
longer interval of 46 days from intravenous cell line injection to day of cull. To exclude the 
possibility that failure to establish a metastatic burden may be biasing the lung biodistribution, 
the HCC1954 group from combined cohorts 1 and 2 was split according to histological 
verification of metastases (yes/no) and differences in lung biodistribution re-evaluated. Once 
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again no statistically significant difference in lung biodistribution was present between groups 







In-DOTA- DARPin biodistribution from mice in cohorts 1 and 2 
A. 111In DOTA-DARPin biodistribution for evaluated organs and excised subcutaneous tumour; 
combined data from lung metastasis and control mice in cohorts 1 and 2. The HCC1954 injected 
mice have been separated into those with (H1 and H2) and without (H3-H7) histologically 
confirmed metastases. Biodistribution of mice in the HCC1954 groups was at day 33 (H1), 
day30 (H2), day 20 (H3 and H4) and day 46 (H5, 6 and 7) after intravenous cell line injection.  
Biodistribution of mice in the MDA-MB-231 group is at day 33 (n=3) after intravenous cell line 
injection. Naïve mice (n=2) provide a non-metastatic control. Organ biodistribution, mean and 
SEM are shown for the four mouse groups.  
B. Comparison of lung biodistribution, mean and SEM shown for mice in HCC1954 with and 
without metastases, MDA-MB-231 and control groups. No statistically significant difference in 
lung biodistribution was present between groups (p = 0.51, one-way ANOVA). 
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 In vivo comparison of 111In-DOTA-DARPin and 111In-CHX-A”-DTPA-trastuzumab 5.5.2
tracer performance 
Contemporaneous with our experiments, mice bearing subcutaneous HCC1954 tumours had 
been prepared by a colleague (Dr. Florian Kampermeir, Imaging Sciences) with a view to 
SPECT-CT evaluation of HER2+ tumours using 111In -CHX-A”-DTPA-trastuzumab. Tumours had 
been established by injection of 3 million cells injected day 0, and measured 4x4mm (T1) and 
5x5mm (T2) on day of tracer injection. SPECT imaging performed at 24 hours (both mice) and 
72 hours (T1 only) following tracer injection (Figure 5.10 Ai and ii) clearly demonstrates 
tumours in both mice in contrast to the images from the 111In-DOTA-DARPin imaged mouse 
(D1).  The ex vivo 111In -CHX-A”-DTPA-trastuzumab biodistribution supports the tumour 
visualisation seen on the SPECT images (Figure 5.11). T2 was culled at 24 hours following tracer 
injection and relatively higher splenic activity is consistent with expected antibody 
biodistribution at this early time point following tracer injection (116, 117). 
Excised tumours from mice D1, T1 and T2 weighed 500.0mg, 108.6mg and 60.0mg 
respectively. As expected H&E sections demonstrated central necrosis was more marked 
within the larger D1 tumour, however HER2 positivity was confirmed in all three tumours 
(Figure 5.10B).  
Given the superior imaging performance of 111In-CHX-A”-DTPA-trastuzumab observed with 
mice bearing subcutaneous HCC1954 tumours, the two remaining HCC1954 tail vein injected 
mice from cohort 2 (H8 and H9) were imaged with this tracer.  SPECT acquisitions performed at 
24 and 72 hours following tracer injection (day 50 following cell line injection) failed to 
visualise lung metastases in either mouse (images not shown) and biodistribution similarly 
provides no lung activity signal compared to mice T1 and T2 with subcutaneous tumours 
(Figure 5.11). However despite the 50 day interval from HCC1954 injection, no metastases 
were identified by subsequent lung histology SPECT images and therefore failure to visualise 
metastasis cannot be attributed to in vivo tracer performance. It is unclear why  lung 
metastases could not be established in this tail vein injected cohort but colocation of BLI 
imaging to track tumour burden prior to SPECT scanning and organ harvest would be desirable 
prior to  any further evaluation of the 111In-CHX-A”-DTPA-trastuzumab tracer in metastatic 






Figure 5-10 Subcutaneous model 
111
In DOTA-DARPin and 
111
In -CHX-A”-DTPA-trastuzumab tracer comparison  
In vivo imaging performance of 111In DOTA-DARPin and 111In-CHX-A”-DTPA-trastuzumab tracer 
performance was compared in mice bearing HCC1954 subcutaneous tumours. Mouse D1 
underwent SPECT-CT imaging 30 minutes following injection 111In DOTA-DARPin (46 days after 
injection of 1 million cells, excised tumour weight 500mg).  111In-CHX-A”-DTPA-trastuzumab 
imaged mice, T1 and T2, underwent SPECT-CT imaging at 24 hours following tracer 
administration, 23 days after injection of 3 million cells. Imaging was repeated in mouse T1 at 
72 hours.  Excised tumours weighed 108.6mg and 60mg respectively for mouse T1 and T2.  
A. SPECT-CT Maximum intensity projection views.  (i) 111In DOTA-DARPin SPECT image 
acquisition. Renal excretion of tracer is clearly visualised within kidney (yellow arrow) and 
bladder (red arrow) but the large palpable tumour (blue arrow) cannot be discerned. (ii) 111In -
CHX-A”-DTPA-trastuzumab SPECT images clearly visualise the palpable subcutaneous tumours 
(yellow boxes).   
B. HER2 immunohistochemistry confirming presence of HER2+ tumour cells in both the 111In 




Figure 5-11  
111
In -CHX-A”-DTPA-trastuzumab organ biodistribution 
Biodistribution for 111In-CHX-A”-DTPA-trastuzumab imaged mice. Mice H8 and H9 underwent 
SPECT imaging at day 50 following intravenous HCC1954 cell line injection; T1 and T2 
underwent SPECT after establishment of HCC1954 subcutaneous tumours (volumes 128 and 
312mm3 respectively). Organ harvest took place immediately following final SPECT image 
acquisition at 72 hours (H8, H9, T1) and 24 hours (T2).  
Lung biodistribution does not discernibly differ between the subcutaneous and tail vein models 
(organ harvest at 72 hours mice H8, H9, T1) and is consistent with the absence of histologically 
verified lung metastasis in any animal. Relatively high biodistribution in histologically verified 
subcutaneous tumours is consistent with the SPECT image acquisitions which demonstrate 




 In vitro 111In-CHX-A”-DTPA-trastuzumab cell binding 5.6
In view of the superior in vivo performance of 111In-CHX-A”-DTPA-trastuzumab for 
subcutaneous tumour imaging, the cell pellet imaging was repeated using cells incubated with 
this tracer to evaluate the minimum cell number that can be visualised using SPECT in vitro. 
111In-CHX-A”-DTPA-trastuzumab binding to the HCC1954 cell line was confirmed and activity 
correlated highly with cell number (r2=0.996). The minimum number of cells that could be 
visualised was 100,000, in contrast to 500,000 using 111In DOTA-DARPin. MDA-MB-231 cells 
could not be visualised even at pellet size of 5 million cells and no activity was present (Figure 







In-CHX-A"-DTPA-trastuzumab cell pellet binding  
To determine the minimal HER2+ cell number detectable by SPECT imaging serial dilutions of  
HCC1954 cells were incubated in triplicate with 111In-CHX-A”-DTPA-trastuzumab for 30 minutes 
at 37˚C. SPECT-CT images were obtained for washed cell pellets prior to gamma counting to 
quantify % tracer binding relative to the 10 nanomolar incubation standard. MDA-MB-231 was 
used as the HER2-negative control.  
A. SPECT-CT images of cell pellets following incubation with 111In-CHX-A”-DTPA-trastuzumab. 
Maximum Intensity Projection (top) views of the three replicates and sagittal view (side) 
through central pellet for each pellet size are shown. HER2+ HCC1954 cell pellets are clearly 
visualised, minimum cell number 1,000,000 cells. No signal is present in MDA-MB-231 cell 
pellets. 
B. Graphical representation of cell pellet activity.  The results represent the mean counts per 
minute and SEM, expressed as a percentage of the incubation standard, three replicates per 




 In vivo pellet experiment 5.7
In view of discrepancy between the in vitro cell pellets images and the in vivo results, an 
experiment to confirm that cells incubated with tracer in vitro could be then visualised in vivo 
was performed.  
A single mouse was injected with cell suspensions that had been pre-incubated with either 
111In-CHX-A”-DTPA-trastuzumab or 111In DOTA-DARPin. For each tracer 5 million cells were 
incubated with tracer at 10nM concentration for 30 minutes at 37˚C, as previously described 
(4.6.1). Following incubation cells were washed twice with sterile PBS and re-suspended in 
250μl sterile PBS for injection.  Measured activity was 100KBq for both preparations.  
2 million cells (100 μl) of 111In-CHX-A”-DTPA-trastuzumab and 111In DOTA-DARPin cell 
preparations, and 0.5 million cells (25μl) of the 111In-CHX-A”-DTPA-trastuzumab cell 
preparation were injected at separate subcutaneous locations in a single mouse prior to 
SPECT-CT image acquisition. All pellets could be visualised (Figure 5.13). Taken together this 
suggests that failure of delivery of tracer to tumours may have contributed to the poor in vivo 
performance of 111In G3 DOTA-DARPin.  
To ensure that tracer could be delivered to tumours in vivo, the vascularity of the excised 
subcutaneous tumours from the second mouse cohort was quantified. These tumours were 
previously imaged using 111In-CHX-A”-DTPA-trastuzumab (mouse T1 and T2) and 111In G3 
DOTA-DARPin (mouse D1). Despite the disparity in tumour size (ex vivo weight T1 = 108mg, T2 
=60mg D1=500mg) no statistically significant difference in the vessel count was present 
between tumours (Figure 14). Taken together it is more likely that the rapid clearance of 111In 
G3 DOTA-DARPin tracer from the circulation, rather than differences in intra-tumoral tracer 






Figure 5-13  in vivo cell pellet imaging 
SPECT acquisition from a single mouse injected with HCC 1954 cell pellets incubated for 30 
minutes with 111In DOTA-DARPin (2 million cells, blue box) or 111In-CHX-A”-DTPA-trastuzumab (2 
million yellow box, 0.5 million orange box). Cell pellets are clearly present on SPECT acquisition 
using both tracers. This suggests that failure to image the tumour using the 111In DOTA-DARPin 





Figure 5-14 Subcutaneous tumour vascularity 
A. CD31 immunohistochemistry was performed on 3μm sections from HCC1954 subcutaneous 
tumours. Vascular endothelium stains brown. (i) Subcutaneous tumour section 0.3mm2 grid 
resected following SPECT imaging with 111In-CHX-A”-DTPA-trastuzumab (mouse T1).  (ii) 
Subcutaneous tumour section 0.3mm2 grids resected following SPECT imaging with 111In DOTA-
DARPin (mouse D1).   
B. The most intense vascular areas (hotspots) were selected subjectively from each tumour 
section and vessel count (Mean and SEM) quantified by counting the number of vessels present 
within three 0.3mm2 grids placed within these areas. There was no statistically significant 








The data presented in this chapter demonstrates that 111In-DOTA-DARPin binds to HER2+ 
HCC1954 cells in vitro and SPECT imaging permits discrimination between HCC1954 and HER2-
negative MDA-MB-231 cell pellets. However, in contrast to radiolabelled trastuzumab, this 
tracer failed to discriminate between HER2+ and HER2-negative tumour models in vivo. The 
(18)F-Z(HER2)(:342)-Affibody has been reported to successfully targeted HER2+ lesions in the 
lung permitting detection of metastases as early as 9 weeks following cell line injection (132). 
It is possible that the small size of pulmonary metastases in our metastatic model accounts for 
failure of the DARPin tracer to visualise lung lesions.  However small target lesion size does not 
explain the failure to visualise the large subcutaneous control tumour with confirmed HER2 
expression and vascularisation ex vivo, particularly given the tracer binding that was 
demonstrated to the HCC1954 cell line in vitro. In the context of previously reported high 
tumour-to-blood and tumour-to-normal tissue ratios permitting same day 111In-DOTA-DARPin 
SPECT imaging of subcutaneous xenografts (BT474 Her2+ breast cell line) (141) the poor in vivo 
performance of this tracer was unexpected. The SPECT images indicated very rapid tracer 
clearance from the blood pool and accumulation of the radioactivity in the kidney on the early 
sequential imaging acquisitions. This is a well-recognised challenge for proteins with a 
molecular weight below 60 kDa (126, 143). Specifically a short half-life of less than 3 minutes 
has previously been reported with the G3 DARPin (4). Therefore rapid clearance from the 
circulation, precluding tracer binding to target tumour sites is a plausible explanation for the 
discrepancy between the observed in vitro and in vivo performance. 
In the current experiments 111In DOTA-DARPin protein was from the same preparation used in 
the experiments performed at UCL (provided courtesy of Dr R Goldstein), radiolabelling was 
performed by the same radiopharmacist and the same 111In DOTA-DARPin tracer dose was 
injected for scanning. Therefore differences in tracer preparation are unlikely to account for 
the results observed.  SPECT imaging was able to discriminate HCC1954 cell pellets incubated 
with 111In DOTA-DARPin and therefore intrinsic differences between the BT474 and HCC1954 
cell lines are also unlikely to explain the tracer failure in vivo. The UCL group used female 
BALB/c mice (Charles River) or SCID-beige mice (Charles River) and as is possible that factors 
related to biology of difference mouse strains impact on tracer performance. However our bio-
distribution data failed to provide a signal of in vivo targeting ability and the high renal bio-
distribution is comparable to that reported by the UCL group (232.0±24.1 %ID/g), mirroring the 
very high renal uptake demonstrated on their  SPECT image acquisitions (141). 
In view of the previously reported efficacy of this tracer in discriminating HER2+ tumours 
established from BT474 breast cancer cell line, a direct comparison between HCC1954 and 
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BT474 subcutaneous xenograft models and a HER-negative control would be recommended as 
a minimum before progressing clinical applications of this tracer. The reason for failure of the 
HCC1954 cell line to establish metastasis in the second tail vein injected cohort is unclear and 
it is regrettable that it was not possible for us to use BLI to indicate presence of lung 
metastases prior to SPECT. Although BLI reflects the number of metabolically active tumour 
cells rather than a volumetric measurement of tumour mass, longitudinal BLI offers the ability 
to efficiently confirm establishment of metastases without animal sacrifice.  Co-location of BLI 
and SPECT imaging facilities within the same BSU would facilitate selection of animals with a 
confirmed metastatic burden permitting more efficient evaluation of tracer performance and 
would be desirable prior to any future work using this or other HER2 targeted tracers in 






 TNPET01 Study set up and methodology 6
 Introduction 6.1
To address the unresolved questions regarding tracer selection, scan acquisition and 
interpretation for response assessment I designed an imaging feasibility study for evaluation of 
early PET response in the TNBC phenotype. To confirm this as an area of unmet need, in 
preparation of the study protocol and funding application, I performed a detailed review of 
over 200 trials listed on clinicaltrials.gov database under the search terms PET, FDG or FLT and 
breast and identified no trials targeted at the TNBC subset.  27 of the 31 listed response 
evaluation trials used only a single tracer in unselected breast cancer (17 trials) or receptor 
positive breast cancer subset (10 trials). The proposed treatment was largely undefined and 
timing of response was variable. Only 4 listed studies evaluated both FLT and FDG tracers, all in 
unselected heterogeneous breast cancer.  
This chapter reports the development of the full study protocol and the methodologies used 
for the imaging research analyses. The design of the PET imaging protocol recognises the 
uncertainties surrounding optimal image acquisition, SUV reporting, and the requirement for 
dynamic evaluation to optimise PET response assessment for future prospective trial design in 
this phenotype. The trial was designed with two parts to include a baseline test-retest 
assessment for each tracer to measure repeatability and assess the confidence with which any 
change in tracer uptake observed during treatment can be interpreted as related to therapy 
within the TNBC population. Included within this chapter is the set-up work completed in 
parallel with protocol writing, including securing funding, regulatory approvals and electronic 
case report form (eCRF) development.  
 Protocol Aims 6.2
The purpose of the trial was to assess the repeatability and utility of PET-CT functional imaging 
using FLT and FDG tracers to predict TNBC tumour response to standard neoadjuvant 
chemotherapy.  
 Primary Objectives 6.2.1
 Part A: To measure PET scan repeatability using FDG and FLT tracers and to determine 
the optimal tracer for response evaluation in part B. 
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 Part B: To evaluate early PET imaging using either FDG or FLT tracer as methods for 
evaluating systemic therapy response in primary triple negative breast cancer with 
respect to MRI response at 3 cycles. 
 Secondary Objectives 6.2.2
 To relate changes in tracer uptake to final clinical and pathological (RCB) response 
 To relate changes in tracer uptake to biopsy derived biomarkers 
 To obtain exploratory data relating to tracer kinetics (i.e. Ki, MRGlucose) 
 To obtain exploratory performance estimates for early PET and early MRI scans at 1 
cycle to predict subsequent clinical and pathological (RCB) response 
 Trial Design 6.3
The study was designed as a single centre randomised phase II trial of FLT and FDG tracers to 
predict systemic therapy response in ER- and HER2- breast cancer compared to standard MRI 
imaging response and biopsy derived biomarkers. The study was designed with two parts 
according to the overview summarised in Figure 6.1. Accrual to Part A has completed and Part 
B recruitment continues. 
In Part A (10 patients) participants underwent two baseline PET-CT scans to measure the 
repeatability of PET scan SUV measurements using FDG and FLT tracers.  Participants 
underwent one PET-CT scan with either FDG or FLT to compare early PET response (day 17±3 
post cycle 1) with standard MRI response at 3 cycles. The protocol mandated criteria for Part A 
to B tracer transition were static scan repeatability of within ±15% and evidence of SUV drop 
of >20% in at least 50% MRI defined responder for either tracer to progress to part A. In the 
event of equivalent results within the limits set for repeatability, the Trial  
Steering Committee (TSG) were required to decide which tracer performed best overall and 
should be taken forward to part B. In the event that neither tracer met the repeatability 
requirement for at least one SUV measure the study would terminate without progression to 
Part B. 
In part B a total of 15 further patients were required to undergo PET-CT imaging, once prior to 
commencing chemotherapy and again at day 14 to 21 post cycle 1 using the single tracer 






Figure 6-1 TNPET-01 study design 
Schematic diagram summarising the TNPET-01 design. For either tracer to be considered for 
Part A to B transition they had to meet protocol mandated SUV repeatability and post-cycle 1 
SUV change criteria.  A single tracer was selected for progression to Part B by the Trial Steering 
Committee following review of the Part A data.  
 
In addition to the PET imaging evaluations, study participation (parts A and B) required 
patients to undergo a research core biopsy performed at three time points (prior to 
chemotherapy, following their day 17±3 PET scan and through the definitive resection 
specimen at the time of surgery) and permitted an optional research blood sample. In part B 
only, an optional early MRI evaluation was included to take place contemporaneously with the 
second PET scan. Due to the sequential use of taxanes and anthracycline chemotherapy in 
standard neoadjuvant chemotherapy, eventual pathological response will be influenced by the 
later chemotherapy cycles of a different class to that reported by an early PET-CT. 
Consequently the selected primary endpoint of the full study is feasibility of early PET-CT to 
determine standard MRI RECIST response after 3 cycles and pathological endpoint will be 
reported as a secondary endpoint. 
 Study population 6.4
Eligible female patients age 18-70 with stage II-III biopsy proven primary ER- (Allred <3) and 
HER2- (IHC 0 or 1+, or IHC 2+ and FISH non-amplified (ratio of Her2 to chromosome 17 of more 
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than 2.0) breast tumours for whom neoadjuvant chemotherapy had been recommended were 
recruited to the study. Pregnant or breast feeding patents and those with diabetes or serious 
medical conditions likely to compromise ability to complete study imaging and translational 
research biopsies were excluded.  
All patients were given a patient information sheet (PIS) approved by the Westminster 
Research and Ethics group (REC reference 11/L0/1492).  Written informed consent was 
obtained prior to any study specific procedures. 
 PET scanning protocol  6.5
 PET-CT scan acquisition 6.5.1
Participants consenting to Part A only were randomised in a 1:1 ratio to receive FDG or FLT 
tracer to balance tumour and patient factors to avoid bias in tracer performance assessment. 
Tracer allocation was stratified for tumour nodal involvement (yes/no) and performed 
centrally via the Institute of Cancer Research Clinical Trials Statistical Unit (ICR-CTSU). All 
patients consenting to Part B were imaged using the progressing FDG or FLT tracer. In all 
patients PET-CT scanning was performed prior to commencing chemotherapy and at day 17±3 
days following the first chemotherapy cycle. In part A only participants underwent a second 
baseline PET-CT scan to assess repeatability a minimum of 24 hours after the first. 
PET imaging was performed using a GE Discovery VCT 64 slice PET-CT scanner prior to the PET 
centre refurbishment (September 2013) or using a GE Discovery 710 64 slice PET-CT scanner 
subsequently.  The injected dose was calculated by measurement of the 18F-FDG activity in 
the syringe before and after the injection. Patient height, weight, fasting time, serum glucose 
prior tracer injection and blood pressure prior to and following the final acquisition were 
recorded. For each scan participants underwent a maximum of 3 CT components for 
attenuation correction and localisation of the dynamic and static scan acquisitions (2 FOV, 
140KVp, mAs=28-42, coll=40mm, pitch=1.375). Static PET scans were reconstructed with 
Iterative VUE Point (OSEM (ordered subset expectation maximisation)-based algorithm; 20 
subsets, 2 iterations, 6.0mm Gaussian filter, matrix 128 x 128). PET scans on the Discovery 710 
scanner were reconstructed with VUE Point FX (time-of-flight incorporated into VUE Point HD); 





 FDG PET  6.5.1.1
Patients received an intravenous injection of maximum 200MBq FDG (MetaTracer FDG 
solution for injection, Siemens PLC, UK) whilst on the scanner couch. A dynamic acquisition 
(1x10, 10x5, 6x10, 3x20, 78x60secs) was performed over the breast primary. The rate of 18F-
FDG is taken uptake and retention varies according to tissue but in malignant tumors the 
accumulation of 18F seldom reaches a plateau by 2 h after injection (144, 145). Therefore to 
address unanswered questions concerning optimal interval following FDG tracer injection for 
image acquisition the dynamic imaging was followed by three static scans over the breast and 
axilla area at 90, 120 and 180 (10 minutes per bed position). Patients were able to get up 
between scan acquisitions and urinate as required. Images were acquired in 3D mode, 1 bed 
position for the dynamic and 1 or 2 bed positions of 10 minute duration for the static views.  
Patients who gave additional consent had a single venous sample taken during the imaging 
studies at 60 minutes to record the radioactivity within the blood following injection of the 
radioactive FDG  IMP. 
 FLT PET 6.5.1.2
FLT was synthesised by the PET centre radio pharmacy (King’s College London/Guys and St 
Thomas’ NHS Foundation Trust, London). Patients received an intravenous injection of 
maximum 200MBq FLT. A dynamic acquisition (1x10, 10x5, 6x10, 3x20, 78x60secs) was 
performed over the breast primary followed by a single static scan over the breast and axilla 
area at 90 minutes. Images were acquired in 3D mode, 1 bed position for the dynamic and 1 or 
2 bed positions of 10 minute duration for the static views. 
Patients who gave consent had 5 venous samples taken during the imaging studies at 5, 10, 30, 
60 and 100 minutes to record the radioactivity within the blood following injection of the 
radioactive FLT IMP and to permit the analysis of metabolites (the glucuronide form of FLT) for 
dynamic scan data correction. These samples were taken via a second venous cannula inserted 
into the opposite arm to the arm into which tracer was administered and linked to a sterile 
cannula tubing. Samples were analysed using a solid phase extraction chromatography 
technique to separate FLT from the FLT glucuronide for dynamic scan interpretation with 
metabolite correction according to previously described methods (146).  
Twenty-four hours after completion of each FLT scan patients were telephoned to document 
any toxicities experienced.  
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 Radiation effective dose 6.5.2
A research ARSAC certificate was obtained for this study. Table 4.2 summarises the radiation 
effective dose for each participant receiving a maximum of three PET-CT scans (Part A) or two 
PET-CT scans (Part B). It was anticipated that the majority of study patients would receive 
therapeutic  adjuvant radiotherapy dose of at least 40-50Gy to the breast or chest wall ± 16Gy 
tumour bed boost that far exceeds the research PET imaging dose.  
 




CT component 4.5mSv * 2mSv 
Total effective dose 
per session 
8.5mSv 8.5mSv 
Part A total effective 
dose (3 sessions) 
25.5mSv 25.5mSv 
Part B total effective 
dose (2 sessions) 
17mSv 17mSv 
 
Table 6-1 Radiation effective dose for study participants 
Radiation effective dose summarised for PET and CT imaging components. *CT dose in the FDG 
groups reflects additional CT acquisitions required in the event participants leave the scanning 
couch between the three static acquisitions at 90, 120 and 180 minutes.  
 PET-CT scan interpretation methods 6.5.3
All scan acquisitions were imported into HERMES workstation (Hermes Medical Solutions, 
Stockholm, Sweden) for research SUV analysis. Suitability of the research scans for Part A and 
B analysis was confirmed through visual inspection of the static scan by an experienced nuclear 
medicine physician (Dr Michael O’Doherty, MD or Dr Sally Barrington, SB). Presence of 
abnormal uptake (where applicable) was defined as uptake not related to expected 
physiological uptake and higher than adjacent normal tissue. In the event that areas of 
previously unknown tumour involvement were identified on the pre-treatment research PET 
scan, a clinical report was issued and the findings were fed back to the clinical team.  Scans 
were subsequently anonymised for research analysis. 
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Static scan evaluation was performed using the HERMES HybridViewer Software version 1.4C. 
All VOIs were defined by a single operator, Jennifer Glendenning (JG). At each scan time point, 
tumour volumes of interest (VOIs) were generated by manually defining a constraint in the 
axial, sagittal and coronal planes around each area of interest. A tumour isocontour was then 
determined within this constraint using a 40% threshold of the maximum uptake to reduce 
operator bias in VOI contouring. Standardised uptake values were evaluated for each tumour 
VOI with (SUL) and without (SUV) lean body mass correction. The calculation methods used 
within the HybridViewer Hermes software are defined as follows 
SUV =A *(W/D) *1000g 
SUL= A * (LBM/D) * 1000g 
where: 
A= Activity Concentration in Bq/cc (calibrated pixel value) 
W=Patient weight in Kg 
H=Patient height in cm 
D=Injected dose in Bq (decay corrected injected dose to time of activity concentration 
measurement)  
LBM= Lean Body Mass in kg; calculated using the formula 1.07*W=148*(W/H2) 
 
The mean and maximum and peak values were recorded for each VOI isocontour structure. 
Mean was defined as the average value of voxels and maximum as the highest voxel value 
within the VOI structure. Peak was defined according to PERCIST criteria as the mean value of 
voxels in the hottest 1 cm2 constrained inside the VOI structure (62). The most widely cited 
parameters in the literature (SUVmax, mean and peak) and the PERCIST recommended 
SULpeak were selected for reporting within in the eCRF.  
 
Exploratory application of PERCIST recommendations for FDG image evaluation was performed 
(62). To minimise radiation exposure to study participants, the FDG static scan was obtained 
using a maximum of two bed positions located over the breast and nodal regions and did not 
encompass sufficient liver for background estimation.  Therefore reference background activity 
was derived on each patient scan using the descending aorta blood pool VOI, defined as a 1 cm 
diameter cylinder extending over 2 cm in the Z axis within the descending aorta at a site away 
from diaphragmatic motion artefacts (62). SULmean and s.d. for each VOI were recorded and 




Background = 2(blood pool SULmean + s.d.) 
 
PMod Biomedical Image Quantification software package version 3.4 (PMOD Technologies Ltd, 
Zurich) was used for quantitative dynamic scan evaluation. The anonymised Dicom PET and CT 
image data was imported from the HERMES workstation and decay corrected within PMOD 
where this had not been performed on the scanner. Tumour volumes of interest (VOI) were 
defined using the 40% isocontour within a manually drawn tumour constraint on a suitable 
late time point frame. The arterial plasma input function was generated from VOIs defined on 
a suitable early frame by placing a 1cm diameter cylindrical volume extending over 2 cm in the 
Z axis within the descending thoracic aorta. VOI and pharmacokinetic analyses were performed 
using the PVIEW PKIN tools of the PMOD Biomedical Image Quantification software package 
(version 3.4, PMOD Technologies LTD, Zurich, Switzerland). For FDG scans, the overall influx 
rate constant (Ki) in min
−1 and the metabolic rate of glucose (MRGlu) in mmol⋅l−1⋅min−1, which 
equals Ki times blood glucose concentration were calculated for each breast tumour VOI using 
non-compartmental (Patlak graphical analysis) and compartmental modeling (FDG two-tissue 
compartment model, FDG 2TCM). In patients with measured blood activity derived from a 
single venous sample acquired at 60 minutes post tracer injection kinetic parameters were also 
calculated by using the manual blood sample to rescale the descending aorta plasma input 
function..  
 Research Tissue Evaluations 6.6
Research tumour tissue was obtained pre and post treatment exposure for correlation with 
change on treatment SUV/SUL (Part A and B) and early MRI response (Part B only). Material 
included surplus tissue from the diagnostic core biopsy, ultrasound guided pre-chemotherapy 
research core, ultrasound guided research core biopsy performed following the day 17 PET-CT 
scan and a research core through the definitive surgical resection specimen. Patients who gave 
consent had an optional research blood sample (20-50 mls) processed into serum, plasma and 
DNA taken contemporaneously with routine pre-chemotherapy blood tests or at a later time 
point according to patient preference. All blood and biopsy material acquired for the purposes 
of the study is being stored in the Human Tissue Authority (HTA) licensed Guys’ and St Thomas’ 
Breast Tissue and Data Bank. The tissue analysis will be completed in two batches by Dr 
Patrycja Gazinska (PG) and Professor Sarah Pinder (SP). 
The planned tissue analysis within the study comprise immunohistochemical assessment of 
apoptosis (activated caspase 3), proliferation (MIB-1, the S-phase specific replication marker -
84 
 
geminin, MCM replication fork licensing factors) and glucose uptake biomarkers (GLUT-1 
receptor). However to permit future work using the tissue resource generated through study 
recruitment documentation was prepared to permit future tumour and blood evaluations. 
Consequently whole tumour genome sequencing techniques and use of specific tests to detect 
copy number change (e.g neu/Her2), mutations (e.g. EGFR and other protein markers), DNA 
methylation status, HER2:HER3 dimer (FRET Efficiency) changes in expression of known and as 
yet unknown oncogenes, tumour suppressor genes and mRNA expression markers of 
proliferation genes, and analysis of blood derivatives for DNA, RNA and protein markers of the 
cancer biology are permitted within the protocol and have regulatory approval.  
 Statistical Plan 6.7
Trial statistical support was provided by Dr Lucy Kilburn and Ms. Holly Tovey (Institute of 
Cancer Research Clinical Trials and Statistics Unit, ICR-CTSU). The design of the statistical 
analysis plan sought to ensure bio-statistical validity and applicability of the generated data to 
future multicentre PET response validation studies within the dual constraints of comparative 
rarity of the TNBC subset and cost which both limit numbers possible in an exploratory PET 
feasibility study. 
 Sample Size and power 6.7.1
The primary objective of TNPET-01 was to assess whether early PET imaging using either tracer 
was associated with standard MRI response. For the tracer progressing to part B, correlation of 
≥85% between SUV change and % change in the sum of the longest diameter of the breast 
cancer lesions using RECIST measurements on breast MRI would indicate SUV response to be a 
good guide to standard MRI response (at 3 cycles). A correlation of 60% or less would be 
considered unreliable. To achieve this required a total of 20 patients for the tracer progressing 
to part B, using a one-sided alpha of 10% and a power of 85%.  
Based on comparable data in non-breast malignancies (147) and feasibility considerations, Part 
A repeatability assessment was planned with 10 patients (5 per tracer) prior to selection of a  
single tracer for progression to part B unless neither tracer met the predefined criteria in 
which case the study would terminate. Part A required tracer repeatability measurements to 
be within ±15% for at least 1 SUV/SUL parameter and SUV/SUL reduction to be at least 20% in 
50% of MRI defined responders to be considered for progression to Part B. In the event that 
both tracers met these repeatability criteria the protocol stipulated that the best overall 
performing tracer was selected for part B. 
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 Statistical analysis methods 6.7.2
The Part A tracer repeatability primary end point analyses were conducted by the ICR-CTSU 
using Stata version 11 according to the pre-specified statistical analysis plan. Briefly, SUVmax, 
SUVmean and SUVpeak and SULpeak measurements determined on scans deemed evaluable 
following visual assessment were considered on a patient-by-patient basis and on a lesion-by-
time point basis. As SUV is known to have log-normal distribution (148) measurements were 
log transformed before analysis. Differences between the two baseline scans were computed 
and the data were displayed using Bland Altman plots, constructed on a lesion-by-time point 
basis and plotted on a log scale (points within ±0.14 indicating that the baseline scan 
measurements at a given time point were within 15% of each other). To take into account 
nesting  of greater than one lesion within some patients repeatability coefficients were 
calculated using a mixed effects model nesting lesion site within patient with the log 
parameter as the dependent variable and fitting models in Stata to estimate the within lesion 
standard deviation from the model.  Repeatability coefficients (RC) were calculated from the 
within-subject variability of the log transformed measurements using the formula ±1.96 x √2 
x within lesion standard deviation and back transformed hence representing one scan 
measurement as a proportion of the other rather than absolute change. Upper and lower RC 
within the range 0.87-1.14 indicates SUV parameters met the predefined 15% criteria. For the 
patient-by-patient analysis, the individual parameters were summarised using the average 
value across lesions and scan-times from the same patient. For the lesion-by-time point 
analysis all individual lesion/time points were analysed.  
The final Part B primary and secondary endpoint analysis will be conducted by the ICR-CTSU on 
completion of full study recruitment. Percent change in SUV parameter on the follow-up day 
17±3 scan and % change in the longest MRI defined tumour dimension will be assessed for 
normality and the appropriate correlation coefficient with a 95% confidence interval 
(Pearson’s correlation coefficient or Spearman’s Rank correlation if non-parametric) 
calculated. Secondary endpoints will be analysed using the relevant summary statistic. 
Additional exploratory analyses included within this thesis and the preliminary Part B primary 
and secondary endpoint analysis (chapters 8 and 9) were performed by JG using SPSS version 
22 statistical software and Excel using the appropriate summary statistic according to the 
statistical plan. Continuous variables have been summarised by mean and standard deviations 
or by median and range according to the skewness of the distribution. Frequencies and 
percentages have been used to summarise categorical data; paired t-test for parametric 
comparison of means or Wilcoxon matched-pairs signed-ranks test for non-parametric data 
comparisons. Correlations were evaluated using Pearson’s correlation coefficient where the 
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assumption of normality holds. The exploratory repeatability analyses provided in the results 
chapters  but not performed by the ICR-CTSU as part of the trial statistical analysis plan were 
calculated using the method described above or for non-nested data by calculating the 95% 
confidence about the mean difference of the log transformed data (149)  
 Supporting work for trial set up  6.8
 Supporting document preparation 6.8.1
In parallel to study protocol preparation, I designed the patient information sheet and 
developed other supporting documentation including the clinical components of the 
Investigator Brochure (IB) and Investigation Medicinal Product Dossier (IMPD) to meet the 
regulatory requirements for clinical trial of investigation medicinal product (CTIMP) 
classification.  
Lay opinion with regard to patient acceptability of the proposed study protocol was sought 
from representatives of the GSTT patient consumer group comprised of current and 
historically treated cancer patients. The committee strongly endorsed the study design 
incorporating novel imaging and serial research tissue.  This feedback and their specific 
recognition of the importance of strategies to improve response evaluation from a patient 
perspective and input into the patient information sheet facilitated progress through the 
ethical review process, REC reference 11/L0/1492. 
A requirement of all Kings Health Partners/Guys and St Thomas’ NHS Foundation Trust (KHP-
GSTFT) sponsored CTIMPs is that data is captured within an eCRF.  I produced design 
specifications for each component of the eCRF content and worked closely with the 
responsible programmer within the Kings Health Partners Clinical Trials Office (KHP-CTO) 
programmer to ensure consistency of the created data fields with source medical record data 
and tested the database to ensure fitness for purpose prior to going live. KHP-CTO data 
extraction for formal analysis by the ICR-CTSU was planned at scheduled analysis time points 
(end of part A and end of part B).  
 Neoadjuvant chemotherapy sequencing for study participants 6.8.2
Future neoadjuvant trials in TNBC are anticipated to address questions of efficacy comparing 
novel agents with the taxane component of standard care. At the time of this protocol design, 
standard sequencing comprised initial anthracycline component regardless of breast cancer 
phenotype. Review of clinical data informing sequence in both neoadjuvant/adjuvant settings 
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indicated enhanced dose delivery, reduced toxicity and pathological response advantage (19, 
150-153) with initial taxane scheduling and beneficial reduction in anthracycline cross-
resistance compared to the reverse in the preclinical setting (154). Furthermore recent 
national and international trial protocols (e.g. neo ALLTO, NSABP-40, I-Spy 2 and SOLD, the 
control arm of the currently recruiting UK randomised phase 3 neoadjuvant study ARTemis and 
the multicentre Neo-tAngo trial) have selected taxane first sequencing in the  standard of care 
arms.                    
Subsequent to data review and with the approval of the breast oncology consultant body I 
updated the South East London Cancer Network (SELCN) systemic guidance to permit taxane 
first sequencing in patients with HER2-ve breast cancer receiving treatment in the neoadjuvant 
setting. This change to the SELCN protocols was formalised following approval by the breast 
tumour working group (Jan 2012), revised prescription proformas approved by pharmacy 
(March 2012) and implemented on electronic (CIS) prescribing platform (May 2012). The 
delivery of taxane first chemotherapy sequencing as standard to study participants ensures a 
dataset reporting PET-CT efficacy evaluation in TNBC following uniform therapeutic exposure. 
 Radiology considerations 6.8.3
The importance of support from the radiology team in terms of RECIST reporting and 
acquisition of research biopsy tissue was recognised as a critical element for the success of the 
study early in the protocol development.  To ensure adequate  resources for their support of 
this and related studies incorporating tissue biomarker endpoints, I successfully sought funding 
to allow purchase of 4 research bio-specimen procurement containers (for storage of research 
tissues in the radiology department and in transit to the Breast Tissue Bank) and towards a 
sonographer advanced practitioner from the London South Clinical Research Network.   
In an effort to develop a non-invasive measure of pCR there is interest in MRI parameters that 
have the potential to predict later response (155). Amongst these, diffusion weighted (DW) 
MRI is an imaging technique where tissue water diffusivity is measured and quantified as the 
Apparent Diffusion Coefficient (ADC) (156). ADC is lower in tumours than normal tissues 
reflecting greater cell density and restriction of water diffusion (157). ADC evaluation increases 
the diagnostic specificity of MRI at staging of breast cancer (158) and quantifiably increases in 
responding disease (157, 159) without compromising RECIST evaluation (160-162). 
Consequently DW-MRI is routinely included in breast assessment at many centres including 
Guy’s and St Thomas’. There is emerging evidence that therapy induced increases in ADC 
predate MRI detectable size change (163) and may be informative from as early as 1 cycle. 
Recognising the potential utility for early MRI with ADC evaluation, the study protocol includes 
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an additional research MRI scan after one cycle of chemotherapy in part B. This  provides a 
unique opportunity to investigate exploratory performance estimates of early ADC which can 
be compared with on treatment PET assessment of proliferation or glucose metabolism, the 
RECIST response and definitive RCB response providing a stronger rationale for incorporation 
of functional imaging in future studies. High temporal resolution DCE MRI protocols evaluate 
tumour microvasculature by permitting pharmacokinetic analysis but currently do not have the 
capability to encompass the whole breast with sufficient spatial resolution to fulfil clinical 
requirements for reporting using the BIRAD lexicon and RECIST response monitoring as well 
(21). This and the additional requirement for a reproducibility DCE MRI at time of the first pre-
treatment MRI to validate the technique mean that exploratory evaluation using DCE MRI 
sequences within this study would mandate further patient attendances for research MRI 
scans at standard and post cycle 1 time points (i.e. a total of 8 MRI scans on separate visits) to 
prevent compromise of clinical scans and evaluation of the PET primary endpoint. In view of 
the additional costs and threat to patient recruitment inherent to the addition of research DCE 
MRIs were not felt to be justified in the TNPET01 PET feasibility study. Consequently DCE 
sequences were not been included in this exploratory study where the primary research focus 
was feasibility of early PET-CT to determine later MRI RECIST response.   
 Funding  6.8.4
I successfully secured funding from the Comprehensive Cancer Imaging Centre CCIC (Part A) 
and the Guys and St Thomas’ Charity (Part B). A prior invited full application to CRUK BIDD 
(November 2011) received supportive reviewers comments but was unsuccessful in its funding 
application.  
 Achieved trial timelines for study set up and opening 6.9
The timeline for completion of the required steps to first patient recruitment is summarised in 
figure 4.2. Non-substantial amendments were required to encompass MHRA mandated 
toxicity assessments (telephone call at 24 hours post FLT PET scan) and specifying that 
randomisation would be performed by the ICR-CTSU rather than by the study sponsor as 
originally planned in the set up phase. The sabbatical taken by the eCRF programmer and the 
time taken for the service level and co-sponsorship agreements contributed to delays to the 




Figure 6-2 Summary of achieved trial time lines in set-up phase  
Key: BCRT Breast Cancer Research Trust, PIS Patient information sheet, IRAS Integrated 
research application service, REC Research Ethics Committee, N/S non substantial, IB 
Investigator Brochure, IMPD Investigational Medicinal Product Dossier, cTIMP clinical trial of 
investigation medicinal product, CRUK Cancer Research UK 
 Study accrual and protocol amendments 6.10
The study opened later than anticipated in August 2012 and the first patient gave consent in 
November 2012.  Based on unit data an accrual rate of at least 12 patients per year was 
anticipated and the initial statistical plan anticipated full trial accrual of 30 patients to 
complete in 24-30 months and progression of both tracers to Part B if repeatability criteria 
were met. Recognising the delays to study opening, inward referral from centres within the 
South East London Cancer Network (SELCN) was sought (presentation to the study to the 
SELCN and to the Queen Elizabeth Hospital and Kings College Hospital MDMs).  Support was 
agreed with the relevant surgical teams for inward referral of eligible and potentially 
interested patients for treatment at GSTT to facilitate accrual. Unfortunately cyclotron failure 
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(Feb/March 2013), PET centre refurbishment (Sept-December 2013) and FLT production failure 
(Feb-July 2014) had a significant impact on recruitment incurring a cumulative delay of 12 
months such that by July 2014, 9 of 11 recruited patients had completed all Part A evaluations. 
Recognising the ongoing radio pharmacy issues thwarting reliable FLT production the decision 
was made to seek REC approval for a substantial protocol amendment permitting repeatability 
evaluation at 9 complete patient datasets and progression of the best performing single tracer 
meeting repeatability criteria through to part B rather than both as had been originally 
planned and approved at study opening. This amendment planned for total number of patients 
scanned using the single tracer to be increased from 15 to 20 for Part B analysis, thus 
tightening the confidence interval for the response assessment data Following REC and MHRA 
approval of this substantial amendment the TSC reviewed the data in October 2014 and the 
first patient was recruited to part B later that month. At the time of writing (June 2016) 13 of 
18 recruited patients have competed all research evaluations and recruitment to Part B 
continues. 
 Conclusions 6.11
The aspiration of improving response evaluations strategies in TNBC with a view to tailoring 
therapeutic decisions to the individual response requires phenotype specific validation of 
imaging biomarkers with reference to relevant clinical outcomes. The study was designed to 
address questions relating to tracer selection, test-re-test repeatability and its relationship to 
therapy induced change for optimisation of imaging response strategy and inform larger scale 
trial design.  
As described in section 6.9 and 6.10 un-anticipated difficulties were encountered in both the 
set up and recruitment phases. Although recruitment to part A has completed; the tempo has 
precluded completion of Part B recruitment within the MD timeframe. Steps taken to mitigate 
the impact of set-up delays and accelerate recruitment through inward referral from centres in 
the network have been frustrated by direct loss of 12 months accrual opportunities resulting 
from the PET centre refurbishment and the FLT IMP production failures. The protocol had been 
originally worded to require replacement of patients in the event of failure of an individual to 
complete of PET imaging at all-time points with the aim of protecting against study completion 
with an incomplete dataset and consequent loss of statistical power. Had this replacement 
requirement not been in place the Part A analyses could potentially have taken place earlier 
when it became clear that FLT production could not be readily reinstated. With hindsight 
omitting the patient replacement strategy for Part A from the outset may have been 
advantageous, but carried the risk of accrual without achieving statistical validity. Recognising 
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the impact of the unresolvable FLT production failures the July 2014 protocol amendment 
successfully permitted Part A evaluation at 9 completed imaging datasets and progression of a 
single tracer to Part B response evaluation reducing the total number of participants from 30 
to 25. At the time of writing 13 of 18 recruited patients have competed all research 
evaluations and recruitment to part B continues.  Permission has been obtained from GSTFT 







 Results: SUV Repeatability 7
 Aims 7.1
This chapter presents the first repeatability parameters for static scan acquisitions using the 
FLT or FDG tracers in the triple negative breast cancer phenotype.  As described in chapter 4, 
participants enrolled in part A underwent two pre chemotherapy PET-CT scans using either the 
FLT or FDG tracer according to randomisation. Static scan acquisitions were performed at 90, 
120 and 180 minutes post tracer in the FDG group and at 90 minutes post injection in the FLT 
group. SUVmax, SUV mean, SUVpeak and SULpeak were measured for all tumour lesions in 
each static acquisition for primary part A endpoint repeatability analysis determining tracer 
progression to part B response evaluation. 
Further exploratory analyses presented in this chapter are measures of repeatability in tumour 
lesions defined using PERCIST, hottest lesion and within breast lesions only evaluability criteria.  
 Patient Cohort 7.2
A total of 11 patients were randomised within part A. 5 participants scanned using the FDG 
and 4 participants randomised to FLT completed both baseline scans and were included in the 
analyses. In the FLT group 1 participant withdrew consent following her first PET scan and a 
further patient was withdrawn from the study without receiving any allocated research 
interventions due to FLT production failure. 
Table 7.1 summarises baseline patient and tumour characteristics. All tumours were confirmed 
ER and HER2 negative and were generally high grade no special type (NST). Stated nodal 
involvement was cytology confirmed. Primary tumours were at least stage T1c by MRI, and 
with one exception were greater than T2. This smallest tumour had clinical measurements of 





Demographics FLT (n=4) FDG (n=5) Overall (n=9) 
Age 
(years) 
Mean (s.d.) 40.3 (10.7) 43.6 (5.0) 42.1 (7.7) 
Median (min-max) 39 (30-53) 44 (36-49) 44 (30-53) 
Race 
Black 1 (25%) 3 (60%) 4 (44.4%) 




Mean (s.d.) 23.35 (4.52) 29.44 (5.28) 26.69 (5.68) 





Mean (s.d) 31.0 (5.72) 32.8 (14.5) 32.0 (10.87) 
Median (min-
max) 
30.5 (28-38) 35 (13-51) 33 (13-51) 
Nodal 
involvement 
Positive 1 (25%) 2 (40%) 3 (33.3%) 
Negative 3 (75%) 3 (60%) 6 (66.7%) 
Number of 
lesions  
1 3 (75%) 3 (60%) 6 (66.7%) 
2 1 (25%) 2 (40%) 3 (33.3%) 
Histological 
type 
NST 2 5 7 
Ductal 2 0 2 
Grade 
2 1 0 1 
3 3 5 8 
ER score 0 4 4 8 
1 0 0 0 
2 0 1 1 
HER2 score 0-1 4 4 8 
FISH -ve 0 1 1 
 
Table 7-1 Baseline characteristics by allocated tracer group 
 Categorical variables are reported by frequencies and column percentages. s.d. = standard 
deviation. Primary tumour size according to MRI longest dimension, mm. Number of lesions 
includes breast and nodal involvement where present. 
The same scanner was used for PET imaging at baseline and post cycle 1 study visits. The 
maximum repeatability acquisition interval was 5 days (Table 7.2). Chemotherapy commenced 
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within 10 days of the first baseline scan and response scans took place in the third week 
following cycle 1 in all study participants. 
 Scan Interval  
 Repeatability scan 
Interval 
Median (range) days 
1st baseline to 1st 
chemotherapy 
Median (range) days 
1st chemotherapy to 
PET response scan 
Median range) days 
FLT group (n=4) 3.5 (3-5) 6.5 (5-7) 19 (17-20) 
FDG group (n=5) 4 (3-4) 8 (6-10) 18 (17-18) 
 
Table 7-2 PET visit interval  
Interval between baseline repeatability scans, first baseline and first chemotherapy cycle and 
the post cycle 1 PET response. Median and range (days) are reported.  
 Static scan acquisition parameters  7.3
FDG scans were acquired after minimum 6 hours fast time. All follow up scans commenced 
within 5 minutes of the scan 1 acquisition time (Figure 7.1 A).  No patient had serum glucose 
level >6.2 (normal range 4.4 to 6.1mmol/L). The group mean serum glucose levels were 5.04 
mmol/L (sd 0.73), 5.42 mmol/L (s.d 0.51) and 4.82 (s.d 0.69) at the first baseline, second 
baseline and post cycle 1 visits respectively. Glucose levels did not statistically differ between 
baseline visits (p= 0.31) or post cycle 1 visits (p=0.19). The mean injected activity was 188.4 (s.d 
7.9) MBq, 183.2 (s.d 5.6) MBq and 188.5 (s.d 6.6) MBq for FDG scans performed at the first 
baseline, second baseline and post cycle 1 visits respectively. Injected activity did not 
statistically differ between the two baseline visits (p=0.38) or post cycle 1 (p= 0.98) and was 
within ±10% for each individual (range -8.20 to 7.70%).  
All FLT follow up scans commenced within 12 minutes of scan 1 acquisition time (Figure 7.1B). 
The FLT mean injected activity was 187.6(s.d 6.6) MBq, 185.2 (s.d 9.5) MBq and 183.7 (s.d 6.2) 
MBq at the first baseline, second baseline and post cycle 1 visits respectively. Injected activity 
did not statistically differ between the two baseline visits (p=0.767) or post cycle 1 (p=0.213) 




Figure 7-1 Static scan acquisition time for baseline and follow-up scans 
A Follow up acquisition time for static scans scheduled to commence at 90, 120 and 180 
minutes following FDG tracer injection. Mean and standard deviation (s.d) shown for each time 
point. No statistical difference in acquisition time was present for any follow up scan 
comparison (p>0.3 for all paired comparisons). B. Follow up acquisition time for static scans 
scheduled to commence at 90 minutes following FLT tracer injection. Mean and s.d shown for 
each 90 minute scan acquisition. No statistical difference in acquisition time was present for 
any follow up scan comparison (p>0.4 for all paired comparisons).  
 Lesion assessment on baseline repeatability scans 7.3.1
All scans were deemed suitable for analysis following visual inspection by an experienced 
nuclear medicine physician (MD or SB). The breast primaries were visualised in all patients. 
Axillary lesions were visualised in 3 patients (1 from FLT group and 2 from FDG group). Tables 
7.3 and 7.4 summarise the SUV parameters for the FLT and FDG tracer groups respectively.  
SUVmax and SUVmean standard uptake parameters were evaluable across all lesions but peak 
parameters could not be derived within HERMES for one (axillary) lesion in the FLT group. 
Using the 40% isocontour In the FDG group, peak parameters of breast lesions could not be 
derived on all scans at all-time points in two patients (MRI breast lesion size 40mm and 13mm) 






  Scan1 Scan 2 
SUVmax 
n 5 5 
Mean (s.d.) 6.32 (2.63) 6.84 (2.83) 
Min-max 2.9-9.8 2.8-10.6 
SUVmean 
n 5 5 
Mean (s.d.) 3.93 (1.73) 4.29 (2.02) 
Min-max 1.8-6.3 1.8-7.1 
SUVpeak 
n 4 4 
Mean (s.d.) 5.25 (2.75) 5.31(2.79) 
Min-max 2.4-8.8 2.5-9.1 
SULpeak 
n 4 4 
Mean (s.d.) 3.76 (1.78) 3.80 (1.74) 
Min-max 1.7-5.7 1.8-5.9 
 
Table 7-3  Summary of standard uptake parameters for the FLT tracer  
Results are reported for the two repeatability scans. Standard uptake values, mean, standard 
deviation (s.d.) and range shown for each parameter. SUVpeak and SUVmax could not be 














 Scan 1 Scan 2 
90 min 120 min 180 min 90 min 120 min 180 min 
SUVmax 















Min-max 5.0-28.0 4.9-30.9 6.0-36.8 4.6-25.9 5.7-26.8 5.8-31.4 
SUVmean 















Min-max 2.9-18.2 2.9-20.2 3.6-24.8 2.8-16.8 3.2-17.8 5.8-31.4 
SUVpeak 















Min-max 5.5-25.3 6.1-29.2 6.6-33.5 5.7-24.4 6.2-24.2 6.7-27.4 
SULpeak 















Min-Max 3.7-16.9 4.2-19.6 3.3-22.4 3.6-16.3 4.1-16.2 4.5-18.3 
 
Table 7-4 Summary of standard uptake parameters for the FDG tracer 
Results are reported for the two repeatability scans at the 90, 120 and 180 minute static 
acquisition time points. Standard uptake values, mean, standard deviation (s.d.) and range 
shown for each parameter. SUVpeak and SULpeak could not be derived for one axillary lesion 
at any acquisition point. For breast lesions the peak parameters could not be fully derived at 90 
minutes (1 patient scan 1, 2 patients scan 2), 120 minutes (2 patients scan 1 and 2) and 180 
minutes (1 patient).  
 Per Protocol Repeatability results 7.4
For Part A repeatability end point analysis Bland-Altman plots were constructed for each tracer 
on a lesion by time point basis (Figure 7.2 A). For the majority of lesions the % change between 
scans is within 15%. Both tracers present lesions with differences in some SUV parameters 
greater than 15% however for all lesions and timepoints the SUV parameters did not differ by 
more than 22% on the two scans (±0.2 on the logarithmic scale). Greater variability was 
present for SUVmean and max parameters than for either SUV or SULpeak parameters.  No 
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repeatability benefit for lean body mass corrected Peak is evident for either tracer or at any 
timepoint.   
Figure 7.2B reports the repeatability coefficents (RC) of the standardised uptake parameters 
for each tracer on a patient by patient basis, expressed as a ratio of scan 1 to scan 2. The 
repeatability of FDG is within 15% for SUVmean and SUVmax and within 16% for SUVpeak and 
SULpeak. The FLT repeatability is within 15% for SUVpeak and SULpeak, but higher for SUVmax 
and SUVmean (within 25% and 20% respectively). Therefore the per-patient repeatability 
criteria (specified in as primary analysis in the Part A analysis plan) were fulfilled by both 
tracers for at least one SUV measure.  
As a sensitivity analysis RC were also computed on a lesion-by–time point analysis to allow for 
the nested nature of the data (patients with more than 1 lesion) (Figure 7.2C). At the 90 
minute time point FDG lesion repeatability for SUVpeak and SULpeak is within 12% increasing 
to 24% for SUVmax.  Lesion repeatability is higher for other parameters and time points; up to 
28% for SUVmean at 120 minutes. For FLT, lesions-by-time point RC’s are generally higher than 




Figure 7-2 Part A repeatability evaluation 
A. Bland Altman plots of log transformed SUV measurement for the two baseline repeatability 
scans. Plots per lesion, time point and allocated tracer for i log SUVmax, ii log SUVmean, iii log 
SUVpeak  and iv log SULpeak. Points on the graph are labelled with the individual number and 
lesion location. Lesions within -0.14 and 0.14 (dashed lines) indicate baseline scan 
measurements were within 15% of each other. B. Repeatability coefficients (RC) for SUV 
parameters and each tracer on a patient by patient basis. RC expressed as ratios of the two 
scans, 0.87-1.15 and 0.83-1.20 representing lower and upper bounds of 15% and 20% change 
between scans,  SUVmean and SUVmax (FDG) and SUVpeak and SULpeak (FLT) parameters are  




 Exploratory lesion repeatability results 7.5
Lesion repeatability was considered using the subset of lesions evaluable according to criteria 
adopted in published breast cancer FDG response evaluation studies, namely breast lesions 
only; the hottest single lesion on the baseline scan (56), and those meeting PERCIST criteria 
with evaluable Peak lesions (62). Using hottest lesion criteria the primary breast tumour was 
target for response evaluation in 4 of the 5 patients (Figure 7.3 A). SUVpeak could not be be 
determined on the second baseline acquisition within the 40% isocontour. Thus using PERCIST 
criteria Patient 1 was not evaluable. In this patient the primary breast tumour measured 
40mm on the baseline MRI and baseline SUVmax values were 12.88 and 13.93 on the first and 
second 90 minute static scan acquisitions respectively. 
At the 90 minute time point SUVmax and SUVmean repeatability was within 12%, 
(corresponding to difference 0.11 on the log scale) using the hottest lesion and PERCIST lesion 
selection method, (Figure 7-3B). Repeatability for peak parameters was within 15% regardless 
of methodology but only 4 of 5 FDG patient scans were evaluable using PERCIST criteria (Figure 
7-3B).  At the 120 minute time point using the hottest lesion and PERCIST criteria similar 
tightening of baseline repeatability was present, to within 16%, corresponding to difference 
0.15 on the log scale for SUVmax and SUVmean parameters. At 180 minutes repeatability was 





Figure 7-3 Baseline tumour repeatability considered in relation to methodology for defining response 
A Lesion evaluability at the 90 minute time point considered according to methodologies 
adopted in published response evaluation studies. The total number of baseline lesions suitable 
for response analysis varies from 7 (visual inspection method) to 4 (PERCIST).  
B. Bland Altman plots of log transformed measurements for the two baseline repeatability 
scans. Plots per lesion, 90 minute time point for i log SUVmax, ii log SUVmean according to 
methodology used to define lesion evaluability. Lesions within -0.14 and 0.14 (dashed lines) 
indicate baseline scan measurements were within 15% of each other. 
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 Impact of scan reconstruction method on repeatability 7.6
All FLT PET-CT scans were performed using the  GE Discovery VCT 64 slice PET-CT scanner 
however  PET centre refurbishment necessitated scanner transition to the GE Discovery 710 64 
slice PET-CT scanner after the first 3 FDG imaged participants. Recognising the new scanner 
capability and published data demonstrating improved visualisation of small lesions with time 
of flight reconstruction (TOF), all clinical and research imaging following scanner installation 
was performed using TOF and 256 matrix reconstruction in contrast to the 128 matrix used 
previously (164-166). To exclude the possibility of detrimental impact of this reconstruction 
technique on SUV repeatability within the TNPET study, the images acquired on the GE 
Discovery 710 64 slice PET-CT scanner were reconstructed using 128 matrix and 256 VPHD 
matrices in addition to TOF for visual comparison of the 3 sets of log transformed SUVmax and 
SUVmean parameters using Bland Altman plots.  
 
Figure 7-4 Comparison of scan reconstuction method (90 minute scan acquistion) 
Bland Altman plots of log transformed 90 minute measurements for the two baseline 
repeatability scans for images acquired post PET centre refurbishment (2 participants, 2 lesions 
per participant). Plots per lesion, for the three scan reconstruction methods,  128 matrix (blue), 
256 matrix (red) and time of flight (TOF, green). Values for lesions imaged prior to PET centre 
refurbishment are shown for comparison (orange). i log SUVmax, ii log SUVmean. Lesions 
within -0.14 and 0.14 (dashed lines) indicate baseline scan measurements were within 15% of 





Considering all lesions, SUVs derived using the TOF reconstruction exhibited the narrowest 
lesion difference between the two baseline 90 minute scan acquisitions (Figure 7-4). For Log 
SUVmax the mean difference and 95% confidence interval for the difference were -0.03 (0.84 
to 1.36); -0.08 (0.77 to 1.39) and -0.002 (0.78 to 1.27) for 128, 256 and TOF reconstructions 
respectively. For LogSUVmean the mean difference and 95% confidence intervals for the 
difference were 0.012 (0.77 to 1.29); 0.11 (0.66 to 1.51) and 0.007 (0.98 to 1.01) for 128, 256 
and TOF reconstructions respectively. Hottest lesion targets were within the protocol defined 
15% repeatability bounds using all three methods. Similar repeatability performance of TOF 
relative to the other reconstructions was present at the 120 and 180 minute time points.  
 Background uptake 7.7
The mean and SD of the calculated background for the baseline and response FDG PET 
acquisitions are shown in Table 7.5. No statistical difference in the calculated blood 
background on the two baseline scans was demonstrated at any static time point (p=0.58, 
p=0.73 and p=0.74 for 90, 120 and 180 minutes respectively, paired sample t-test). 
Comparison of group background SUL at first baseline with the post cycle 1 response scan  
showed significant difference only at the 120 minutes time point (p=0.72, p=0.04, p=0.256 for 
90, 120 and 180 minutes respectively, paired sample T-test).   
Scan acquisition 
Group background SUL 
Baseline scan 1 
Mean (s.d) 




90 minutes 2.54 (0.56) 2.68 (0.40) 2.60 (0.42) 
120 minutes 2.10 (0.39) 2.17 (0.52) 2.41 (0.48) 
180 minutes 2.17 (0.53) 2.12 (0.49) 1.93 (0.18) 
 
Table 7-5 Group background SUL for FDG part A scans 
Background SUL calculated for each FDG static acquisition according to the method defined in 
PERCIST. Mean  and standard deviation  shown for the group at each of 90, 120 and 180 PET 
image acquisitions. 
All scans with tumour peak parameters evaluable within HERMES met PERCIST criteria for 
baseline lesion evaluability (SULpeak greater than the calculated background). For follow up 
response assessment PERCIST recommends background is within 20% of baseline for that 
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individual. Although the group background was within 20% of group baseline at all time points 
this criterion was not met when considered on a per patient basis for images acquired at 120 
and 180 minutes.   
 
 Response assessment 7.8
For tracers to be considered for progression to Part B an SUV/SUL reduction of at least 20% in 
50% of MRI defined responders was required in addition to repeatability within ±15% for at 
least 1 SUV/SUL parameter. All patients with an objective response (complete or partial) or 
stable disease had drop of ≥20% in SUV and SUL. The single patient with progressive disease 
(FLT group) had an SUV and SUL drop of less than 20%. Therefore both tracers met the 
predefined criteria. The % change for each SUV parameter at the post cycle 1 scan compared 
to the mid-MRI response is shown in Figure 7-5. 
In the FDG group the mid MRI reported disease response as complete (1 patient), partial (2 
patients) and stable disease (2 patients). Compared to the second baseline scan all patients 
exhibited  change in the peak parameters which exceed the PERCIST suggested threshold 
change of 30% to discriminate responders at the 90 minute scan acquisition. Similarly the 
minimum observed drop in SUVpeak was 41.6% and 42% respectively at the exploratory 120 
and 180 minutes scan acquisitions. This individual with the poorest level of SUV response had 
stable disease on her post cycle 3 scan but clinical concern regarding progression necessitated 
surgery prior to transition to the second component of neoadjuvant treatment.  It is therefore 
possible that the recommended threshold change of 15% (EORTC) and 30% (PERCIST) to define 
responders is insufficiently stringent in TNBC. However a larger cohort would be required to 




Figure 7-5 Part A PET response as a function of post cycle 3 MRI RECIST response 
A. FDG response at each of 90, 120 and 180 minute acquisitions for i SUVmax, ii SUVpeak, iii 
SUVmean and iv SULpeak parameters. Colour scale indicates post cycle 3 reference MRI 
response for each individual. Where 2 bars are present, this indicates evaluation of breast 
and nodal lesions, in each case the bar with the greatest magnitude of change represents 
the hottest lesion. The patient denoted in dark red underwent surgery prior to transition to 
anthracycline chemotherapy due to unequivocal clinical progression despite the MRI 
findings.  
B. FLT response for each of i SUVmax, ii SUVpeak, iii SUVmean and iv SULpeak parameters. 
Colour scale indicates post cycle 3 reference MRI response for each individual. Where 2 
bars are present, this indicates evaluation of breast and nodal lesions, the bar with the 




PERCIST guidance makes a number of recommendations pertaining to FDG imaging acquisition 
for serial imaging which include ensuring that follow up scanning occurs within 10 minutes of 
planned acquisition time post tracer, consistency of scanner and injected dose within +/- 20%. 
In the FDG repeatability cohort these criteria were met. No comparable recommendations 
have been published for non-FDG tracer but the FDG acquisition standards were also applied 
to patients imaged using the FLT tracer. For both tracers image acquisition was optimised with 
PET imaging performed at fixed intervals after tracer injection avoiding potential confounding 
impact of technical variability between scans within the same individual on repeatability 
evaluation (79). 
We report the first breast cancer subtype specific repeatability data for commonly reported 
standardised uptake parameters (SUVmax, SUVmean, SUVpeak and SULpeak) assessed at 
conventional (90 minutes) and exploratory (120 and 180 minute) acquisition time points.  
When considering all breast and nodal lesions our data demonstrates that SUV intrinsic 
variability is 12-24% in both tracers, that is dependent on scan acquisition time and SUV 
parameter.  This intrinsic variability raises questions about the validity of suggested EORTC 
threshold SUV change of 15% for defining responders in treatment assessment of TNBC. 
Furthermore this phenotype specific repeatability and preliminary response data indicate SUV 
threshold change in TNBC will exceed currently recommended 15-30% SUV change for solid 
tumour chemotherapy response prediction. In the context of an aspiration to ultimately 
improve outcomes for those with RCB2/3 response  by implementing therapy change early in 
the course of neoadjuvant more stringent criteria may be required for defining PET response 
as a predictive biomarker for chemo sensitivity.  Furthermore although overall repeatability 
was less robust for SUVmax or mean parameters, where a response evaluation approach 
considering only the single hottest lesion is adopted repeatability improves to within 12%. 
The current data identifies the PERCIST recommended peak parameter (with or without BSA 
correction) to be problematic in assessment of some breast cancers or involved nodal lesions. 
Concerns regarding impact of change in weight and BMI through a course of cytotoxic therapy 
on tracer kinetics and SUV evaluation underlie PERCIST recommendations for lean body mass 
correction.  However unlike the metastatic disease context, in those undergoing neoadjuvant 
treatment significant cachexia at diagnosis or change in BMI early in the course of 
chemotherapy would be rare and as expected was not evident in the repeatability population 
and may explain why LBM correction did not improve either peak evaluability or repeatability. 
All patients in the test re-test cohort had T1c tumours as measured by baseline MRI and were 
>2cm by palpation with PET images considered evaluable by experienced nuclear medicine 
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physicians. Published data evaluating the diagnostic role of PET in  breast cancer reports 98% 
tumours >15mm tumour to be evaluable using SUVmax and recommends minimum stage T1C 
to be suitable for response monitoring (167). Nevertheless it is possible that limiting eligibility 
to participants with larger primary breast tumours, for example >3cm, may have improved 
both repeatability and lesion evaluability according to PERCIST definition of peak. However 
where this approach has been previously adopted only the SUVmax parameter has been 
reported (72, 73). As neoadjuvant sequencing is increasingly recommended to patients with 
TNBC at the lower end of the T2 or T1c stage, particularly in the context of cytological evidence 
of nodal involvement, the ability to evaluate these smaller lesions is a key requirement of 
imaging biomarkers for response assessment. Our data suggests advantages in terms of lesion 
evaluability using SUVmax or mean parameters compared to the peak parameter with or 
without LBM correction in the neoadjuvant breast cancer setting.  
Based on the Part A results and also recognising the problems with FLT reliability, the FDG 
tracer alone was selected for progression through to part B. Full study completion (anticipated 
2017) will inform future use of early FDG-PET as an exploratory biomarker novel therapy neo-
adjuvant trials in TNBC. The optimal strategy for evaluating PET response remains undefined 
but the Part A data suggests strategies using SUVmax or mean and considering SUV change in 
the hottest lesion may be optimal in TNBC and that a threshold change in excess 30-40% would 





 Preliminary evaluation of FDG SUV response 8
 Aims 8.1
Based on the repeatability results (Chapter 7) the FDG tracer was selected for progression to 
part B response evaluation. In all visualised tumour lesions SUVmax, SUV mean, SUVpeak and 
SULpeak parameters were evaluated and PET response considered with respect to the 
protocol defined mid-chemotherapy contrast-enhanced MRI RECIST primary endpoint as well 
as end of chemotherapy secondary endpoints (end of treatment MRI RECIST response and 
definitive RCB pathological response). This chapter presents the emerging response data for 
static scan acquisitions in the nine recruited patients who have completed scheduled Part B 
PET imaging response evaluations. Recruited participants who have not yet completed 
neoadjuvant chemotherapy are not considered in the analyses presented in this chapter. 
 Patent characteristics 8.2
Baseline patient and tumour characteristics for nine of the planned 20 patients that have 
completed neoadjuvant chemotherapy are summarised in Table 8.1.  All primary tumours were 
confirmed ER and HER2 negative and were generally high grade NST. One patient had 
multicentric disease at the outset, the larger ER- HER2- primary defining her neoadjuvant 
treatment pathway and study participation. Only this lesion was considered for imaging and 
tissue evaluations purposes. All stated axillary nodal involvement was cytology confirmed. 
Scheduled neoadjuvant sequential chemotherapy comprised 4 cycles of docetaxel (T) 
100mg/m2 followed by 4 cycles of epirubicin 90mg/m2 and cyclophosphamide 600mg/m2 (EC). 
A single patient underwent surgery without transition to EC due to overt clinical progression 






Age (years) Mean (s.d.) 44.5 (4.7) 
Median (min-max) 45.5 (35-49) 
Race Black 3 (33.3%) 
White 5 (55.5%) 
Asian 1(11%) 
Body Mass Index Mean (s.d.) 27.22 (5.5) 
Median (min-max) 27.2 (22-37.6) 
Baseline Tumour characteristics 
Primary tumour  
(MRI longest dimension, mm) 
Mean (s.d) 34.8 (13.6) 
Median (min-max) 29 (13-55) 
Nodal involvement Positive 5 
Negative 4 
Number of lesions  
(breast and axilla) 
1 4 (44.4%) 
2 5 (55.6%) 
Histological type NST 9 (100%) 
Grade 2 1 (11%) 
3 8 (89%) 
ER Score 0 7 (78%) 
1 0 (0%) 
2 2 (22%) 
HER2 score 0-1 8 (89%) 
FISH -ve 1 (11%) 
Chemotherapy (completed patients only, n=9) 
Administered T 
3 cycles 1 
4 cycles 8 
Administered EC 4 cycles 8 
 
Table 8-1 Overall characteristics of recruited Part B patients. 
Clinical characteristics of the nine recruited Part B patients who have completed all study 
investigations. Categorical variables are reported by frequencies and column percentages. s.d. 





 MRI response 8.3
Table 8-2 summarises MRI RECIST response following 3 cycles of docetaxel (mid-MRI) and end 
of sequential neoadjuvant chemotherapy (EOT-MRI). On the mid-MRI scan no patient 
exhibited progression by RECIST criteria however one participant underwent early surgery due 
to overt clinical progression following 3 cycles of docetaxel.   
 Pathological response 8.4
All patients have undergone definitive surgery. Breast conserving surgery (BCS) was performed 
in three patients and mastectomy (M) in the remainder. The 5 patients with initially node 
positive disease underwent axillary nodal clearance (ANC). Sentinel lymph node biopsy (SNB) 
was performed in the remainder. Contralateral prophylactic mastectomy was performed in 
one patient.  
RCB scores are summarised in Table 8-2. Patient 3 presented with multicentric disease from 
synchronous ER- HER2- and ER+ HER2- primaries. Persisting disease at synchronous ipsilateral 
ER+ breast primary gave an overall RCB score of 2, RCB index 1.812. However the mastectomy 
specimen demonstrated no evidence of residual disease at the coil marked ER- HER2- breast 
cancer site (RCB0). As the imaging assessments for purposes of this study considered the TNBC 
primary only and ER+ RCB2 response predicts a substantially lower relapse risk than the same 
score arising from residual TNBC (76% vs. 54% 10 year RFS) (16) the RCB score pertaining to 
the TNBC cancer only is considered  for comparative analysis . 
The chi-squared test was applied to examine associations between mid-MRI response and later 
EOT-MRI and RCB response. No statistically significant association was seen between mid-MRI 
categories of ‘responder’ (complete and partial) or ‘non-responder’ (stable or progression) 
with EOT-MRI response category, p= 0.22 or with RCB categories of responder (RCB0-1) and 





Patient 1 2 3* 4 5 6 7 8 9 
MRI Imaging response  
Mid-MRI  CR SD PR SD PR PR SD PR PR 
EOT-MRI  CR - PR SD CR PD PD CR PR 





0 55 0 0 0 95 14 0 0 
Involved 
Nodes (n) 
0 0 0 2 0 8 1 0 0 
RCB Index 0 2.672 0* 1.100 0 3.955 3.775 0 0 
RCB Class 0 2 0* 1 0 3 3 0 0 
Table 8-2 Summary of cross-sectional imaging and definitive Residual Cancer Burden response 
MRI response categorised according to RECIST 1.1 (31): CR = complete response; PR = partial 
response; SD = stable disease; PD = progressive disease. * denotes patient who had residual 
disease at the site of a  second ER+ cancer at a separate location within the index breast (RCB2, 
index 1.812) but pathological response RCB0 to the separate TNBC lesion.  
 PET scan acquisition parameters 8.5
The same scanner was used for image acquisition at each patient study visit. Where 
repeatability imaging was performed (Part A patients scanned with FDG), the second of the 
two pre-chemotherapy image acquisitions was taken as baseline for Part B response 
assessment. Chemotherapy commenced within median 4 (range 3-8) days of the baseline scan. 
Response PET imaging took place in the third week following cycle 1 in all study participants at 
median 18 (range 17-19) days.  
All FDG scans were acquired after minimum 6 hours fast time. Follow up scan acquisition 
commenced within 4 minutes of the baseline acquisition at each of 90, 120 and 180 minute 
time points.  No patient had serum glucose level greater than 6.2 mmol/l (normal range 4.4 to 
6.1 mmol/L). The group mean serum glucose levels were 5.34 mmol/L (s.d. 0.43) and 5.1 
mmol/L (s.d. 0.73) at the baseline and post cycle 1 visits respectively and did not statistically 
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differ between the scan visits (p=0.46). Mean injected activity was 183.1 (s.d. 5.9) MBq and 
185.1 (s.d. 7.2) MBq for baseline and post cycle 1 scans respectively and did not statistically 
differ between visits (p=0.50). Response scan injected activity was within 10.4% (range -4% to 
10.4%) of baseline injected activity for each participant. Comparison of group background SUL 
at baseline with the post cycle 1 response scan showed no significant difference at any time 
point (p=0.81, p=0.19, p=0.70 for 90, 120 and 180 minutes respectively). At each acquisition 
time point the group background SUL was within 20% of group baseline. However when 
considered on a per patient basis only the 90 minute acquisition met this PERCIST criterion 
(maximum 19% difference in background).    
 Lesion evaluability on baseline and follow-up PET scans 8.5.1
All scans were deemed suitable for analysis following visual inspection by an experienced 
nuclear medicine physician (MOD or SB) and scan analysis was performed by JG. The SUV 
parameters for baseline and post cycle 1 response scans are summarised in Table 8.3. 16 
lesions were visualised on the baseline acquisitions, comprising all known breast primaries and 
involved axillary nodal lesions. A previously undiagnosed internal mammary chain (IMC) node 
was visualised in 1 patient and axillary nodal lesion in one further patient. All lesions were 
evaluable using SUVmax and SUVmean parameters at baseline 90, 120 and 180 minute 
acquisitions. Consistent with the Part A data, peak parameters could not be derived for all 
lesions within the 40% isocontour (Table 8-3) including  breast tumours at 90 minutes (3 
patients), 120 minutes (4 patients) and 180 minutes (3 patients)  respectively. The 40% 
isocontour was selected based on existing data from other tumour sites which indicates the 
best size match between isocontour and pathological site is obtained using a 40% isocontour 
(65)(66, 67). It seems likely the evaluability of the Peak parameter is a function of the 
isocontour selected to define the metabolically active tumour size.  In the current dataset peak 
lesion evaluability on baseline scans could be increased by applying a lower (e.g 20%) 
isocontour to define an expanded tumour VOI. Similarly reduced peak evaluability was 
observed where thr isocontour threshold to define tumour VOI was increased. PERCIST 
guidance proposes use of the 70% isocontour threshold to define tumour VOI however using 
this approach only a single participant had Peak evaluable tumour at baseline using this 
approach (patient 2, MRI tumour dimension 55mm) 
On post cycle 1 PET imaging the 15 breast and axillary nodal lesions were visualised and 
evaluable using maximum and mean SUV parameters at all three acquisition time-points. It 
was not possible to visualise the IMC node. Fewer lesions were non evaluable using peak 
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parameters (Table 8-3). These lesions were not necessarily those evaluable on the baseline 
scan and consequently paired baseline and response peak parameters could be derived for a 
single lesion in only 4, 6 and 5 participants at 90, 120 and 180 minute acquisitions respectively. 
 
FDG scan Acquisition 
Baseline  Response  
90 120 180 90 120 180 
SUV 
max 




10.7 (5.9) 11 (6.3) 12.4 (7.3) 5.2 (3.3) 5.3 (3.7) 6.0 (4.7) 
Median 9.9 9.9 11.0 9.9 4.1 4.8 
Range 2.7-25.9 2.7-26.8 2.7-31.4 1-16 1.3-16.3 1.8-21.0 
SUV 
mean 
Lesion n 16 16 16 15 15 15 
Mean (s.d.) 6.4 (3.7) 7.0 (3.8) 7.7 (4.7) 3.0 (2.1) 3.2 (2.3) 3.5 (2.7) 
Median 6.0 6.7 2.9 6.7 2.4 2.9 





Lesion n 10 9 9 7 8 7 
Mean (s.d.) 10.4(5.6) 10.5 (5.8) 12.6(6.3) 
15) 
4.5 (3.7) 3.9 (4.1) 4.7 (5) 
Median 10.1 9.6 0.6 3.4 2.9 3.2 
 Range 4.2-24.4 4.1-24.2 6.7-27.4 
27.424.19 




Lesion n 10 9 9 7 8 7 
Mean (s.d.) 7.1(3.9) 
((3.9)(3.9
) 
7.6(4.0) 8.5 (4.5) 3.1 (2.5) 2.7(2.7) 
(2.7) 
3.2 (3.3) 




2.5-16.3 4.1-16.2 4.5-18.3 1.4-8.6 0.6-9.2 1.07-10.67 
 
Table 8-3 Summary of standard uptake parameters for the FDG tracer 
Results reported for group baseline and response scans at the 90, 120 and 180 minute static 
acquisition time points, all evaluable lesions for each parameter. Raw standard uptake values, 
mean, standard deviation (s.d.) and range shown for each parameter. SUVpeak and SULpeak 
could not be consistently derived on the baseline images at each of 90 minutes (5 lesions, 4 




 SUV response 8.6
Table 8.4 reports the % change in SUVmax and SUVmean parameters at the post cycle 1 time 
point. In 3 of the 9 participants axillary lesions exhibited the highest baseline uptake, meeting 
hottest lesion criteria for response monitoring. The observed % decrease in target lesion 
(breast or axilla) SUVmax was in the range -39.9 to -76.7%, -37.2 to -82.4% and -33 to -84.5% at 
each of the 90, 120 and 180 minute scan acquisitions respectively irrespective of later 
radiological or pathological response. Similarly, % change in SUVmean was in the range -42.8 
to -79.2%, -39.4 to -81.8% and -41.3 to -86.9% at 90, 120 and 180 minute acquisitions 
respectively. Thus all target lesions exceeded 15-30% SUV change and would be classified as 
metabolic responders using PERCIST and EORTC criteria. 
Patient Lesion % change SUVmax % change SUVmean Mid-MRI 
response 
RCB 
90 120 180 90 120 180 
1 Breast -76.7 -82.4 -84.5 -79.2 -81.8 -86.9 CR 0 
2 Breast -39.9 -39.3 -33.0 -42.8 -43.1 -41.3 SD 2 
3 Breast -52.5 -51.1 -55.6 -55.4 -54.9 -52.7 PR 0 
4 Breast -50.9 -43.5 -50.7 -54.5 -46.1 -52.7 
SD 1 
 Axilla -57.0 -59.5 -57.0 -57.2 -58.8 -56.2 
5 Breast -46.9 -51.7 -52.8 -48.6 -52.2 -53.8 
PR 0 
 Axilla -23.9 -36.3 -19.6 -27.2 -37.7 -16.2 
6 Breast -44.1 -39.4 -45.2 -46.3 -39.4 -44.2 
PR 3 
 Axilla -57.4 -58.4 -55.6 -60.8 -59.5 -56.7 
7 Breast -50.7 -50.0 -48.9 -56.3 -57.3 -56.5 
SD 3  Axilla -44.5 -37.2 -40.8 -47.3 -40.2 -45.3 
 IMC - - - - - - 
8 Breast  -52.7 -60.8 -58.4 -52.9 -60.7 -58.9 
PR 0 
 Axilla -54.9 -47.9 -59.4 -55.0 -48.2 -60.9 
9 Breast -72.4 -76.3 -75.8 -73.9 -76.0 -77.3 
PR 0 
 Axilla -46.9 -50.7 -35.2 -49.7 - 37.7 -39.6 
 
Table 8-4 SUVmax and SUVMean response following 1 cycle of chemotherapy 
Per lesion % change in SUVmax and SUVmean parameters shown for the 90, 120 and 180 
minute scan acquisitions. Where patients presented with more than one visible lesion, the 
hottest lesion target is denoted in bold. The IMC node (patient 7, non target lesion) was 
visualised on the baseline acquisitions only, thus % change in max and mean parameters could 
not be calculated for this lesion.  
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Non-evaluability of peak parameters within the 40% isocontour on both baseline and response 
scans meant % change could only be calculated in 4, 5 and 6 lesions at the 90, 120 and 180 
minute acquisitions respectively. This precludes meaningful interpretation of response using 
SUV and SULpeak in the current cohort and if confirmed at full study accrual indicates that 
neither peak parameter is suitable for application as a response biomarker in TNBC. 
 Primary endpoint comparison of % change in SUV with mid MRI response 8.6.1
Mid-MRI RECIST response was categorised as ‘responder’ (complete and partial; n=6 patients 
with total 10 lesions) or ‘non-responder’ (stable or progression; n=3 with total 5 tumour 
lesions) for comparison with % SUV change.  The distribution in % SUV change did not 
statistically differ between categories of mid-MRI response when considering all lesions 
(p=0.56, 0.21 and 0.38 for SUVmax and 0.64, 0.46 and 0.64 for SUVmean at 90, 120 and 180 
minutes scan acquisitions respectively) (Figure 8-1i). Similar findings were present when 
considering hottest lesion targets only (Figure 8-1ii) (p=0.27, 0.29 and 0.11 for SUVmax and 











Figure 8-1 Distribution of % SUV change according to mid-MRI response category 
i.  Mid-MRI RECIST response was categorised as ‘responder’ (complete and partial, n=6 patients 
with total 10 lesions) or ‘non responder’ (stable or progression, n=3 with total 5 tumour lesions) 
for comparison with % SUV change. SUVmax and SUVmean parameters were evaluated for 
tumour lesions visualised on the 90, 120 and 180 minute static acquisitions. Box plots show 
comparison of distribution for % SUVchange in categories of mid-MRI Responder and Non 
responder (i) all lesions, n=15 lesions and  (ii) hottest lesion target only, n=9 lesions. No 
significant difference in distribution of % SUV change was present for any parameters or 
acquisition time point. Outlier lesions (i) were from patients 1 and 5, both of whom later 
achieved complete radiological response on the EOT-MRI scan and RCB0 definitive pathological 
response 
 Secondary endpoint comparison of % change with EOT-MRI and RCB response 8.6.2
EOT-MRI RECIST response was categorised as ‘responder’ (complete and partial; n=6 patients 
with 8 lesions) or ‘non-responder’ (stable or progression; n=2 patients with 4 lesions) for 
comparison with % SUV change (Figure 8-2 Ai). The distribution of % SUV change did not 
significantly differ not between categories of EOT-MRI response when considering all lesions 
(p=0.61, 0.48 and 0.24 for SUVmax and 0.46, 0.73 and 0.64 for SUVmean at 90, 120 and 180 
minutes scan acquisitions respectively).  
Considering the hottest lesion target only, inspection of box and whisker plots suggests 
separation between the two categories of EOT-MRI response.  Patient 3 underwent early 
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surgery due to clinical progression after only 3 cycles of chemotherapy but had SUV values 
within range of the non-responding group for all parameters and acquisition time points 
(Figure 8-2 Aii). Considering hottest lesion target only significant differences in distribution of 
% SUV change between categories of EOT-MRI were most marked for the 120 and 180 scan 
acquisition  (p=0.048, 0.034, 0.019 for SUVmax and p=0.063, 0.037 and 0.043 for SUVmean at 
90, 120 and 180 minutes respectively) in the current cohort. Full accrual will be required to 
definitively comment on the statistical significance of differences between the two categories.  
  
RCB score was categorised as ‘responder’ (RCB 0 or 1; n=6 patients with 10 lesions) or ‘non-
responder’ (RCB 2 or 3; n=3 patients with 5 lesions) for comparison with % SUV change. 
Considering all lesions, no significant differences in the distribution of % SUV change between 
responding and non-responding categories was present for  SUVmax and SUVmean at any 
timepoint (Figure 8-2Bi) (p=0.37, 0.14 and 0.18 for SUVmax and 0.48, 0.21 and 0.38 for 
SUVmean at 90, 120 and 180 minutes scan acquisitions respectively). Considering hottest 
lesion targets only, inspection of box and whisker plots suggests separation between the two 
groups that is more marked at 120 and 180 time points for both SUV parameters. Significant 
differences in distribution of % SUV change is present between categories of RCB response, 
p<0.05 at all scan acquisition times, (p=0.048, 0.012 and 0.019 for SUVmax and p= 0.022, 0.012 





Figure 8-2 Distribution of % SUV change according to EOT-MRI and RCB response categories 
A.  Box plots showing comparison of distribution for  % change in SUVmax and SUVmean in 
categories of EOT-MRI response  (i) all lesions, n=15 and  (ii) hottest lesion target only (n=9). 
Significant difference in distribution of % SUV change is present when considering hottest lesion 
target for SUVmax at each of 90, 120 and 180 minute FDG scan acquisitions and for SUVmean 
at 120 and 180 minutes.  Patients with outlier lesions (i) subsequently achieved pathological 
complete response, RCB0 at definitive surgery. % SUV change also shown for the single patient 
underwent early surgery following the mid MRI due to overt clinical progression and therefore 
did not receive EOT-MRI. 
B.  Box plots showing comparison of distribution for  % change in SUVmax and mean in 
categories of RCB response  (i) all lesions (n=15) and  (ii) hottest lesion target only (n=9). 
Considering hottest lesions only, significant differences in distribution of % SUV change are 




 Pre neoadjuvant SUV assessment  8.7
The distributions of baseline SUVmax and mean parameters were compared with categories of 
mid-MRI, EOT-MRI and RCB response.  No significant differences in distribution were present 
at any FDG scan acquisition time-point (p>0.1 for all comparisons). 
 Research Tissue Evaluations 8.8
Biopsy derived biomarkers such as ki-67 may have prognostic and predictive potential (36) and 
potentially therapy induced changes in the tumour correlate with subsequent survival 
outcome (37) and may add to RCB (38). However there is little data considering relationship of 
these metabolic changes with FDG PET derived SUV indices. To address these questions 
research biopsies were required with the study protocol to enable exploratory correlation of 
biopsy derived markers of proliferation, apoptosis and glucose transport with PET imaging 
(baseline SUV and post cycle 1 SUV change) and later pathological response at definitive 
surgery.  
Research breast core biopsy specimens from the 11 patients (part A and B cohort) who had 
completed neoadjuvant chemotherapy and definitive surgery by August 2015 were examined 
to confirm presence of tumour (Professor Sarah Pinder, SP). In tumour containing samples Ki-
67, Geminin, Activated Caspase 3, Mini-chromosome maintenance protein 2 (MCM2) and 
Glucose transporter 1 (GLUT-1) staining assessment was performed and scored as a 
percentage of positive cells within the tumour cell population (PC and SP) using standard 
methods (88, 168-170).  
The raw data for both FDG and FLT imaged participants (Table 8-5) were considered for RCB 
comparisons. Baseline and post cycle 1 biopsies contained evaluable tumour in 7 of the 11 
patients. Comparison of baseline and post cycle 1 scores revealed statistically significant 
differences for GLUT-1 only (Wilcoxon Signed Rank Test). As expected the on-treatment 
samples were less likely to be evaluable in those achieving RCB 0 or 1 at definitive surgery. The 
three individuals with tumour containing samples at each of baseline, post cycle 1 and end of 
chemotherapy time points achieved RCB 2 or 3 definitive histology response. For those with 
poor pathological response (RCB 2 or 3) inspection of the data provided in Table 8.5 provides 
little evidence of tissue biomarker change compared to baseline between RCB responding and 
non-responding subsets. Application of the Mann Whitney U test to compare the distribution 
of Ki-67, cleaved caspase 3, geminin, GLUT-1 and MCM2 between RCB responding and non-
responding subsets identified no statistically significant differences for any parameter at 
baseline (p=0.56, p=0.11, p=0.56, p=0.73 and p=0.2 respectively) or the post cycle 1 time point 
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(p=0.86, p=0.56, p=0.40, p=1 and p=0.5 respectively). Similarly in the 7 patients with evaluable 
tissue samples at baseline and post cycle 1 time points no statistically significant difference in 
distribution of % change in Ki-67, cleaved caspase 3, geminin, GLUT-1 and MCM2 was present 
between responding and non-responding patients (p=0.63, p=0.1, p=0.63, p=0.63 and p=1 
respectively). No patient achieving RCB 0 or 1 had residual tumour in the breast precluding 
tissue evaluation at this time-point. The validity of statistical comparison is with the currently 
small sample size is highly constrained and the full dataset will be required for meaningful 
biopsy derived biomarker comparisons.  
In this dataset research tissue evaluations did not exhibit normal or log normal distributions 
precluding linear regression analysis for comparison with log transformed SUVs. Correlations 
between the pre-chemotherapy SUV parameters (FDG imaged breast lesions only) and 
baseline research tissue evaluations were explored using the Spearman correlation coefficient. 
At all scan acquisition time points statistically significant correlation was present at the p=0.05 
level between SUV (max and mean) and the Ki-67 and MCM2 parameters only (Table 8-6). 




FDG Group FLT Group 
Median  
 p (comparison 
with baseline)  1 2 3 4 5 6 7 1 2 3 4 
Ki-67 
Baseline 75.65 88.53 37.12 23.20 - 79.59 85.00 87.5 85.24 65.00 - 79.59   
1 cycle - 94.33 20.38 - - 65.58 80.00 75.00 85.10 60.00 - 75 0.90 




Baseline 16.31 32.92 10.90 13.61 - 21.29 28.75 37.71 0.03 24.34 - 21.29  
1 cycle - 36.64 5.26 - - 11.92 31.73 34.26 0.01 28.83 - 21.83 0.18 
EOT - 26.00 - - - 4.65 18.78 - - - 6.79 12.78 0.11 
Cleaved 
Caspase 3 
Baseline 0.65 0.315 0.27 1.18 - 1.18 1.3 1.19 0.62 0.88 - 0.88   
1 cycle - 0.27 0.38 - - 1.15 1.22 1.25 0.43 1.09 - 1.09  0.87 
EOT - 0.285 - - - 0.34 0.65 - - - 0.00 0.31  0.11 
MCM2 
Baseline 62 62.38 12.9 5 - 47.44 73.37 58.03 52.03 36.85  52.03  
1 cycle - 43.48 11.5 - - 24.88 85.34 45.00 36.85 - - 40.17 0.08 
EOT - 49.81 - - - 25.07 60.02 - - - 6.21 37.44 0.11 
GLUT-1 
Baseline 69.02 37.63 4.38 4.77 - 15.80 71.63 42.69 31.69 27.09 - 31.69  
1 cycle - 2.34 3.24 - - 2.63 21.19 14.80 0.10 0.75 - 2.63 .02 
EOT - 33.19 - - - 41.25 52.32 - - - 1.15 33.22 0.11 
RCB Class 0 2 0* 1 0 3 3 0 0 2 2   
 
Table 8-5 Tissue analyses for evaluable samples (Part A and B cohorts) 
Ki-67, Geminin, Cleaved Caspase 3 , GLUT-1 and MCM2 scored as a percentage of positive cells within the tumour cell population. Results from 
evaluable baseline, post cycle 1 chemotherapy and end of treatment (EOT) samples in patients who completed neoadjuvant and definitive surgery 
(combined patient from Parts A and B. – denotes non evaluable sample. Group comparison of baseline and on treatment tissue scores revealed 




 90 minute 120 minute 180 minutes 




0.83 0.083 0.77 0.83 0.83 0.83 




0.77 0.77 0.71 0.77 0.77 0.77 






-0.15 -0.15 -0.23 -0.15 -0.15 -0.15 




0.12 0.12 0.36 0.12 0.12 0.12 




0.83 0.83 0.66 0.83 0.83 0.83 
p 0.04 0.04 0.16 0.04 0.04 0.04 
 
Table 8-6 Correlation of baseline breast SUV with tissue evaluations (FDG cohort) 
Results from FDG imaged patients with evaluable baseline tissue samples (n=6). Ki-67, Geminin, 
Cleaved Caspase 3 and GLUT-1 scored as a percentage of positive cells within the tumour cell 
population. Significant correlation is present for Ki-67 and MCM2 with baseline SUVmax and 
SUVmean parameters only (Spearman’s Rank correlation coefficient, 2 sided) 
 Discussion 8.9
Part B seeks to relate changes seen on post cycle 1 PET to later conventional imaging and 
pathological response. The tempo of recruitment has been much slower than hoped due to the 
tracer production and scan delivery challenges that slowed completion of part A and the 
comparative rarity of TNBC. Despite this, strengths of the current PET data set include the 
clean TNBC phenotype and representation of the full spectrum of pathological response 
following neoadjuvant therapy. EANM control/quality assurance procedures concerning 
consistency in patient preparation, scan procedure and image reconstruction for FDG image 
interpretation have been tightly adhered to (69) and consistency of scan scheduling in relation 
to therapy and acquisition time following tracer injection achieved. PERCIST criterion (62) 
relating to group background activity at the 90 minute scan acquisition were met. Nevertheless 
a significant proportion of patient lesions were not evaluable using  SUL and SUV peak 
measures.  In this dataset tumour VOI was defined using a 40% isocontour  and increasing the  
isocontour threshold above 40%detrimentally impacted on lesion  evaluability using Peak 
parameters. PERCIST guidance (62)  suggests a 70% threshold, however using this method only 
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a single patient had peak evaluable tumour at baseline (patient 2, clinical dimension 55mm). 
Although the current sample size is small, it has clinical parameters representative of the TNBC 
population for whom neoadjuvant therapy is commonly recommended (171). An alternative 
study design that excluded those with primary breast tumours at the lower end of the T2 (2-
5cm) spectrum may have permitted higher rates of lesion evaluation using peak measures but 
this approach risks inherently constraining the future clinical population in whom the PET 
response data might be applied as well as further slowing study accrual. In contrast these data 
confirm SUVmax and SUVmean parameters are evaluable in all biopsy or cytology proven 
lesions and in this regard better meet the needs of the neoadjuvant TNBC population.  
Study recruitment continues but within the current dataset there is no indication that % SUV 
change differs between categories of the primary end-point mid-MRI response. This mirrors 
the lack of a clear relationship observed between mid MRI response and later EOT-MRI or 
pathological outcome. However the emerging data suggests magnitude of % change in SUV 
(max and mean) may differ between categories of later EOT-MRI and RCB response. 
Furthermore the % change in hottest lesion target, either breast or axilla, appears to provide 
the best relationship with response at completion of neoadjuvant chemotherapy. In the 
context of a clinical requirement for early identification of poorly responding sub-populations 
who may derive most benefit from participation in clinical trials of novel agents, this 
preliminary data provides a strong rationale for completing recruitment. Considering hottest 
lesion targets only, significant differences in distribution of % SUV change between categories 
of RCB response are present, but the full accrual will be required to properly comment on 
superiority of delayed image acquisition or the optimal SUV parameter. In addition the 
magnitude of SUV change present in those with later poor pathological response raises the 
possibility that the relatively tighter repeatability present at the 90 minute time point (Chapter 
7) may be an important factor in defining the most predictive acquisition time and SUV 
parameter.  
FDG PET performance is recognised to be dependent on breast cancer subtype (172). Despite 
the mix in subsequent pathological response, all target lesions in the current dataset exhibited 
greater than 30% drop in SUV at the post cycle 1 time point thus meeting existing criteria to 
define metabolic response (62). Groheux et al. suggest as high as 42% threshold drop 
(SUVmax) is required to differentiate between those who will achieve pCR from those with 
residual TNBC at the post cycle 2 time point (56). More data will be required prior to receiver 
operator curve assessment or consideration of subcategories of RCB in the TNPET dataset. 
However it seems likely discriminatory threshold for later RCB0/1 level of response will 
similarly exceed the 30% level at the earlier post cycle 1 time point further supporting 
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requirement for TNBC specific response criteria. The current promising early data suggests 
FDG PET response assessed using change in SUVmax or SUVmean will be predictive at the 
clinically desirable post cycle 1 timepoint however completions of the planned accrual will 
increase confidence in this finding and may inform future validation studies.  
The protocol design included tissue sampling at time points contemporaneous with PET 
imaging and at definitive surgery to permit comparison of tracer performance with biopsy 
derived indices of cell proliferation, apoptosis and glucose metabolism. Consistent with prior 
data in other high proliferation malignancies (173, 174) and in unselected breast cancer (44, 
46) the cell proliferation-associated nuclear antigen, Ki-67, demonstrates significant 
correlation with SUV. Raw Ki-67 values have been presented (Table 8-5), but it should be noted 
that all samples in the current cohort exceeded a threshold staining level of 10-20% used to 
define high proliferation (88). Such high Ki-67 across the study cohort is consistent with 
published TNBC datasets (175) where average Ki-67 is in the range 35-48% (176-178) and only 
11% samples have values below 20% (178). It is therefore unlikely Ki-67 in our dataset is an 
artefact of technical limitations associated with biopsy rather than whole tumour specimen 
assessment (87) or the low overall sample size.  
In unselected breast cancer high Ki-67 at completion of neoadjuvant chemotherapy strongly 
predicts poorer outcome in patients not achieving a pathological complete response, 
particularly in ER+ subsets (37, 175). However the prognostic ability of Ki-67 alone is 
confounded by the underlying molecular subtype (179) and intuitively tumour cells that retain 
high proliferation at completion of treatment are also likely to be those most resistant to 
chemotherapeutic agents.  Consistent with this, four of the five individuals achieving RCB 2 or 
3 exhibited persisting high Ki-67 at completion of neoadjuvant therapy, two of whom have 
already developed metastatic relapse (FLT patient 3 and FDG patient 6), the latter within a few 
months of surgery. In contrast, lack of residual primary breast cancer at the end of treatment 
meant Ki-67 could not be reported for those achieving RCB 0 and 1 (FDG patient 4, single node 
residual disease). Although the current sample size is small, pCR rates in the breast are 
recognised to be higher in TNBC compared to other breast cancer phenotypes (5, 17), 
consequently an earlier on treatment biopsy may be required for Ki-67 change to be a 
meaningful biomarker. However the current data provides no suggestion that distribution of 
baseline Ki-67 nor change after 1 cycle significantly differs according to later RCB response; 
indeed two of the seven patients with evaluable tumour samples had very high Ki-67 at the 
post cycle 1 time point but subsequent RCB0 response.  This may simply be an artefact of the 
current small sample size, technical issues associated with biopsy sampling (87), inter-lesion as 
well as intra-lesion heterogeneity of Ki-67 expression and differential impact of therapy on 
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breast and involved nodal disease.  However if full study accrual confirms relationships 
between SUV change in hottest lesion target (breast or axilla site) and later RCB response but 
not Ki-67  it is plausible that some of the challenges associated with early tissue acquisition for 
response assessment may be mitigated by ability to ‘sample’ the whole tumour burden using 
PET imaging.  
Other markers of proliferation have been identified as participants in the process of DNA 
replication and may have prognostic value. Mini-chromosome maintenance protein 2 (MCM2), 
is present in all phases of the cell cycle and detects cells capable of initiating DNA replication. It 
has been reported to be a more sensitive marker of proliferation than Ki-67 or geminin and in 
an unselected breast cancer cohort baseline MCM2 provided a more robust and sensitive 
prognostic marker for breast cancer specific survival (170). Geminin, expressed from S to M 
phase, identifies the sub-fraction that have entered S phase, but not exited mitosis thereby 
providing a more specific indicator of the fraction of cells that are replicating. Increased 
expression has been identified as an independent indicator of adverse prognosis in unselected 
breast cancer, predicting both poor overall survival and the development of distant metastases 
(169). Published data suggests MCM2 expression exceeding 12% defines high proliferation 
(170). In the current dataset this threshold was exceeded in 10 of 11 baseline samples (Table 
8-5) indicating high levels of proliferation within the cohort.  Published thresholds for defining 
high geminin are more dispersed, varying from 2.3 to 30% (170, 180) thus in this preliminary 
TNPET dataset between 2 and 7 of the 8 evaluable baseline samples exhibited high expression.  
Correlation of baseline geminin scores with FDG SUV parameters approached significance at 
the earlier (90 minute) scan acquisition (spearman’s correlation coefficient 0.77, p=0.07) and 
significant correlation was present for MCM2 scores (spearman’s correlation coefficient 0.83. 
p=0.04). However the current data provides no indication of statistically significant difference 
in the distribution of geminin or MCM2 between RCB responding and non-responding subsets 
at either baseline  or the post cycle 1 time point nor significant difference in distribution of % 
change in these tissue biomarkers  at 1 cycle.  Apoptosis mediated by either the intrinsic or 
extrinsic pathways results in cleavage of caspase-3 and assessment of the activated caspase-3 
antibody staining is a validated marker of apoptosis in breast cancer (168). However the 
current TNPET data provides no indication that baseline, post cycle 1 or on treatment change 
in activated caspase-3 antibody differs between categories of RCB good and poor response.  
 
Published data reports association between FDG uptake in breast and GLUT-1 expression (42), 
with greatest expression levels in TNBC (177) or IHC defined basal phenotype (54). We are not 
aware of published clinical data reporting impact of cytotoxic therapy on GLUT-1 receptor 
expression for any tumour site but preclinical data suggests successful anticancer therapy 
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induces reduction in glycolysis that may be explained by downregulation of GLUT-1 expression 
(166) or loss of membrane GLUT-1 localisation (165). In the current cohort, group comparison 
of baseline and post cycle 1 scores identifies statistically significant difference in GLUT-1 
expression.  However high heterogeneity in intensity and extent of staining across whole 
tumour specimens is recognised (42) and may contribute to lack of correlation observed 
between pre-chemotherapy SUV parameters (FDG imaged breast lesions only) and GLUT-1 
expression as well as the lack of significant difference in distribution of the staining level at 
baseline, post cycle 1 time point or the % change in GLUT-1 expression in the current data.  
Accrual of the full cohort will be required to more definitively comment on this. 
 
In summary the emerging Part B response data suggests FDG PET response assessed using 
change in SUVmax or SUVmean derived from the hottest breast or axillary lesion does not 
differ between categories of mid-MRI response but will be predictive of later RCB response at 
the clinically desirable post cycle 1 time point. As early differentiation between categories of 
later good (RCB0/1) and poor (RCB2 and 3) response is of greater clinical value than prediction 
of the mid MRI response this finding is potentially very important. However completion of the 
planned accrual will be required to increase confidence in this finding and inform future 





 Preliminary Evaluation of FDG Dynamic Imaging in TNBC 9
 Objectives 9.1
Clinical PET-CT imaging is usually performed using static imaging and SUV evaluation over 
tumour sites. However full kinetic approaches, as they use the entire (measured) arterial input 
and tumour time-activity curves (TAC) in combination with a tracer kinetic model and plasma 
glucose levels to delineate both the temporal and spatial pattern of tracer uptake, are 
considered the most accurate quantitative measures and potentially provide greater 
information about in vivo tumour biology. 
 
This chapter reports evaluation of the dynamic scan acquisitions using the FDG tracer to assess 
early docetaxel response in TNBC.  The dynamic parameters of overall influx rate constant (Ki) 
in min−1 and the metabolic rate of glucose (MRGlu) in mmol⋅l−1⋅min−1, which equals Ki times 
blood glucose have previously been reported as  potentially superior to SUV for in vivo 
interrogation of malignant tumours  (181) and were therefore selected for evaluation using 
Patlak and FDG two tissue compartment modelling (FDG TCM). Repeatability estimates and 
preliminary response evaluation data for the nine FDG imaged patients who have completed 
research imaging and undergone definitive surgery are presented.    
 FDG Dynamic Scan Evaluation Methods 9.2
The anonymised DICOM PET and CT image files for FDG imaged participants were imported 
from the HERMES workstation for quantitative dynamic interpretation using PMod3.4 (PMOD 
Technologies Ltd, Zurich) according to the method described (6.5.3). Scan acquisitions in each 
individual were performed using the same scanner at all time points, but the GSTT PET Centre 
refurbishment required a change of scanner after the first three FDG imaged participants. 
PMOD assumes that all data loaded for kinetic modelling is already decay corrected unless in-
programme correction is performed. Initial evaluation of the time activity curves (TAC) 
generated within PMOD indicated need for decay correction of scans acquired using the GE 
Discovery VCT 64 slice PET-CT.  To verify the PMOD 3.4 decay correction process FDG phantom 
DICOM datasets acquired using the VCT PET-CT with and without on-scanner decay corrected 
image reconstruction were loaded for kinetic analysis (four 30 minute dynamic acquisitions 
performed using a cylindrical phantom over 6 hours, provided courtesy of PET physicist Lucy 
Pike). Phantom time activity curves (TACs) derived from the dataset decay corrected within 
PMOD (‘operations’ tool and inputting the 18F half-life, 109.8 minutes) exactly matched the on 
scanner decay corrected dataset (Figure 9.1) confirming suitability of this method for decay 
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correction of the clinical image data prior to analysis. Scans acquired post refurbishment using 
the GE Discovery 710 were decay corrected on the scanner and did not require within PMOD 
decay correction. 
 
Using decay corrected imaging data, tumour and blood input volumes of interest (VOI) were 
defined within PMOD 3.4 on each dynamic FDG acquisition and  Ki and MRGLu values for each 
breast tumour using the image derived arterial blood input using Patlak and FDG 2TCM models 
as described (Section 6.5.3). Measured blood activity derived from a single venous sample 
acquired at 60 minutes post tracer injection permitted rescaling of the arterial input by 
multiplying the kinetic parameter by ratio of the manual blood sample to the time matched 
descending aorta region of interest in 7 of the 8 imaged participants. 
 
To facilitate assessment of SUV change over time, dynamic PET acquisitions obtained using the 
GE Discovery 710 64 slice PET-CT scanner (n=5) were reconstructed to provide four sequential 
static datasets at 40-50, 50-60, 60-70 and 70-80 minutes following tracer injection. SUV 
evaluation was performed using HERMES Hybrid Viewer Software version 1.4C Hermes, as 
previously (Section 6.5.3). 
 
Figure 9-1 Validation of PMOD decay correction using FDG Phantom dataset 
Verification of PMOD decay correction using a phantom dataset reconstructed with and 
without on scanner decay correction.  Match between TACS generated using on-scanner and 




 Dynamic results 9.3
Breast primaries could be visualised on dynamic acquisitions in all patients but as expected the 
15 cm field of view precluded evaluation of involved nodal lesions. Both FDG two tissue 
compartment (2TCM) and Patlak models were applied for dynamic scan interpretation. Table 
9.1 summarises group results for Ki and MRGlu parameters assessed at baseline (2 scans for 
Part A, 1 scan Part B) and at post cycle 1. The raw values (9 participants; 23 scans) and blood 
rescaled values (8 of 9 total participants, 21 scans) are presented. A wide dispersal of 
individual scan scaling factors is present (2TCM mean 1.12, range 0.72-2.14; Patlak mean 1.23, 
range 0.73-2.08), consistent with recognised limitations associated with use of image derived 
blood input including impact of partial volume effect, spillover to hot regions and patient 
movement. Consequently it was not appropriate to apply a generalised scaling factor to the 
















n 5 8 8 5 8 8 
Mean 0.018 0.020 0.007 9.94 12.01 3.52 
s.d 0.019 0.016 0.009 10.09 11.04 4.39 
Median 0.011 0.016 0.003 7.07 8.83 1.90 
Min-max 0.004-0.052 0.003-0.056 
0.0001-
0.028 
1.83-27.55 1.96-37.33 0.04-13.72 
2TCM 
(raw) 
n 5 9 9 5 9 9 
Mean 0.019 0.018 0.008 10.05 11.54 4.00 
Median 0.016 0.013 0.004 8.01 7.31 2.63 
s.d 0.017 0.015 0.012 8.87 15.37 6.10 
Min-max 0.004-0.047 0.003-0.058 
0.00004-
0.003 
1.71-25.01 1.71-38.78 0.02-14.73 
Patlak 
(scaled) 
n 5 8 8 5 8 8 
Mean 0.018 0.015 0.006 9.83 10.93 3.23 
Median 0.014 0.011 0.003 6.96 6.42 1.51 






1.75-25.21 1.43-34.31 -0.03-14.04 
Patlak 
(raw) 
n 5 9 9 5 9 9 
Mean 0.018 0.014 0.006 9.86 8.38 3.14 
Median 0.014 0.010 0.003 8.43 5.57 2.08 




-0.004-0.03 1.81-22.94 0.02-35.56 -0.02-15.02 
 
Table 9-1 Ki and MRGlu  
Group Ki and MRGlu derived using FDG 2-tissue compartment model (2TCM) and Patlak 
models. In eight of the nine participants a venous activity sample at 60 minutes was available 
permitting rescaling of Ki and MRGluc parameters. Two baseline scan acquisitions were 
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performed in Part A participants. Mean, standard deviation (s.d.) median and range for raw 
and scaled kinetic parameters are presented.  * First baseline in Part A imaged patients only 
 Repeatability of Dynamic Parameters 9.3.1
Ki and MRGlu parameters were confirmed to follow log normal distribution in the current 
dataset. For repeatability end point analysis (Part A participants only, n=5) Bland-Altman plots 
were constructed using the log transformed values derived using FDG two tissue compartment 
and Patlak models with and without rescaling using the venous activity sample (Figure 9-2 A 
and B). Overall Ki and MRGlu values derived using the rescaled 2TCM model exhibited tighter 
repeatability than values derived from either model with solely  the image derived blood input 
or Patlak with rescaling but both parameters present breast lesions with differences of greater 
than 15% (0.14 on the log scale). Using the 2TCM, rescaled Ki values did not differ by more 
than 22% on the two scans (±0.2 on the logarithmic scale) and greater variability was present 
using MRGlu values (Figure 9.2 Ai and ii respectively).  Rescaled Ki and MRGlu values derived 
using the Patlak model performed less well, differing by more than 50% (±0.41 on the log 








Figure 9-2 Bland Altman plots of log transformed tumour parameters 
A. Bland Altman plots of log transformed measurements for raw and rescaled Ki (i) and MRGlu 
(ii) for breast lesions on the two baseline repeatability scans derived using the FDG two tissue 
compartment model. Lesions within -0.14 and 0.14 (dashed lines) indicate baseline scan 
measurements were within 15% of each other.  
B. Bland Altman plots of log transformed measurements for raw and rescaled Ki (i) and MRGlu 
(ii) for breast lesions on the two baseline repeatability scans (Patlak model). Lesions within -










 PET response assessment using Ki and MRGlu  9.3.2
Based on the repeatability data, Ki and MRGlu values derived using rescaled 2TCM model only 
were considered for response evaluation.  Table 9-2 reports the % change for each parameter 
at the post cycle 1 time point for the 7 of 8 evaluable breast lesions in relation to standard MRI 
















1 Breast -90.2 -90.6 -76.7 CR CR 0 
2 Breast -50.2 -63.2 -39.9 SD . 2 
3 Breast -69.0 -67.8 -52.5 PR CR 0 
4 Breast -97.0 -97.7 -57.0 SD PR 1 
5 Breast -66.6 -67.2 -46.9 PR CR 0 
6 Breast -57.3 -62.0 -44.1 PR PD 3 
7 Breast - - -44.5 SD PD 3 
8 Breast  -61.4 -66.2 -54.9 SD CR 0 
9 Breast -89.4% -88.4% -72.4 PR PR 0 
 
Table 9-2 Dynamic response assessment for evaluable breast lesions 
Per lesion % change in breast lesion Ki and MRGlu parameters. Where patients presented with 
more than one visible lesion, the SUV defined breast hottest lesion target is denoted in bold. 
Rescaled values only presented, thus participant 7 in whom no venous activity samples could 
obtained is considered non evaluable. Reference hottest lesion SUVmax change (90 minute 
scan acquisitions), mid and EOT MRI RECIST response and the definitive RCB response are 
shown for comparison.  CR = complete response, SD = stable disease, PR = partial response, PD 
= progressive disease. 
Mid- and EOT-MRI RECIST response was categorised as ‘responder’ (complete and partial) or 
‘non-responder’ (stable or progression) for comparison with % change in Ki and MRGlu  (Figure 
9-3i and ii).  No differences in distribution of % change in either parameter were present on 
visual inspection of box plots or statistically between categories of MRI response at either mid 
(p=1 for % change in both Ki and MRGlu) or EOT (p=0.13  for % change in Ki and MRGlu) time 
points. RCB score was categorised as ‘responder’ (RCB 0 or 1) or ‘non responder’ (RCB 2 or 3) 
for comparison with % Ki and MRGlu change. Visual inspection of the boxplots (Figure 9.3iii) 
suggests differences in the % change in Ki and MRGlu according to definitive RCB response 
category may be present (9-3 iii). This difference does not reach statistical significance (p=0.07) 
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for both dynamic parameters, Mann-Whitney U test), but is potentially an artefact of 
insufficient numbers for statistical validity within the current dataset.  Full accrual will be 
required to definitively comment on possible predictive value of the dynamic PET parameters 
(Figure 9-3iii).  
 
 
Figure 9-3  Distribution of dynamic parameter change according to conventional response assessment 
Box plots showing comparison of distribution for Ki and MRGlu % change according to 
categories of (i) mid-MRI and (ii) EOT RECIST response and (iii) RCB response in n=8 breast 
lesions. No statistically significant difference in distribution of dynamic response parameter is 
present in the current dataset. Outlier patient 1 went on to achieve RCB0 pathological 
response, and outlier patient 6 RCB3.  
The data presented in Chapter 8 suggest the predictive value of % change in SUV might be 
greatest when considering hottest lesion (breast or axilla) only as target for response 
assessment. The current dynamic breast dataset includes 6 patients where the evaluated 
breast lesion was also the SUV defined hottest lesion (Table 9.2). Considering distribution of % 
change in Ki and MRGlu between responding and non-responding categories within this 
subgroup only, no statistically significant differences in distribution of % change were present 
between categories of MRI response at mid (p=0.33 and 0.66 for % change in Ki and MRGlu 
respectively) or EOT (p= 0.17 for % change in both dynamic parameters) time points or 
between category of RCB response (p=0.13 for both dynamic parameters). For the EOT MRI 
and RCB comparisons this is potentially an artefact of insufficient numbers for statistical 





 Segmented Dynamics 9.4
To facilitate assessment of SUV change over time the dynamic PET acquisitions obtained using 
the GE Discovery 710 64 slice PET-CT scanner (n=5) were reconstructed to provide four 
additional 10 minute ‘static’ views over the breast primary tumours at 40-50, 50-60, 60-70 and 
70-80 minutes following tracer injection.  SUV evaluation for each static reconstruction was 
performed using HERMES Hybrid Viewer Software version 1.4C Hermes as described previously 
(6.5.3) for comparison with the later 90, 120 and 180 minute static acquisitions.  
Figure 9-4 presents the group mean SUVmax and SUVmean parameters for serial baseline and 
post cycle 1 acquisitions. Both parameters exhibit incremental increase with time following 
tracer injection that is steeper for the baseline acquisitions than following the first cycle of 
chemotherapy. Breast was hottest lesion target in only 2 of the 5 participants achieving RCB 0 
(participant 5) and RCB3 (participant 6) respectively. It was not possible to derive static 
reconstructions from dynamic scan acquisitions performed using the GE Discovery VCT 64 slice 
PET-CT and consequently further datasets will be required to permit more meaningful 
exploration of the suitability of later image acquisition for response assessment or for 
consideration of hottest lesion targets on the relationship between SUV change and later 
pathological response. However given the increased baseline uptake on the later baseline 
acquisitions it is plausible that response assessment using the 120 or 180 minute acquisitions 
will be more clinically meaningful.  
 
Figure 9-4 Change in SUV parameters with time 
Mean baseline and post cycle 1 SUV parameters for the serial 10 minute static views acquired 
between 40 and 180 minutes following FDG tracer injection. The early static acquisitions were 
derived from summed dynamic data for the five participants imaged using the GE Discovery 
710 64 slice PET-CT scanner. (i) SUVmax time course for FDG imaged breast tumours (ii) 
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SUVmean time course for FDG imaged breast tumours. Group mean and s.d. deviation shown 
for SUV parameters at each acquisition start time.  
 Conclusion 9.5
To our knowledge these are the first data reporting repeatability of dynamic parameters in 
FDG imaged breast tumours. Overall Ki and MRGlu values derived using the blood sample 
rescaled 2TCM model exhibited tighter repeatability than values derived from either model 
using only the image derived blood input; however both were outside +/-15% repeatability 
bounds. The FDG two tissue compartment model is the most commonly used PET metabolic 
model. This  describes the biology of FDG exchange of the tracer between blood and tissue 
(tumour) compartments by fitting the tumour TAC to the standard two-tissue irreversible 
compartment model three rate constants, k1, k2 and k3 (FDG influx, efflux and 
phosphroylation respectively) plus blood volume fraction parameter (VB, vessel density). An 
alternative model, Patlak graphical analysis has been recommended by the EORTC (74) as the 
method of choice for a full quantitative analysis of dynamic FDG PET studies. This method is 
based on a linearization of the standard FDG model over a user defined interval, and assumes 
that the free concentration of FDG in tissue reaches a steady state and that binding/trapping is 
irreversible. With both methods the primary outcome parameters are Ki and MRGlu. However 
in the current dataset the Patlak model provided very poor reproducibility for breast lesions 
imaged using the FDG tracer even with rescaling. There are no published repeatability data in 
breast cancer for quantitative indices derived using FDG 2TCM or Patlak models, but mean 
percentage difference of 8%–10%  has been reported in studies assessing reproducibility of 
Patlak Ki, derived from dynamic dataset comprising double imaged mixed primary and 
metastatic tumours (182). A trend for poorer reproducibility was observed with Ki  but not SUV 
values in smaller tumours which was attributed to the impact of movement through the 
dynamic acquisition (182). Given the relatively small tumour volume in the current cohort 
(Table 8.1) which is representative of the neoadjuvant TNBC population this is likely to be a 
pertinent consideration in selecting the optimal reporting parameter for PET assessment 
neoadjuvant response.    
To optimise patient acceptability and avoid the risks of invasive arterial blood sampling, an 
image-derived arterial input function was obtained using an ROI manually placed over the 
descending thoracic aorta to acquire the time course of tracer blood concentration. This 
method is widely accepted but risks contamination due to spill-over from other tissues, 
movement and partial volume effects compared to an arterial derived input function.  To 
mitigate this, a venous activity sample at 60 minutes was secured where possible to permit 
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rescaling using the ratio of the manual blood sample to the time matched DA-ROI.  The current 
data demonstrates the best repeatability for rescaled Ki evaluated using the 2TCM, not 
differing by more than 22% on the two scans (±0.2 on the logarithmic scale).  However, 
although the shapes of the arterial blood clearance curves were similar between patients, the 
wide dispersal of the blood correction factor precludes generalisation where a venous sample 
could not be obtained.  
Based on the repeatability data, Ki and MRGlu values derived using only rescaled 2TCM model 
were considered for response evaluation. In contrast to SUV change (Chapter 8), the current 
dataset provides no statistically significant difference in distribution of either dynamic 
response parameter between categories of MRI or RCB response. In addition to differential 
impact of patient movement on dynamic indices (182), discrepancies between SUV and full 
kinetic analysis results may be caused by changes in plasma glucose levels or differences in 
FDG plasma clearance among scans.  No patient in the current cohort had serum glucose level 
greater than 6.2 mmol/l (normal range 4.4 to 6.1 mmol/L) and group mean serum glucose did 
not statistically differ between the scan visits (Chapter 8.4); therefore it seems unlikely that 
differences in blood glucose between scans explain the current data. Data in unselected breast 
cancer reports significant association between change in PET Ki and change in MRI tumour 
volume and later pathological response (76) and changes in K(1) and K(i) predicted both DFS 
and OS, whereas changes in SUV predicted OS only (77). In both studies PET response was 
assessed at mid or end of treatment but as SUV and Ki are not equivalent they may be 
differently affected by therapy induced metabolic changes with a different impact on the PET 
parameters at the post cycle 1 by treatment relative to later time points. The proportion of 
patients who had TNBC in these studies is unclear but is likely to be small, and differences in 
tumour biology of TNBC relative to other breast cancer phenotypes may therefore be relevant. 
There are few publications  comparing SUV and  2TCM derived indices in cancer generally, 
however large differences between fractional change in  SUV  and  Patlak derived MRGlu  using 
an image derived input function have been reported for urological but not lung primary sites 
(181). Similarly in renal cancer comparison of on treatment change in tumor SUV with Patlak 
derived changes in Ki during serial PET imaging identified poor correlation between the two 
indices and the discrepancy was sufficient to result in conflicting conclusions regarding the 
progression of disease in some patients. Full accrual will be required to definitively comment 
on the predictive ability of Ki and MRGlu relative to SUV in TNBC however the emerging data 
suggest that these parameters may be less informative than hottest lesion SUV change. 
 
It is disappointing that static reconstructions could not be derived from dynamic scan 
acquisitions performed using the GE Discovery VCT 64 slice PET-CT and further data will be 
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required for more robust assessment of the impact of acquisition interval on SUV in TNBC 
within the current study. However the current data clearly demonstrates steep incremental 
increase in SUVs with time following tracer injection that is most marked on the baseline 
compared to the cycle 1 scan. This is consistent with published data reporting diagnostic utility 
of FDG-PET unselected breast cancer (79, 80) and further supports requirement for consistent 
acquisition interval for comparison of pre and post treatment scans. SUVs should ideally be 
obtained after the tumor uptake reaches a plateau, and although earlier scan acquisitions 
facilitate patient throughput in a busy department, our observations suggest an uptake period 
longer than the 60-90 minute interval commonly applied for clinical imaging may be optimal. 
Using hottest lesion criteria we have demonstrated acceptable baseline repeatability to within 
16%, corresponding to difference 0.15 on the log scale for SUVmax and SUVmean on the 120 
minute acquisition and within 12% for SUVmax, 21% for SUVmean at 180 minutes (Chapter 7).  
Full accrual will be required to determine if delayed static scan acquisition beyond 90 minute 
confers a relatively greater magnitude of SUV change that is advantageous for differentiating 





Given the expense and resource implication of imaging studies for researchers and participants 
it is imperative that early phase clinical trials select emerging tracers with the greatest 
likelihood of successfully addressing a clinical need.  Despite prior promising data using a single 
(BT474) HER2+ breast cancer cell line (141)  and anticipated rapid trajectory to first in man 
evaluation, the preclinical data presented in Chapter 5 demonstrates unexpected failure of a 
HER2 targeted DARPin radio-tracer designed to differentiate HER2 status of pre-clinical tumour 
xenografts models created using different breast cancer cell lines. This poor in vivo 
performance was disappointing but raises significant questions regarding suitability of a 
DARPin radiotracer for clinical evaluation as a HER2 diagnostic in its current form that may 
reduce the risk of proceeding to a futile and costly clinical study. 
 
The tempo of accrual to the TNPET study was significantly slower than expected with many 
contributory factors including delays in the set up phase, issues with FLT production and the 
comparative rarity of TNBC despite the simple study design and use of established 
radiotracers. At the time of writing 12 of 18 recruited patients have competed all imaging 
research evaluations and recruitment to part B continues. Statistical validity of the analysed 
study data will be contingent on achieving full accrual and time only extension until Feb 2017 
has been secured to allow adequate time for study completion. Strengths of the current PET 
data set include the clean TNBC phenotype and representation of the full spectrum of 
pathological response following neoadjuvant therapy. EANM control/quality assurance 
procedures concerning consistency in patient preparation scan procedure and image 
reconstruction for FDG image interpretation have been tightly adhered to (69) and consistency 
of scan scheduling in relation to therapy and acquisition time following tracer injection were all 
achieved. 
 
Chapter 7 provides the first repeatability data for FDG-PET in breast cancer and for both 
tracers this is uniquely evaluated in a homogeneous population of patients with the  TNBC 
biological subtype. Both tracers fulfilled per-patient repeatability criteria specified in the Part A 
analysis plan for at least one SUV measure. Considering all breast and nodal lesions the current 
data demonstrates that SUV intrinsic variability is 12-24% in both tracers, but is dependent on 
scan acquisition time and SUV parameter. PERCIST criteria (62) relating to group background 
activity at the 90 minute scan acquisition were met. Nevertheless a significant proportion of 
patient lesions were not evaluable using  SUL and SUV peak measures, likely due to small 
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lesion size. As the recruited cohort are representative of the population with TNBC in whom 
neoadjuvant treatment would be recommended this strongly suggests that SUV peak 
parameters are impractical for response monitoring in this setting. 
 
Following steering committee review of the repeatability data  and recognising the impact of 
the unresolvable FLT production failures, the FDG tracer only was selected for progression to 
Part B. Subsequent to this decision two studies addressing questions concerning the predictive 
ability of FLT response assessment after 1 cycle of neoadjuvant chemotherapy have reported 
(94, 183). In both the recruited population comprised mixed breast cancer phenotypes and 
only limited numbers with TNBC. However neither baseline nor SUV change after 1 cycle 
predicted later pathological response irrespective of the SUV parameter selected. The larger 
data set noted a weak correlation between SUV change and pCR in the breast alone (183) but 
given the prognostic significance of residual nodal disease the clinical utility of this observation 
is unclear. It is disappointing that FLT could not continue to response assessment phase within 
the current study. Compared to FDG, FLT is more costly lack of commercial availability would 
hinder application for routine clinical use and with only four Part A patients imaged using this 
tracer further comment on the potential utility of this tracer in TNBC is not possible. 
 
Defining pathological response following neoadjuvant chemotherapy using a minimum 
composite of residual breast and nodal disease to predict of long-term outcome is well 
established (25) and RCB continues to be the recommended international standard, delivering 
prognostic information for individual patients and also facilitating comparison of treatment 
outcomes within and across clinical trials (184, 185). In contrast the majority of publications 
reporting PET response have considered only the primary breast lesion, ignoring involved 
axillary disease (Appendix 11.1). PERCIST guidance recommends the % difference between the 
single most intense tumour on study 1 and study 2 is considered for response assessment (62) 
but no published data reporting neoadjuvant response in breast cancer has adopted this 
methodology. Two publications, subsequent to inception of the current study, pre-defined 
target lesion according to greatest baseline SUVmax, accepting that axilla rather than breast 
may be the index lesion for response evaluation (57, 75). Amongst 50 patients with TNBC, 
axillary nodal disease was target in 22%  of patients (57).  Using hottest lesion criteria to define 
the index tumour lesion in FDG imaged patients, the data presented in Chapter 7 
demonstrates tighter repeatability of SUVmax and SUVmean parameters to within 12% and 
16% at the 90 minute and 120 minute scan acquisitions and to within 12% for SUVmax, 21% 
for SUVmean at 180 minutes. Thus the 42% threshold reduction in SUVmax following 2 cycles 
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of neoadjuvant chemotherapy in TNBC suggested by Groheux et al. (57) comfortably exceeds 
these repeatability bounds. Using hottest lesion methodology to define target lesion for 
response assessment, the data presented in Chapter 8 suggests FDG PET will likely be 
informative of later pathological response at the even earlier post cycle 1 time point.  It also 
seems likely discriminatory threshold for later RCB0/1 level of response will exceed the 15-30% 
level indicating unsuitability of the current PERCIST and EORTC guidance in this setting and the 
need for TNBC specific response criteria. However full accrual will be required for more 
definitive comment on this or the optimal scan acquisition time following tracer injection. 
 
With the aspiration of future response adaptive therapy there remains considerable interest in 
identifying the optimal biomarker predictive of later pathological response and survival 
outcomes. Breast MRI provides better anatomical information than CT, and for prediction of 
RCB volumetric MRI imaging performs better than clinical (calliper) assessment of the breast 
primary particularly early in the course of neoadjuvant following 2 cycles of therapy (FTV2) 
(33). Nevertheless end of treatment imaging (FTV4) predicts RCB response with greater 
accuracy than either mid- or post cycle 2 time points (34) and multivariate analyses reported in 
the 2015 update identified equal contribution of MRI FTV2 and the histopathological variables 
(RCB class and  tumor subtype defined by hormone and HER2 receptor status) for prediction of 
three year relapse free survival (33). MRI RECIST response at the mid-point of therapy was 
selected as the clean primary endpoint in the TNPET01 study but this poorly predicts later 
pathological response in the current dataset (Table 8.2). MRI measures including FTV do not 
consider nodal disease and, if the differential importance of nodal and breast disease between 
individuals with TNBC indicated by the current FDG PET data is confirmed, this may be 
pertinent to MRI methodology for neoadjuvant monitoring.  Similarly in the interval from 
inception of the TNPET01 study, data demonstrating improvement in the predictive utility of 
RCB for survival outcomes by addition of parameters such post-treatment Ki-67 has been 
published (38, 186). However no tissue biomarker independently predictive of later 
pathological response or survival outcome has been identified and validated.  If full study 
accrual confirms relationships between SUV change in hottest lesion target (breast or axilla 
site) and later RCB response it is plausible that some of the challenges associated with early 
tissue acquisition for response assessment may be avoided by ability to ‘sample’ the whole 
tumour burden using PET imaging alone or by using PET directed tissue acquisition to guide 




 Future Directions 10.1
Despite the slower than expected tempo of accrual the emerging data suggest the potential 
predictive utility of the FDG tracer at a more clinically desirable post cycle 1 stage justifying the 
completion of the current study. Specifically, full accrual will permit more definitive comment 
on the optimal scan methodology including acquisition interval, reporting parameter and 
target lesion definition using the widely available FDG tracer. Currently there are no TNBC 
specific tissue biomarkers that might be suitable for futureimaging application. However 
improved MRI visualisation of breast anatomy compared to CT might confer advantages for 
PET-MRI over PET-CT for neoadjuvant response evaluation in breast cancer. The limited data in 
breast cancer indicates equivalent performance in terms of qualitative lesion detection to PET-
CT although significant differences in tracer uptake quantification was present, being most 
marked in normal lung, liver and muscle (187). In cancer imaging more generally  PET-MRI 
performs as well as PET-CT for diagnostic purposes (188). However access to PET-MRI is limited 
and potential for integrating functional MRI parameters such as FTV with SUV  for response 
evaluation remains unexplored. 
In contrast to many other imaging study designs, the acquisition of research biopsy samples 
prior to and during the course of neoadjuvant and at definitive surgery provides an allied 
tissue resource permitting comparison with the imaging dataset. In addition, further work 
comparing tracer performance with biopsy derived indices of cell proliferation, apoptosis and 
glucose metabolism will be undertaken by my colleague Dr Sheeba Irshad (NIHR Clinical 
Lecturer, KCL) to better understand the molecular mechanisms driving the poor prognosis of 
TNBC patients using the tissue resource comprised of matched primary, on treatment and 












 Overview of FDG response evaluation studies 11.1
Literature search updated March 2015 
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(201) 66 P Unselected ER+: 56% 
HER2+: 41% 
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Sn =70%  
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40% Metabolic response correlates 
with ki-67 change but not pCR 
 
Key: Highlighted studies were those included in meta-analysis (55). Tumour receptor status classified according to oestrogen receptor positive or negative (ER+ or 
ER-); Human Epidermal Growth Factor Receptor 2 positive or negative (HER2 + or -) or TNBC if both ER and HER2 negative. For these studies ER- criteria were 
either undefined or <10% threshold. 
 
Pathological response scoring systems: Miller Payne classifies pathological response according to a 5-step scale based on tumor cellularity in the 
excision/mastectomy specimen as compared with the pretreatment core biopsy; a score of 4 +5 defines  those with >90% response or pCR(20). Sataloff separately 
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assess tumour response (A= total or near total therapeutic effect, B= >50% therapeutic effect) and nodal response (A +B= no nodal disease with or without 
evidence of therapy response) (22). Honkoop A = pCR, B =minimal residual disease  
Chemotherapy regimen classified according to anthracycline (A), taxane (T) or  Trastuzumab (H) based. †Where scans performed after multiple cycle sensitivity 
and specificity data refers to scan timepoint denoted in bold. Sn=sensitivity, Sp=specificity, NPV= negative predictive value, P=prospective, R= retrospective, 
BW=bodyweight, BSA=body surface area
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PET parameter/endpoints  Conclusion Ref 
Response evaluation studies 
n=20 
LABC  and MBC  




1 or 2  
RECIST  
(at 3 or 4 cycles) 
Predefined PET response  
1. (SUV60,av) of >20%   
2. irreversible uptake (Ki) of >31% 
1.SUV60,av: Sn=0.85, Sp= 0.80         
2. median 40.2% decrease (responders) vs. 10.5% (non-
responders). Ki reduction 51.1% (±28.4%, p<0.01)        
(205) 
n=13 
LABC and MBC 





(at day 60) 
1. FLT repeatability of SUV90 & Ki  
2. SUV response 
1. SD of mean % difference =10.5% (SUV90) and 15.1% (Ki); 
test-retest correlation coefficient ≥0.97 
2. mean 41.3% (range 63.4 to 15.6%) & 52.9% (range 80.3 to 
20.4%) decrease in SUV90 and ki respectively in RECIST 
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kinetics 
( Non linear regression gold 
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-ve bias for SUV change (no ki change corresponding to 11% 







C Post cycle 
1 
No non PET 
reference 
Establish impact of TS inhibition on 
FLT tracer (SUV60 & ki) 
Increased FLT retention in tumour but not normal tissue  (92) 
Literature search (updated March 2015). E= endocrine therapy, Ch = mixed chemotherapy, unless classified according to anthracycline (A), taxane (T), 




 Protocol Summary 11.3
Title of clinical trial  
A randomised phase II trial of [18F]fluorothymidine and 
the standard tracer [18F]fluorodeoxyglucose in the 
assessment of systemic therapy response in triple 
negative breast cancer and their utility compared to 
conventional MRI imaging response, early ADC change 





Triple negative breast cancer: novel functional imaging to 
determine early chemotherapy response/TNPET01 
Trial Phase if not 
















Medical condition or 
disease under 
investigation 
Imaging response biomarker study in triple negative 
breast cancer 
Purpose of clinical 
trial 
 
Phase II early imaging response biomarker study using 
PET-CT imaging for monitoring on treatment change in 
triple negative breast cancer 
Primary objective 
 
Part A: To confirm PET scan SUV measurement 
repeatability using [18F]FDG and [18F]FLT  tracers 
 
Part B: To evaluate PET imaging using 18F]FLT or 
[18F]FDG) as methods for evaluating response to 
systemic therapy in primary triple negative breast 





(Combined Part A and 
B data) 
 
1. Ascertain the optimal scan initiation time after  [18F]FLT 
and [18F]FDG tracer administration in patients with triple 
negative breast cancer 
2. To correlate PET imaging response  in breast and 
axillary lymph nodes with residual cancer burden (RCB) 
at definitive surgery 
3. To correlate  PET imaging response using each tracer 
with blood and biopsy derived biomarkers.  
4. Non invasive assessment of Ki and k1 from this data set 
5. To obtain performance estimates for the ability of the 
Part B tracer (FDG or FLT) to report MRI response 
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derived from integration of  Apparent Diffusion Coefficient 
(ADC) and size change data at 3 cycles 
6. To obtain exploratory performance estimates for early 
MRI size and ADC evaluation on Diffusion Weighted MRI 
sequences after 1 cycle to report RECIST response at 3 
cycles and RCB at definitive surgery 
7. To correlate  MRI  imaging ADC change  with blood and 
biopsy derived proliferation biomarkers and apoptosis 
biomarkers 
8. To confirm the safety of [18F]FLT in patients with breast 
cancer. 
Trial Design  
 
Single centre, non-therapeutic randomised open label 
Phase II trial with two parts 
Trial Interventions Part A 
 10 participants randomly allocated to FDGor FLTtracer 
will have two PET-CT scans separated by a minimum of 
24 hours performed at baseline prior to chemotherapy.  
Participants will have a third scan at day 17±3 following 
the first cycle of chemotherapy to assess SUV response 
to treatment 
Part B 
 15 patients will be scanned once prior to commencing 
chemotherapy and again at day 14-21 post cycle 1 
using the single tracer selected for progression to Part 
B according to end of Part A criteria .  
 Optional study specific MRI scan performed at the end of 
cycle 1 (day 17±3) for early size change and apparent 
diffusion coefficient (ADC) evaluation. 
 
All particpants (A and B) will have a research core biopsy 
performed  prior to chemotherapy, following their day 
17±3 PET scan and through the definitive resection 
specimen at the time of surgery. All participants may 





Part A (n=10) 
Final patient completing pre chemotherapy test-retest 




Tracers will be expected to achieve SUV repeatability 
of within ±15% and SUV reduction of 20-40% in at least 
50% of MRI defined responders evaluable at the point 
the last patient is entered into part A. If these criteria 
are not met for a single tracer the alternative tracer will 
proceed to Part B of the study. If both tracers meet the 
criteria the tracer with the highest proportion of MRI 
defined responders with a drop in SUV of >20% will be 
selected to go through to part B. In the event of equal 
proportions the decision will be based on consensus 
between the team on which tracer performs the best 
overall. All consenting patients in part B will be followed 
using this single tracer.   The study will terminate if 
neither tracer meets these criteria.  
 
 
Part B (n=15) 
On confirmation of tracer repeatability and after 
approval as a result of the Part A analysis the database 
will continue forward for a single tracer and Part A data 
contribute for Part B endpoint analysis.  
 
End of Study 
The end of the trial is the date of surgery of the last 
patient participating in the trial. This will be either 
completion of the last patients surgical visit if no IMP-
related AE's have been seen of until any IMP-related 









 Female age 18 to 70 years 
 Stage II-III biopsy proven early breast cancer for 
which primary chemotherapy is recommended.  
 HER2  negative primary tumours (IHC 0 or 1+, or 
IHC 2+ and FISH non-amplified (ratio of Her2 to 
chromosome 17 of more than 2.0) 
 ER negative primary invasive breast cancer 
(Allred <3) 
 ECOG PS of 0 or 1 
 Primary tumour size >2cm 
 Eligible for neoadjuvant chemotherapy according 
to departmental protocols  
 Able to comply with treatment plans, scheduled 
visits, all study PET imaging and biopsy 
procedures and follow-up 
 Agree to use a medically acceptable birth control 
during the duration of their chemotherapy if of 
childbearing age.  
Exclusion 
 Any prior treatment for the breast cancer 
 Patients who are pregnant or breast feeding 
 Evidence of metastatic disease at diagnosis 
precluding neoadjuvant chemotherapy. 
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 Requirement for concurrent radiotherapy 
treatment 
 Serious medical condition or concurrent medical 
illness likely to compromise ability to complete 
chemotherapy course. 
 Anticoagulation requirement which would 
preclude serial biopsy 
 Diabetes Mellitus 
 Any other problems that may make the patient 
unable to tolerate the PET  scans or 
translational biopsies 
 Investigational Medicinal Product in the 
previous 28 days 
 
 




Intravenous radiotracer administration at time 0 on day of 
PET imaging (3 sessions per patient Part A, 2 per patient 
Part B). Single IMP per patient 
 
1. [18F]-fluorothymidine (FLT):  
maximum 200 MBq FLT: 6.5 mSv per administration 
The study IMP [18F]-fluorothymidine is supplied by: 
 
The  PET Imaging Centre 





MIA(IMP) No. 11387 
 
2. [18F]-fluorodeoxyglucose (FDG):  
maximum 200 MBq of FDG: 4mSv per administration 
The study IMP [18F]-FDG is MetaTrace FDG Solution 
for injection.  






Version and date of 
protocol amendments  






 Summary of  FLT productions issues (23/06/2014) 11.4
Problems underlying FLT production: 
There has been considerable difficulty in producing research tracers consistently, which has increased 
over time due to an ageing cyclotron (22 years old; lifetime usually 10-15 years) and outdated 
radiochemistry infrastructure with limited hot cells available to enable multiple tracers to be produced.  
There was a flood in the cyclotron in 2013 and a subsequent prolonged period of downtime during May 
2014.  The cyclotron service was successfully recovered after both these events but further problems 
are likely and replacement parts for the cyclotron and industry support have not been commercially 
available for some time with all work done by engineers in house.  This reliability/infrastructure issue 
will be addressed with the Phase II development of the PET Centre with new cyclotron and 
radiochemistry facilities anticipated for 2016/7.   
There has also been underinvestment in staffing and a key member of staff responsible for FLT 
production and development left the centre in October 2013. A researcher from the Division of Imaging 
Sciences has been drafted in to support Radiochemistry development and troubleshooting of the ageing 
equipment but this single member of staff is the only individual in house with sufficient specialist skill to 
work in this area and is currently working on restarting FLT production.  The issues with FLT production 
are not isolated – these have been in parallel with problems producing tracers for the clinical service in 
particular C11 methionine and C11 choline which over the past weeks has taken priority as well as other 
research tracers with projects and students dependent on them.   
Attempts to address these: 
To deal with the staffing issues, new posts were requested 3 months ago but only approved yesterday 
due to funding constraints.  A contractor was also arranged as a short term position last week but that 
member of staff is unfortunately currently unable to work due to an acute illness.  It is difficult to find 
people with appropriate expertise for this type of role.  
Alternative sources for FLT have been looked into however there is only one commercial supplier of FLT 
with IMP standard but tracer is only produced once a week and therefore not able to be used for the 
final repeatability study. 
A new more robust cassette based system for FLT production is planned but work to implement this to 
produce IMP quality FLT has not been possible due to lack of staff, who are currently fully stretched 
supporting the clinical service and research tracer production. 
Ways forward: 
In the short term work we will continue to address problems encountered with FLT production including 
the possibility of employing contract staff to assist and free up time for the existing member of the 
research team to restart FLT production. 
In the medium term once new posts are in place the cassette based system should offer a more robust 
production. 
In the longer term new facilities will address these problems.  
 




 DARPin and Trastuzumab tracer preparation 11.5
 111In DOTA conjugated (HE)3-G3 DARPin (
111In DOTA-DARPin) tracer 11.5.1
preparation 
DOTA (HE)3G3 DARPin was prepared and supplied for radiolabelling by Dr Robert Goldstein 
(UCL) (141).  All radiolabelling was performed by Dr Margaret Cooper. 
 Radiolabelling of DARPin 11.5.1.1
To DOTA-G3 DARPin (50 μL, 15 μg) in 0.2M ammonium acetate, pH 6 (UCL, prepared by Rob 
Goldstein), was added 30 MBq (50 μL) 111Indium chloride in 0.05M HCl (Covidien, Petten, 
Netherlands) and the radiolabelling reaction was heated at 37°C for 90 min. The radiolabelled 
DARPin was analysed by reverse phase HPLC using an Eclipse XDB-C8 5 μm, 4.6 x 150 mm 
column (Agilent) at 1 mL/min with a gradient of 0-60% B over 20 min, where solvent A is 0.1% 
TFA in water and solvent B 0.1% TFA in acetonitrile. 
The radiolabelled antibody was diluted with 0.9% sodium chloride for injection to give 3 μg (6 
MBq) 111In-G3 DARPin per 80 µL injection volume. Standard solutions were prepared from the 
injection stock solution in order to calculate the % injected dose for biodistribution analysis. 
 Results 11.5.1.2










8.4.14 2.77 6.16 2.23 
9.4.14 2.76 4.85 1.76 
17.6.14 3 5.14 1.71 
 
 111In -CHX-A”-DTPA-trastuzumab tracer preparation 11.5.2
 Conjugation 11.5.2.1
To 10 mg trastuzumab (Herceptin, Roche), which had been reconstituted to 21mg/mL 
according to the manufacturer’s instructions, was added 50 mM EDTA (25 µL) to chelate any 
free metal in the antibody solution. After 30 min the solution was transferred to an 
ultracentrifugation tube (Vivaspin 15, 30,000 mwco, HY membrane) and the buffer was 
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exchanged for 0.1 M HEPES buffer, pH 8.9 by washing three times with HEPES buffer and 
concentrating the solution to approximately 1.5 mL during each centrifugation step. 
Trastuzumab in 0.1 M HEPES buffer was collected in a final volume of approximately 1.5 mL. 
CHX-A”-DTPA bifunctional chelate (2 mg) in DMSO (40 µL) was added to the trastuzumab 
solution and the conjugation allowed to proceed at room temperature for 3 hr then overnight 
at 4°C. 
Excess ligand was removed by ultracentrifugation as above and the buffer exchanged for 0.2 M 
ammonium acetate buffer, pH 6 by washing 8 times with ammonium acetate buffer and 
concentrating the solution to approximately 3 mL during each centrifugation step. The 
trastuzumab-conjugate was finally collected in approximately 0.7 mL 0.2 M ammonium acetate 
buffer, pH 6.  
The concentration of the trastuzumab-conjugate was measured by Nanodrop 2000c UV-
spectrometer (Thermo Scientific, USA) nm and calculated to be 13 mg/mL. 
 Radiolabelling 11.5.2.2
CHX-A”-DTPA-Herceptin (10μL, 130μg) was diluted to 1.86 mg/mL with 0.2 M ammonium 
acetate buffer, pH 6 (60µL). 111Indium chloride in 0.05M HCl (Covidien, Petten, Netherlands) 
was added (26 MBq, 33µL) and the radiolabelling reaction allowed to proceed at room 
temperature for 20 min. The radiolabelled antibody was analysed by size exclusion HPLC using 
a BioSep SEC-S-2000 column (Phenomenex, Macclesfield, UK) with an isocratic mobile phase of 
phosphate buffered saline, pH 7, containing 2 mM EDTA, and a flow rate of 1 mL/min. The 
retention time of the radioimmunoconjugate was 7 min and that of the unbound 111In 
impurities was 10 min 30 sec and 12 min. 
The radiolabelled antibody was diluted with 0.9% sodium chloride for injection to give 25µg (5 
MBq) 111In-CHX-A”-DTPA-trastuzumab per 80 µL injection volume. Standard solutions were 
prepared from the injection stock solution in order to calculate the %-injected dose for 
biodistribution analysis. 
 Results 11.5.2.3
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